_unit_id,_created_at,_canary,_id,_started_at,_channel,_trust,_worker_id,_country,_region,_city,_ip,b1,b2,confirmids1,confirmids2,e1,e2,factor1,factor2,firstfactor,saveselectionids1,saveselectionids2,secondfactor,sentence,wordid1,wordid2,orig_b1,orig_b2,orig_e1,orig_e2,expertdecision,relation,sent_id,orig_sentence,term1,term2
503010537,7/14/2014 20:58:54,,1323095596,7/14/2014 20:58:29,prodege,1,28255346,GBR,L9,Sheffield,2.125.183.137,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,Thyrotoxicosis in GRAVES' DISEASE,0-18-26-15,0-15-18-26,THYROTOXICOSIS in Graves' disease,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 21:10:31,,1323101434,7/14/2014 21:10:23,clixsense,1,28037714,GBR,P5,Covent Garden,90.199.50.107,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,Thyrotoxicosis in GRAVES' DISEASE is often aggravated,0-15-18-26-34-37-43,0-15-18-26,THYROTOXICOSIS in Graves' disease,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 21:13:03,,1323102541,7/14/2014 21:12:47,instagc,1,27770607,USA,TX,El Paso,72.183.248.75,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 21:30:45,,1323111119,7/14/2014 21:30:12,clixsense,1,16827630,GBR,A7,Birmingham,86.146.169.103,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 21:37:38,,1323114949,7/14/2014 21:37:27,instagc,1,28301350,GBR,K4,Plymouth,92.28.215.248,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0-18-26,THYROTOXICOSIS Graves' disease,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 21:38:54,,1323115739,7/14/2014 21:38:44,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 22:08:25,,1323133030,7/14/2014 22:08:12,instagc,1,24252915,GBR,B7,Bristol,77.98.139.82,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 22:17:32,,1323138688,7/14/2014 22:17:13,elite,1,27385296,GBR,U8,Edinburgh,77.102.46.226,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 22:17:38,,1323138729,7/14/2014 22:17:25,pedtoclick,1,20864559,GBR,B8,Bromley,213.106.94.78,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010537,7/14/2014 22:17:57,,1323138945,7/14/2014 22:16:58,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,18,0,,,33,14,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,18-26,0,THYROTOXICOSIS,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis.,18 26,0,18,0,33,14,-1,RO-cause_of,900105,Thyrotoxicosis in Graves' disease is often aggravated in early pregnancy and this aggravation is associated with postpartum relapse of thyrotoxicosis,Graves' disease,Thyrotoxicosis
503010538,7/14/2014 20:46:03,,1323088753,7/14/2014 20:45:24,instagc,1,28524232,CAN,ON,Toronto,99.244.116.246,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,Clindamycin vaginal cream oral metronidazole BACTERIAL VAGINOSIS: clinical trial.,37-49-57-70-75-109-119-166-157,37-49-57-70-75-109-119-157-166,Clindamycin vaginal cream oral METRONIDAZOLE bacterial vaginosis: clinical trial.,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 20:53:01,,1323092359,7/14/2014 20:52:52,tremorgames,1,28013393,USA,CA,Rancho Cordova,71.197.67.37,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,70-75,oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 21:09:15,,1323100795,7/14/2014 21:08:48,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS:,92-96-106-109-119,37-49-57-63-70-75-89-92-96-106-109-119,Clindamycin vaginal cream versus oral METRONIDAZOLE in the treatment of bacterial vaginosis:,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 21:12:52,,1323102469,7/14/2014 21:12:45,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS: a prospective double,92-96-106-109-119-130-132-144,57-63-70-75-89-92-96,cream versus oral METRONIDAZOLE in the treatment,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 21:12:57,,1323102491,7/14/2014 21:12:52,elite,1,27888773,GBR,"","",128.199.166.81,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS: a prospective double,92-96-106-109-119-130-132-144,57-63-70-75-89-92-96,cream versus oral METRONIDAZOLE in the treatment,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 21:16:51,,1323104311,7/14/2014 21:16:21,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS:,92-96-106-109-119,75-89-92-96-106-109-119,METRONIDAZOLE in the treatment of bacterial vaginosis:,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 22:07:18,,1323132269,7/14/2014 22:06:44,clixsense,1,21034659,AUS,04,Brisbane,49.189.14.88,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 22:07:35,,1323132482,7/14/2014 22:05:55,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS:,92-96-106-109-119,37-57-63-70-75-49,Clindamycin vaginal cream versus oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 22:12:52,,1323135659,7/14/2014 22:12:17,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,75,METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010538,7/14/2014 22:17:12,,1323138467,7/14/2014 22:16:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,109,75,,,128,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS:,109-119,70-75,oral METRONIDAZOLE,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial.",109 119,75,109,75,128,88,1,RO-may_treat,907603,"Andres FJ, Parker R, Hosein I et al. Clindamycin vaginal cream versus oral metronidazole in the treatment of bacterial vaginosis: a prospective double-blind clinical trial",bacterial vaginosis,metronidazole
503010539,7/14/2014 20:51:24,,1323091555,7/14/2014 20:51:09,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,263,299,,,266,302,DIC,APL,"(DIC),",262,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 20:53:52,,1323092821,7/14/2014 20:53:40,clixsense,1,25419319,GBR,H8,Liverpool,94.4.192.228,263,299,,,266,302,DIC,APL,"prevent disseminated intravascular coagulation (DIC), complicating the treatment",223-236-250-262-269-282-286-215,282-286-296-299-303-308-312,the treatment of APL when the promyelocytes,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:01:06,,1323096764,7/14/2014 21:00:47,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,263,299,,,266,302,DIC,APL,"intravascular coagulation (DIC), complicating the treatment",236-250-262-269-282-286,282-286-296-299-303-308-312,the treatment of APL when the promyelocytes,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:04:15,,1323098470,7/14/2014 21:04:00,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,263,299,,,266,302,DIC,APL,disseminated intravascular coagulation,223-236-250,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:11:00,,1323101669,7/14/2014 21:10:34,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,263,299,,,266,302,DIC,APL,"disseminated intravascular coagulation (DIC),",223-236-250-262,37-43-57-299,"acute promyelocytic leukemia, APL","The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:26:49,,1323108946,7/14/2014 21:26:21,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,263,299,,,266,302,DIC,APL,"disseminated intravascular coagulation (DIC),",223-236-250-262,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:29:25,,1323110395,7/14/2014 21:28:56,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,263,299,,,266,302,DIC,APL,APL,299,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:32:45,,1323112181,7/14/2014 21:32:15,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,263,299,,,266,302,DIC,APL,APL,299,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 21:34:04,,1323112904,7/14/2014 21:33:50,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,263,299,,,266,302,DIC,APL,"disseminated intravascular coagulation (DIC), the",223-236-250-262-282,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010539,7/14/2014 22:04:59,,1323130807,7/14/2014 22:03:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,263,299,,,266,302,DIC,APL,"disseminated intravascular coagulation (DIC),",223-236-250-262,299,APL,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation.",,299,263,299,266,302,1,RO-disease_may_have_finding,902931,"The M3 subtype of AML, also known as acute promyelocytic leukemia, is almost universally treated with the drug ATRA (all-trans-retinoic acid) in addition to induction chemotherapy.[36][37][38] Care must be taken to prevent disseminated intravascular coagulation (DIC), complicating the treatment of APL when the promyelocytes release the contents of their granules into the peripheral circulation",DIC,APL
503010540,7/14/2014 20:53:19,,1323092507,7/14/2014 20:53:01,elite,1.0,26544151,GBR,"","",94.196.251.237,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 20:53:58,,1323092863,7/14/2014 20:51:58,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,66,100,,,76,105,POLIOVIRUS,POLIO,"vaccine POLIOVIRUS reservoirs, Polio oral poliovirus vaccines (OPVs) paralytic poliomyelitis.",8-66-77-100-217-222-233-242-306-316,8-66-77-100-217-222-233-242-306-316,"vaccine poliovirus reservoirs, POLIO oral poliovirus vaccines (OPVs) paralytic poliomyelitis.","As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:04:38,,1323098690,7/14/2014 21:04:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,66,100,,,76,105,POLIOVIRUS,POLIO,"POLIOVIRUS reservoirs,",66-77,93-100-106-118,Global POLIO Eradication Initiative,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:08:30,,1323100492,7/14/2014 21:08:04,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100-106-118,POLIO Eradication Initiative,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:09:56,,1323101165,7/14/2014 21:09:18,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:12:17,,1323102259,7/14/2014 21:11:50,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:14:48,,1323103370,7/14/2014 21:14:41,elite,1.0,27888773,GBR,"","",128.199.166.81,66,100,,,76,105,POLIOVIRUS,POLIO,"of the last POLIOVIRUS reservoirs, the Global",54-57-61-66-77-89-93,77-89-93-100-106-118-129,"reservoirs, the Global POLIO Eradication Initiative is","As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:19:11,,1323105225,7/14/2014 21:18:57,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:32:22,,1323111976,7/14/2014 21:32:11,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010540,7/14/2014 21:33:10,,1323112440,7/14/2014 21:33:00,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,66,100,,,76,105,POLIOVIRUS,POLIO,POLIOVIRUS,66,100,POLIO,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis.",66,100,66,100,76,105,-1,RO-has_causative_agent,903661,"As this vaccine is being introduced to eliminate some of the last poliovirus reservoirs, the Global Polio Eradication Initiative is planning for the eventual synchronized worldwide cessation of the routine use of all oral poliovirus vaccines (OPVs) because of their capacity to cause, rarely, outbreaks of paralytic poliomyelitis",poliovirus,Polio
503010541,7/14/2014 20:48:38,,1323090011,7/14/2014 20:48:36,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,which originates from LYMPH VESSELS.,77-83-94-99-105,3-7-12-20-33-36-38,"the oral cavity, LYMPHANGIOMA is a rare,","In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 20:50:50,,1323091268,7/14/2014 20:50:32,elite,1.0,26544151,GBR,"","",94.196.251.237,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 20:52:41,,1323092178,7/14/2014 20:52:34,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 20:56:05,,1323093911,7/14/2014 20:55:44,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 21:01:03,,1323096748,7/14/2014 21:00:52,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 21:10:15,,1323101302,7/14/2014 21:10:01,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,which originates from LYMPH VESSELS.,77-83-94-99-105,20-33-36-38-44-48-61-68,"LYMPHANGIOMA is a rare, non odontogenic, benign neoplasm","In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 21:11:24,,1323101814,7/14/2014 21:10:51,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,lymphangioma LYMPH VESSELS.,99-105-20,3-7-12-20,"the oral cavity, LYMPHANGIOMA","In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 21:23:10,,1323106999,7/14/2014 21:22:50,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 22:04:37,,1323130573,7/14/2014 22:04:25,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,LYMPH VESSELS.,99-105,20,LYMPHANGIOMA,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010541,7/14/2014 22:05:51,,1323131374,7/14/2014 22:05:32,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,99,20,,,112,32,LYMPH VESSELS,LYMPHANGIOMA,"oral cavity, lymphangioma non odontogenic, benign neoplasm LYMPH VESSELS.",7-12-20-44-48-61-68-99-105,7-12-20-44-48-61-68-99-105,"oral cavity, LYMPHANGIOMA non odontogenic, benign neoplasm lymph vessels.","In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels.",99 105,20,99,20,112,32,1,RO-disease_has_primary_anatomic_site,902202,"In the oral cavity, lymphangioma is a rare, non-odontogenic, benign neoplasm which originates from lymph vessels",lymph vessels,lymphangioma
503010542,7/14/2014 20:47:24,,1323089371,7/14/2014 20:47:13,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,overt CONGESTIVE HEART FAILURE,25-31-42-48,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 21:40:32,,1323117048,7/14/2014 21:40:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,overt CONGESTIVE HEART FAILURE,25-31-42-48,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 21:44:33,,1323120309,7/14/2014 21:44:28,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,woman with overt CONGESTIVE HEART FAILURE with pleural and,14-20-25-31-42-48-56-61-69,94-98-106-111-122-126-138,"was treated with FUROSEMIDE and nifedipine, leading","A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:01:22,,1323128832,7/14/2014 22:01:07,instagc,1.0,18960682,GBR,"","",86.29.147.112,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,overt CONGESTIVE HEART FAILURE with pleural and pericardial effusion,25-31-42-48-56-61-69-73-85,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:03:44,,1323130090,7/14/2014 22:03:22,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,51 year old woman with overt CONGESTIVE HEART FAILURE,2-5-14-20-25-31-42-48-10,98-106-111-122-126,"treated with FUROSEMIDE and nifedipine,","A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:04:50,,1323130698,7/14/2014 22:04:18,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,overt CONGESTIVE HEART FAILURE,25-31-42-48,111-122-126,"FUROSEMIDE and nifedipine,","A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:12:50,,1323135657,7/14/2014 22:12:31,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,overt CONGESTIVE HEART FAILURE,25-31-42-48,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:14:07,,1323136531,7/14/2014 22:13:01,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,CONGESTIVE HEART FAILURE,31-42-48,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:14:13,,1323136651,7/14/2014 22:13:43,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,CONGESTIVE HEART FAILURE,31-42-48,111,FUROSEMIDE,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010542,7/14/2014 22:14:34,,1323136850,7/14/2014 22:14:02,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,31,111,,,55,121,CONGESTIVE HEART FAILURE,FUROSEMIDE,"overt CONGESTIVE HEART FAILURE pleural and pericardial effusion furosemide and nifedipine, effusions.",25-31-42-48-61-69-73-85-111-122-126-196,25-31-42-48-61-69-73-111-122-126-138-196,"overt congestive heart failure pleural and pericardial FUROSEMIDE and nifedipine, leading effusions.","A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions.",31 42 48,111,31,111,55,121,1,RO-may_treat,908068,"A 51-year-old woman with overt congestive heart failure with pleural and pericardial effusion was treated with furosemide and nifedipine, leading to improvement in her condition and a decrease in effusions",congestive heart failure,furosemide
503010543,7/14/2014 20:50:50,,1323091271,7/14/2014 20:50:43,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 20:52:08,,1323091888,7/14/2014 20:51:47,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:03:15,,1323097876,7/14/2014 21:02:40,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,secondary HYPERTENSION,39-49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:09:17,,1323100815,7/14/2014 21:08:46,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,evaluation for secondary HYPERTENSION should be deferred,24-35-39-49-62-69-72,0-3-16-24-35-39,"In HYPERTENSIVE CRISIS, evaluation for secondary","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:11:44,,1323101994,7/14/2014 21:11:21,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,secondary HYPERTENSION,39-49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:12:47,,1323102431,7/14/2014 21:12:31,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,secondary HYPERTENSION,39-49,3-16-24,"HYPERTENSIVE CRISIS, evaluation","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:36:07,,1323114110,7/14/2014 21:35:58,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,HYPERTENSION,49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:44:52,,1323120553,7/14/2014 21:44:47,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,evaluation for secondary HYPERTENSION should be deferred,24-35-39-49-62-69-72,0-3-16-24-35-39,"In HYPERTENSIVE CRISIS, evaluation for secondary","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:53:16,,1323125353,7/14/2014 21:53:06,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,secondary HYPERTENSION,39-49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010543,7/14/2014 21:58:42,,1323127446,7/14/2014 21:58:27,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,49,3,,,61,22,HYPERTENSION,HYPERTENSIVE CRISIS,secondary HYPERTENSION,39-49,3-16,"HYPERTENSIVE CRISIS,","In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable.",49,3 16,49,3,61,22,-1,RO-disease_has_finding,901585,"In hypertensive crisis, evaluation for secondary hypertension should be deferred until the patient is stable",hypertension,hypertensive crisis
503010544,7/14/2014 20:48:23,,1323089865,7/14/2014 20:48:21,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,126,80,,,134,96,HEADACHE,TENSION HEADACHE,traumatic headache and HEADACHE associated with hypertension.,103-113-122-126-135-146-151,62-66-75-80-88-98-103-113,"did patients with TENSION HEADACHE, post traumatic headache","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 20:54:19,,1323093033,7/14/2014 20:54:00,elite,1.0,26544151,GBR,"","",94.196.251.237,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE,126,80-88,"TENSION HEADACHE,","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:02:39,,1323097520,7/14/2014 21:01:52,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE,126,80-88,"TENSION HEADACHE,","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:07:35,,1323100077,7/14/2014 21:06:36,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,126,80,,,134,96,HEADACHE,TENSION HEADACHE,traumatic headache and HEADACHE associated with hypertension.,103-113-122-126-135-146-151,62-66-75-80-88-98-103-113,"did patients with TENSION HEADACHE, post traumatic headache","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:13:29,,1323102739,7/14/2014 21:13:25,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,126,80,,,134,96,HEADACHE,TENSION HEADACHE,traumatic headache and HEADACHE associated with hypertension.,103-113-122-126-135-146-151,62-66-75-80-88-98-103-113,"did patients with TENSION HEADACHE, post traumatic headache","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:14:28,,1323103166,7/14/2014 21:14:08,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE associated with hypertension.,126-135-146-151,80-88-98-103-113-126-135-146-151,"TENSION HEADACHE, post traumatic headache headache associated with hypertension.","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:20:42,,1323105921,7/14/2014 21:20:25,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE,126,80-88,"TENSION HEADACHE,","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:27:25,,1323109274,7/14/2014 21:27:13,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE,126,80-88,"TENSION HEADACHE,","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:29:51,,1323110673,7/14/2014 21:29:42,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,126,80,,,134,96,HEADACHE,TENSION HEADACHE,HEADACHE,126,80-88,"TENSION HEADACHE,","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010544,7/14/2014 21:44:17,,1323119958,7/14/2014 21:44:12,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,126,80,,,134,96,HEADACHE,TENSION HEADACHE,traumatic headache and HEADACHE associated with hypertension.,103-113-122-126-135-146-151,62-66-75-80-88-98-103-113,"did patients with TENSION HEADACHE, post traumatic headache","Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension.",126,80 88,126,80,134,96,-1,RO-has_definitional_manifestation,904659,"Patients with migraine did not respond to placebos as well as did patients with tension headache, post-traumatic headache and headache associated with hypertension",headache,tension headache
503010545,7/14/2014 20:46:53,,1323089168,7/14/2014 20:46:04,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,"Differential diagnosis CUSHING'S SYNDROME plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing CRH, testing vasopressin bilateral simultaneous petrosal sinus sampling CRH stimulation.",0-13-26-36-55-62-67-88-93-98-112-121-132-141-154-159-172-213-223-236-245-251-265-269-73,0-13-26-36-55-62-67-73-88-93-98-112-121-132-141-154-159-172-187-213-223-236-245-251-269-265,"Differential diagnosis Cushing's syndrome plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE testing, testing CRH, testing vasopressin combination, bilateral simultaneous petrosal sinus sampling CRH stimulation.","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 20:46:59,,1323089197,7/14/2014 20:46:49,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,121-132,"METYRAPONE testing,","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 20:48:48,,1323090103,7/14/2014 20:48:44,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH,0-13-23-26-36-45-55-62,93-98-112-121-132-141-149,"dose dexamethasone testing, METYRAPONE testing, testing with","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 20:49:39,,1323090597,7/14/2014 20:49:30,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,121,METYRAPONE,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:00:51,,1323096633,7/14/2014 21:00:38,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,121-132,"METYRAPONE testing,","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:05:49,,1323099180,7/14/2014 21:05:32,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,121-132,"METYRAPONE testing,","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:06:21,,1323099454,7/14/2014 21:05:10,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,"Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, vasopressin bilateral simultaneous petrosal sinus sampling CRH stimulation.",0-13-23-26-36-45-55-62-67-73-88-93-98-112-121-132-141-149-154-213-223-236-245-251-265-269-172,0-13-23-26-36-45-55-62-67-73-88-93-98-112-121-132-141-149-154-172-213-223-236-245-251-265-269,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, METYRAPONE testing, testing with CRH, vasopressin bilateral simultaneous petrosal sinus sampling CRH stimulation.","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:11:56,,1323102100,7/14/2014 21:11:52,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,Differential diagnosis of CUSHING'S SYNDROME involves: plasma ACTH,0-13-23-26-36-45-55-62,93-98-112-121-132-141-149,"dose dexamethasone testing, METYRAPONE testing, testing with","Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:20:48,,1323105952,7/14/2014 21:20:24,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,121,METYRAPONE,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010545,7/14/2014 21:37:52,,1323115121,7/14/2014 21:37:39,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,26,121,,,44,131,CUSHING'S SYNDROME,METYRAPONE,CUSHING'S SYNDROME,26-36,26-36-121,Cushing's syndrome METYRAPONE,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation.",26 36,121,26,121,44,131,1,RO-may_diagnose,906876,"Differential diagnosis of Cushing's syndrome involves: plasma ACTH level determination, high dose dexamethasone testing, metyrapone testing, testing with CRH, testing with vasopressin or combination, and finally, bilateral simultaneous petrosal sinus sampling with CRH stimulation",Cushing's syndrome,metyrapone
503010546,7/14/2014 21:01:55,,1323097151,7/14/2014 21:01:28,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,191-208-211-231-243,supersensitivity to parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 21:11:08,,1323101712,7/14/2014 21:10:39,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,NEUROGENIC BLADDERS,134-145,211-231-243,parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 21:18:40,,1323105053,7/14/2014 21:18:12,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,231-243,BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 21:37:26,,1323114825,7/14/2014 21:37:05,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,126-134-145-231-243,chronic neurogenic bladders BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 21:53:05,,1323125292,7/14/2014 21:52:46,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,211-231-243,parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 22:05:01,,1323130850,7/14/2014 22:04:02,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,urethral pressure to administration alpha - stimulant patients with chronic NEUROGENIC BLADDERS denervation supersensitivity to parasympathomimetic bethanechol chloride ten control patients.,16-25-34-37-58-63-64-112-121-126-134-145-179-191-211-231-243-267-271-279-208,16-25-34-37-58-63-64-112-121-126-134-145-179-191-208-211-231-243-267-271-279,urethral pressure to administration alpha - stimulant patients with chronic neurogenic bladders denervation supersensitivity to parasympathomimetic BETHANECHOL CHLORIDE ten control patients.,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 22:08:12,,1323132855,7/14/2014 22:07:39,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,urethral pressure alpha stimulant patients chronic NEUROGENIC BLADDERS positive denervation supersensitivity parasympathomimetic bethanechol chloride,16-25-58-64-112-126-134-145-170-179-191-211-231-243,16-25-58-64-112-126-134-145-170-179-191-211-231-243,urethral pressure alpha stimulant patients chronic neurogenic bladders positive denervation supersensitivity parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 22:10:49,,1323134360,7/14/2014 22:10:31,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,211-231-243,parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 22:14:26,,1323136796,7/14/2014 22:13:59,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,chronic NEUROGENIC BLADDERS,126-134-145,211-231-243,parasympathomimetic BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010546,7/14/2014 22:15:53,,1323137675,7/14/2014 22:15:32,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,134,231,,,153,251,NEUROGENIC BLADDERS,BETHANECHOL CHLORIDE,NEUROGENIC BLADDERS,134-145,231-243,BETHANECHOL CHLORIDE,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients.,134 145,231 243,134,231,153,251,1,RO-may_diagnose,906758,The response of urethral pressure to administration of an alpha-stimulant was compared between a group of eight patients with chronic neurogenic bladders as evidenced by positive denervation supersensitivity to parasympathomimetic bethanechol chloride and a group of ten control patients,neurogenic bladders,bethanechol chloride
503010547,7/14/2014 20:46:11,,1323088819,7/14/2014 20:45:52,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,58-65,79-89-92,CARCINOMA IN SITU),"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 20:48:42,,1323090042,7/14/2014 20:48:39,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"WHO (mild, moderate, SEVERE DYSPLASIA and carcinoma in",37-41-48-58-65-75-79-89,58-65-75-79-89-92-98-102-112,severe dysplasia and CARCINOMA IN SITU) and according to,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 20:49:16,,1323090356,7/14/2014 20:49:04,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,58-65,79-89-92,CARCINOMA IN SITU),"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 20:49:47,,1323090677,7/14/2014 20:49:44,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"WHO (mild, moderate, SEVERE DYSPLASIA and carcinoma in",37-41-48-58-65-75-79-89,58-65-75-79-89-92-98-102-112,severe dysplasia and CARCINOMA IN SITU) and according to,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 21:05:27,,1323099026,7/14/2014 21:05:07,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"(mild, moderate, SEVERE DYSPLASIA and carcinoma in situ)",41-48-58-65-75-79-89-92,41-48-58-65-75-79-89-92,"(mild, moderate, severe dysplasia and CARCINOMA IN SITU)","Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 21:11:48,,1323102036,7/14/2014 21:11:30,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,58-65,79-89-92,CARCINOMA IN SITU),"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 21:13:03,,1323102544,7/14/2014 21:12:54,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"WHO (mild, moderate, SEVERE DYSPLASIA and carcinoma in",37-41-48-58-65-75-79-89,58-65-75-79-89-92-98-102-112,severe dysplasia and CARCINOMA IN SITU) and according to,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 21:39:06,,1323115893,7/14/2014 21:38:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,SEVERE DYSPLASIA,58-65,79-89-92,CARCINOMA IN SITU),"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 21:58:51,,1323127575,7/14/2014 21:58:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"Lesions were classified according to WHO (mild, moderate, SEVERE DYSPLASIA and carcinoma in situ)",0-8-13-24-34-37-41-48-58-65-75-79-89-92,79-89-92,CARCINOMA IN SITU),"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010547,7/14/2014 22:01:36,,1323128946,7/14/2014 22:00:34,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,58,79,,,74,96,SEVERE DYSPLASIA,CARCINOMA IN SITU,"Lesions (mild, moderate, SEVERE DYSPLASIA and carcinoma in situ) (warty, basaloid, combined warty basaloid or basaloid warty types or mixed (warty, basaloid and simple)",0-41-48-58-65-75-79-89-92-134-142-152-161-167-176-179-188-194-200-203-209-217-226-230,0-41-48-58-65-75-79-89-92-134-142-152-161-167-176-179-188-194-200-203-209-217-226-230,"Lesions (mild, moderate, severe dysplasia and CARCINOMA IN SITU) (warty, basaloid, combined warty basaloid or basaloid warty types or mixed (warty, basaloid and simple)","Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms.",58 65,79 89 92,58,79,74,96,-1,RO-disease_has_finding,901609,"Lesions were classified according to WHO (mild, moderate, severe dysplasia and carcinoma in situ) and according to Toki et al. (1991) (warty, basaloid, combined warty/basaloid or basaloid/warty types or mixed (warty, basaloid and simple) forms",severe dysplasia,carcinoma in situ
503010548,7/14/2014 21:01:27,,1323096903,7/14/2014 21:01:06,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"overt CUSHING'S SYNDROME,",46-52-62,135,DEXAMETHASONE,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:06:12,,1323099387,7/14/2014 21:05:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",52-62,135-149,DEXAMETHASONE administration.,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:07:21,,1323099993,7/14/2014 21:07:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"overt CUSHING'S SYNDROME,",46-52-62,135-149,DEXAMETHASONE administration.,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:18:11,,1323104855,7/14/2014 21:17:59,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"of overt CUSHING'S SYNDROME,",43-46-52-62,135,DEXAMETHASONE,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:26:16,,1323108637,7/14/2014 21:25:54,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",52-62,135,DEXAMETHASONE,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:27:51,,1323109471,7/14/2014 21:27:40,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",52-62,135,DEXAMETHASONE,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:38:52,,1323115735,7/14/2014 21:38:48,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"feature of overt CUSHING'S SYNDROME, her serum cortisol",35-43-46-52-62-72-76-82,116-122-125-135-149,after an overnight DEXAMETHASONE administration.,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:44:02,,1323119793,7/14/2014 21:43:26,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"overt CUSHING'S SYNDROME, dexamethasone administration.",46-52-62-135-149,46-52-135-149-62,"overt Cushing's syndrome, DEXAMETHASONE administration.","Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 21:47:04,,1323122275,7/14/2014 21:46:49,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",52-62,135,DEXAMETHASONE,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010548,7/14/2014 22:01:50,,1323129044,7/14/2014 22:01:30,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,52,135,,,70,148,CUSHING'S SYNDROME,DEXAMETHASONE,"CUSHING'S SYNDROME,",52-62,76-82-91-97-101-116-122-125-135-149-105,serum cortisol level was not suppressed after an overnight DEXAMETHASONE administration.,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration.",52 62,135,52,135,70,148,1,RO-may_diagnose,906655,"Although she had no characteristic feature of overt Cushing's syndrome, her serum cortisol level was not suppressed after an overnight dexamethasone administration",Cushing's syndrome,dexamethasone
503010549,7/14/2014 20:55:23,,1323093554,7/14/2014 20:55:13,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:01:05,,1323096761,7/14/2014 21:00:42,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:04:20,,1323098537,7/14/2014 21:04:09,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA and ovarian cancer,227-236-244-248-256,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:11:30,,1323101876,7/14/2014 21:10:47,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,"secondary leukemia: Hodgkin's disease MOPP and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer",149-159-169-179-205-209-223-227-236-244-248-256-200,149-159-169-179-209-223-227-248-256-263-271-276-200,"secondary leukemia: Hodgkin's disease MOPP radiotherapy, and multiple ovarian cancer treated with MELPHALAN.","The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:32:10,,1323111891,7/14/2014 21:31:30,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:33:35,,1323112637,7/14/2014 21:33:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:42:24,,1323118522,7/14/2014 21:41:02,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,cancers and cytotoxic therapies secondary leukemia: Hodgkin's disease MULTIPLE MYELOMA ovarian cancer treated with Melphalan.,91-99-103-113-149-159-169-179-227-236-248-256-271-276-263,91-99-103-113-149-159-169-227-236-248-256-263-271-276-179,cancers and cytotoxic therapies secondary leukemia: Hodgkin's disease multiple myeloma ovarian cancer treated with MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:45:25,,1323120954,7/14/2014 21:45:19,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,"and radiotherapy, and MULTIPLE MYELOMA and ovarian cancer",205-209-223-227-236-244-248-256,256-263-271-276,cancer treated with MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 21:47:15,,1323122372,7/14/2014 21:47:04,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010549,7/14/2014 22:01:09,,1323128708,7/14/2014 22:00:26,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,227,276,,,243,285,MULTIPLE MYELOMA,MELPHALAN,MULTIPLE MYELOMA,227-236,276,MELPHALAN.,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan.",227 236,276,227,276,243,285,1,RO-may_treat,908204,"The highest MCV and MCV increases during therapy among 203 patients were observed in those cancers and cytotoxic therapies most commonly followed by secondary leukemia: Hodgkin's disease treated with MOPP and radiotherapy, and multiple myeloma and ovarian cancer treated with Melphalan",multiple myeloma,Melphalan
503010551,7/14/2014 20:49:06,,1323090269,7/14/2014 20:49:03,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS Adjunctive treatment with,18-28-32-47-61-72-82,61-72-82-87-104-117-120,Adjunctive treatment with ANTITUBERCULOSIS chemotherapy in fulminating,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 20:50:49,,1323091245,7/14/2014 20:50:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Extrapulmonary TUBERCULOSIS Adjunctive treatment,32-47-61-72,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 20:54:19,,1323093049,7/14/2014 20:54:08,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS Adjunctive treatment with antituberculosis,18-28-32-47-61-72-82-87,61-72-82-87-104-117-120,Adjunctive treatment with ANTITUBERCULOSIS chemotherapy in fulminating,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 20:56:43,,1323094247,7/14/2014 20:56:07,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS,18-28-32-47,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 21:02:08,,1323097259,7/14/2014 21:01:40,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS Adjunctive treatment,18-28-32-47-61-72,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 21:03:01,,1323097725,7/14/2014 21:02:37,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS Adjunctive treatment,18-28-32-47-61-72,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 21:11:55,,1323102088,7/14/2014 21:11:31,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Pulmonary and Extrapulmonary TUBERCULOSIS Adjunctive treatment with,18-28-32-47-61-72-82,32-47-61-72-82-87-104-117-120-18,Pulmonary Extrapulmonary Tuberculosis Adjunctive treatment with ANTITUBERCULOSIS chemotherapy in fulminating,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 21:14:37,,1323103271,7/14/2014 21:14:16,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,TUBERCULOSIS,47,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 22:16:28,,1323138001,7/14/2014 22:16:04,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,TUBERCULOSIS,47,87,ANTITUBERCULOSIS,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010551,7/14/2014 22:16:49,,1323138191,7/14/2014 22:16:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,47,87,,,59,103,TUBERCULOSIS,ANTITUBERCULOSIS,Advanced Pulmonary and Extrapulmonary TUBERCULOSIS,9-18-28-32-47,87-104,ANTITUBERCULOSIS chemotherapy,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis.",47,87,47,87,59,103,1,RO-may_treat,907853,"a ,   k  Advanced Pulmonary and Extrapulmonary Tuberculosis  Adjunctive treatment with antituberculosis chemotherapy in fulminating or disseminated pulmonary tuberculosis",Tuberculosis,antituberculosis
503010552,7/14/2014 20:48:32,,1323089955,7/14/2014 20:48:09,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"single gene OBESITY syndrome,",75-82-87-95,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 21:12:18,,1323102262,7/14/2014 21:11:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"OBESITY syndrome,",87-95,113-119-120-126-135-138-145-151,"Prader - Willi syndrome or BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 21:21:32,,1323106249,7/14/2014 21:21:16,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,OBESITY,87,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:06:01,,1323131495,7/14/2014 22:05:44,instagc,1.0,18960682,GBR,"","",86.29.147.112,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"single gene OBESITY syndrome,",75-82-87-95,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:09:50,,1323133803,7/14/2014 22:09:13,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,OBESITY,87,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:13:34,,1323136136,7/14/2014 22:12:40,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"single gene OBESITY syndrome,",75-82-87-95,113-120-126-135-138-145-151,"Prader Willi syndrome or BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:17:49,,1323138904,7/14/2014 22:17:11,sendearnings,1,11896941,USA,FL,Seminole,97.106.105.251,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"single gene OBESITY syndrome,",75-82-87-95,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:18:00,,1323138955,7/14/2014 22:17:39,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,OBESITY,87,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:18:33,,1323139413,7/14/2014 22:18:01,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"a single gene OBESITY syndrome,",73-75-82-87-95,138-145-151,"BARDET BIEDL SYNDROME,","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010552,7/14/2014 22:20:40,,1323140775,7/14/2014 22:18:52,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,87,138,,,94,159,OBESITY,BARDET-BIEDL SYNDROME,"obesity single gene OBESITY syndrome, Prader - Willi syndrome Bardet - Biedl syndrome, genes encoding proteins pro - opiomelanocortin ( POMC ) gene, melanocortin - stimulating hormone (? MSH); melanocortin receptor (MC4); leptin; leptin receptor; prohormone convertase enzymes.",29-75-82-87-95-113-119-120-126-138-144-145-151-194-200-209-268-271-272-289-291-296-298-318-330-331-343-351-354-364-377-386-393-405-412-426-437-448,29-75-81-82-87-95-113-119-120-126-138-145-151-194-200-209-268-271-272-289-291-296-298-318-330-331-343-351-353-354-364-377-386-393-405-412-426-437-448,"obesity single - gene obesity syndrome, Prader - Willi syndrome BARDET BIEDL SYNDROME, genes encoding proteins pro - opiomelanocortin ( POMC ) gene, melanocortin - stimulating hormone (? - MSH); melanocortin receptor (MC4); leptin; leptin receptor; prohormone convertase enzymes.","23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes.",87,138 145 151,87,138,94,159,-1,RO-has_manifestation,906084,"23   Rarely, childhood-onset obesity will manifest itself as a result of a single-gene obesity syndrome, such as Prader-Willi syndrome or Bardet-Biedl syndrome, or from a mutation in one of the genes encoding proteins involved with body weight regulation, such as the pro-opiomelanocortin ( POMC ) gene, which makes ?-melanocortin-stimulating hormone (?-MSH); the melanocortin receptor (MC4); leptin; the leptin receptor; and prohormone convertase enzymes",obesity,Bardet-Biedl syndrome
503010553,7/14/2014 20:48:33,,1323089971,7/14/2014 20:48:32,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"disease characterised by SPLENOMEGALY, sustained neutrophilia, raised",60-68-82-85-99-109-123,0-8-21-31-34-36,CHRONIC NEUTROPHILIC LEUKAEMIA is a rare,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:08:29,,1323100488,7/14/2014 21:08:16,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"disease characterised by SPLENOMEGALY, sustained neutrophilia, raised",60-68-82-85-99-109-123,0-8-21-31-34-36,CHRONIC NEUTROPHILIC LEUKAEMIA is a rare,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:12:46,,1323102432,7/14/2014 21:12:32,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"SPLENOMEGALY, sustained neutrophilia,",85-99-109,0-8-21-31-34-36-41-60,CHRONIC NEUTROPHILIC LEUKAEMIA is a rare myeloproliferative disease,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:12:48,,1323102450,7/14/2014 21:12:31,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"SPLENOMEGALY, neutrophilia,",85-109,0-8-21-41,CHRONIC NEUTROPHILIC LEUKAEMIA myeloproliferative,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:14:53,,1323103397,7/14/2014 21:14:40,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"SPLENOMEGALY,",85,0-8-21,CHRONIC NEUTROPHILIC LEUKAEMIA,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:15:13,,1323103573,7/14/2014 21:15:08,elite,1.0,27888773,GBR,"","",128.199.166.81,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"disease characterised by SPLENOMEGALY, sustained neutrophilia, raised",60-68-82-85-99-109-123,0-8-21-31-34-36,CHRONIC NEUTROPHILIC LEUKAEMIA is a rare,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:32:52,,1323112283,7/14/2014 21:32:32,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"SPLENOMEGALY,",85,0-8-21,CHRONIC NEUTROPHILIC LEUKAEMIA,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:35:07,,1323113469,7/14/2014 21:34:52,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"Chronic neutrophilic leukaemia SPLENOMEGALY,",0-8-21-85,0-8-21,CHRONIC NEUTROPHILIC LEUKAEMIA,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:44:41,,1323120430,7/14/2014 21:44:34,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"disease characterised by SPLENOMEGALY, sustained neutrophilia, raised",60-68-82-85-99-109-123,0-8-21-31-34-36,CHRONIC NEUTROPHILIC LEUKAEMIA is a rare,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010553,7/14/2014 21:52:58,,1323125262,7/14/2014 21:52:38,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,85,0,,,97,30,SPLENOMEGALY,CHRONIC NEUTROPHILIC LEUKAEMIA,"SPLENOMEGALY,",85,0-8-21,CHRONIC NEUTROPHILIC LEUKAEMIA,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome.",85,0 8 21,85,0,97,30,1,RO-disease_has_finding,901967,"Chronic neutrophilic leukaemia is a rare myeloproliferative disease characterised by splenomegaly, sustained neutrophilia, raised vitamin B12 level and absence of the Philadelphia chromosome",splenomegaly,Chronic neutrophilic leukaemia
503010554,7/14/2014 20:49:50,,1323090718,7/14/2014 20:48:49,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV) pathogenesis acquired immune deficiency syndrome (AIDS),30-36-53-59-72-88-97-104-115-124,30-36-53-59-72-88-97-104-115-124,human immunodeficiency virus (HIV) pathogenesis ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS),Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 20:52:12,,1323091919,7/14/2014 20:52:03,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115-124,ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS),Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:04:15,,1323098479,7/14/2014 21:04:01,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115-124,ACQUIRED IMMUNE DEFICIENCY SYNDROME (AIDS),Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:12:53,,1323102471,7/14/2014 21:12:35,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:13:34,,1323102757,7/14/2014 21:13:15,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:32:47,,1323112230,7/14/2014 21:32:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:36:47,,1323114409,7/14/2014 21:36:30,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,30-36-53-59-88-97-104-115,human immunodeficiency virus (HIV) ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:49:17,,1323123575,7/14/2014 21:49:03,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 21:59:53,,1323128052,7/14/2014 21:59:21,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010554,7/14/2014 22:15:38,,1323137486,7/14/2014 22:15:01,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,30,88,,,63,123,HUMAN IMMUNODEFICIENCY VIRUS (HIV,ACQUIRED IMMUNE DEFICIENCY SYNDROME,HUMAN IMMUNODEFICIENCY VIRUS (HIV),30-36-53-59,88-97-104-115,ACQUIRED IMMUNE DEFICIENCY SYNDROME,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature.,30 36 53 59,88 97 104 115,30,88,63,123,-1,RO-has_causative_agent,903982,Current models of the role of human immunodeficiency virus (HIV) in the pathogenesis of acquired immune deficiency syndrome (AIDS) are inadequate and inconsistent with the literature,human immunodeficiency virus (HIV,acquired immune deficiency syndrome
503010555,7/14/2014 20:48:11,,1323089796,7/14/2014 20:48:09,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,135,106,,,148,120,THYROID GLAND,THYROID CANCER,even when the THYROID GLAND is outside of,121-126-131-135-143-149-152-160,85-88-98-106-114-121-126-131,of radiation induced THYROID CANCER even when the,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 20:54:51,,1323093296,7/14/2014 20:54:39,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,135,106,,,148,120,THYROID GLAND,THYROID CANCER,thyroid cancer even when the THYROID GLAND is outside of,114-121-126-131-135-143-149-152-160-106,85-88-98-106-114-121-126-131,of radiation induced THYROID CANCER even when the,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:11:31,,1323101881,7/14/2014 21:11:23,elite,1.0,27888773,GBR,"","",128.199.166.81,135,106,,,148,120,THYROID GLAND,THYROID CANCER,even when the THYROID GLAND is outside of,121-126-131-135-143-149-152-160,85-88-98-106-114-121-126-131,of radiation induced THYROID CANCER even when the,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:15:50,,1323103871,7/14/2014 21:15:28,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,135,106,,,148,120,THYROID GLAND,THYROID CANCER,even when the THYROID GLAND is outside of the irradiated field.,121-126-131-135-143-149-152-160-163-178-167,15-23-35-38-42-50-59-69-75-78-80-85-88-98-106-114,"extreme sensitivity of the thyroid gland children, there is a risk of radiation induced THYROID CANCER","Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:16:47,,1323104274,7/14/2014 21:16:35,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,135,106,,,148,120,THYROID GLAND,THYROID CANCER,THYROID GLAND,135-143,88-98-106-114,radiation induced THYROID CANCER,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:21:52,,1323106383,7/14/2014 21:21:06,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,135,106,,,148,120,THYROID GLAND,THYROID CANCER,thyroid gland radiation induced thyroid cancer THYROID GLAND,42-50-88-106-114-135-143-98,42-50-88-98-106-114-135-143,thyroid gland radiation induced THYROID CANCER thyroid gland,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:31:17,,1323111465,7/14/2014 21:31:05,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,135,106,,,148,120,THYROID GLAND,THYROID CANCER,THYROID GLAND,135-143,106-114,THYROID CANCER,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:31:40,,1323111641,7/14/2014 21:31:21,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,135,106,,,148,120,THYROID GLAND,THYROID CANCER,thyroid cancer THYROID GLAND,106-114-135-143,106-114,THYROID CANCER,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 21:43:55,,1323119708,7/14/2014 21:43:52,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,135,106,,,148,120,THYROID GLAND,THYROID CANCER,even when the THYROID GLAND is outside of,121-126-131-135-143-149-152-160,85-88-98-106-114-121-126-131,of radiation induced THYROID CANCER even when the,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010555,7/14/2014 22:07:49,,1323132657,7/14/2014 22:07:28,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,135,106,,,148,120,THYROID GLAND,THYROID CANCER,THYROID GLAND,135-143,98-106-114-88,radiation induced THYROID CANCER,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field.",135 143,106 114,135,106,148,120,1,RO-disease_has_primary_anatomic_site,902448,"Because of the extreme sensitivity of the thyroid gland in children, there is a risk of radiation-induced thyroid cancer even when the thyroid gland is outside of the irradiated field",thyroid gland,thyroid cancer
503010556,7/14/2014 20:56:42,,1323094241,7/14/2014 20:55:24,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM,18,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:03:00,,1323097722,7/14/2014 21:02:11,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM eggs,18-27,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:12:39,,1323102390,7/14/2014 21:12:19,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM DISEASE: HOOKWORM eggs,0-9-18-27,0-9-18-27,HOOKWORM DISEASE: Hookworm eggs,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:15:39,,1323103793,7/14/2014 21:15:34,elite,1.0,27888773,GBR,"","",128.199.166.81,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM DISEASE: HOOKWORM eggs deposited on,0-9-18-27-32-42,0-9-18-27-32,HOOKWORM DISEASE: Hookworm eggs deposited,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:20:08,,1323105659,7/14/2014 21:19:46,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM eggs,18-27,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:30:38,,1323111078,7/14/2014 21:30:14,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,DISEASE: HOOKWORM,18-9,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:37:17,,1323114708,7/14/2014 21:36:08,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM DISEASE: HOOKWORM eggs,0-9-18-27,0-9-18-27,HOOKWORM DISEASE: Hookworm eggs,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:51:24,,1323124600,7/14/2014 21:50:59,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM,18,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 21:54:14,,1323125753,7/14/2014 21:53:43,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,"HOOKWORM DISEASE: HOOKWORM eggs deposited on the soil in feces mature into larvae capable of penetrating the skin,",0-9-18-27-32-42-45-49-54-57-63-70-75-82-90-93-105-109,0-9-18-27-32-42-45-49-54-57-63-70-75-82-90-93-105-109,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin,","HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010556,7/14/2014 22:04:02,,1323130247,7/14/2014 22:03:44,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,18,0,,,26,16,HOOKWORM,HOOKWORM DISEASE,HOOKWORM,18,0-9,HOOKWORM DISEASE:,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot.",18,0 9,18,0,26,16,-1,RO-has_causative_agent,903915,"HOOKWORM DISEASE: Hookworm eggs deposited on the soil in feces mature into larvae capable of penetrating the skin, esp. the bare skin of the foot",Hookworm,HOOKWORM DISEASE
503010557,7/14/2014 20:46:31,,1323088999,7/14/2014 20:46:20,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,132,62,,,138,72,SEPSIS,GENTAMYCIN,rat SEPSIS model;,128-132-139,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 20:47:46,,1323089534,7/14/2014 20:46:54,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,132,62,,,138,72,SEPSIS,GENTAMYCIN,therapeutic doses indomethacin gentamycin clinically relevant rat SEPSIS model; indomethacin (iii) indomethacin human clinical sepsis.,25-37-46-62-108-119-128-132-139-190-219-225-276-285-270,25-37-46-62-108-119-128-132-139-190-219-270-276-285-225,therapeutic doses indomethacin GENTAMYCIN clinically relevant rat sepsis model; indomethacin (iii) indomethacin human clinical sepsis.,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:06:26,,1323099481,7/14/2014 21:06:10,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,132,62,,,138,72,SEPSIS,GENTAMYCIN,SEPSIS,132,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:09:28,,1323100878,7/14/2014 21:09:10,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,132,62,,,138,72,SEPSIS,GENTAMYCIN,SEPSIS,132,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:13:34,,1323102769,7/14/2014 21:13:30,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,132,62,,,138,72,SEPSIS,GENTAMYCIN,clinically relevant rat SEPSIS model; the,108-119-128-132-139-151,43-46-59-62-73-81-90,of indomethacin or GENTAMYCIN clearly improved the,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:19:52,,1323105549,7/14/2014 21:19:35,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,132,62,,,138,72,SEPSIS,GENTAMYCIN,SEPSIS,132,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:27:01,,1323109013,7/14/2014 21:26:50,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,132,62,,,138,72,SEPSIS,GENTAMYCIN,SEPSIS,132,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:28:03,,1323109558,7/14/2014 21:27:53,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,132,62,,,138,72,SEPSIS,GENTAMYCIN,SEPSIS,132,62,GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 21:45:35,,1323121103,7/14/2014 21:45:27,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,132,62,,,138,72,SEPSIS,GENTAMYCIN,clinically relevant rat SEPSIS model; the,108-119-128-132-139-151,43-46-59-62-73-81-90,of indomethacin or GENTAMYCIN clearly improved the,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010557,7/14/2014 22:02:51,,1323129580,7/14/2014 22:02:32,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,132,62,,,138,72,SEPSIS,GENTAMYCIN,rat SEPSIS model;,128-132-139,46-59-62,indomethacin or GENTAMYCIN,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis.,132,62,132,62,138,72,1,RO-may_treat,908225,Conclusions are that (i) therapeutic doses of indomethacin or gentamycin clearly improved the survival in a clinically relevant rat sepsis model; (ii) the exact mechanism of protection with indomethacin is unknown; and (iii) indomethacin should be considered for use in human clinical sepsis,sepsis,gentamycin
503010558,7/14/2014 21:01:48,,1323097095,7/14/2014 21:01:19,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,154,195,,,158,207,BONE,OSTEOMALACIA,"low BONE turnover,",150-154-159,182-186-195,low turnover OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:05:06,,1323098859,7/14/2014 21:04:49,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,154,195,,,158,207,BONE,OSTEOMALACIA,"low BONE turnover,",150-154-159,182-186-195-208-211-220-225,"low turnover OSTEOMALACIA or adynamic bone disease,","In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:07:03,,1323099821,7/14/2014 21:06:39,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,154,195,,,158,207,BONE,OSTEOMALACIA,BONE,154,195,OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:16:24,,1323104117,7/14/2014 21:16:06,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,154,195,,,158,207,BONE,OSTEOMALACIA,"BONE turnover,",154-159,186-195,turnover OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:16:44,,1323104250,7/14/2014 21:14:58,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,154,195,,,158,207,BONE,OSTEOMALACIA,BONE,154,195,OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:21:58,,1323106431,7/14/2014 21:21:34,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,154,195,,,158,207,BONE,OSTEOMALACIA,"low BONE turnover,",150-154-159,182-186-195,low turnover OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:28:55,,1323110155,7/14/2014 21:28:35,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,154,195,,,158,207,BONE,OSTEOMALACIA,"BONE osteomalacia adynamic bone disease,",154-195-211-220-225,195-211-220,OSTEOMALACIA adynamic bone,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:40:04,,1323116594,7/14/2014 21:39:21,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,154,195,,,158,207,BONE,OSTEOMALACIA,BONE,154,195,OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 21:59:24,,1323127821,7/14/2014 21:59:09,instagc,1.0,18960682,GBR,"","",86.29.147.112,154,195,,,158,207,BONE,OSTEOMALACIA,"low BONE turnover,",150-154-159,182-186-195,low turnover OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010558,7/14/2014 22:05:22,,1323131060,7/14/2014 22:04:57,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,154,195,,,158,207,BONE,OSTEOMALACIA,BONE,154,195,OSTEOMALACIA,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease.",154,195,154,195,158,207,1,RO-disease_has_primary_anatomic_site,902178,"In all centers, independent of the aluminum staining technique used, the extent of aluminum deposited in bone was greater in patients presenting with low bone turnover, whether from low turnover osteomalacia or adynamic bone disease, than in the predominant hyperparathyroid bone disease",bone,osteomalacia
503010559,7/14/2014 20:51:21,,1323091496,7/14/2014 20:50:49,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,primary HEADACHE,37-45,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 20:54:00,,1323092867,7/14/2014 20:53:41,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,45,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:03:43,,1323098141,7/14/2014 21:03:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,primary HEADACHE conditions,37-45-54,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:13:12,,1323102595,7/14/2014 21:13:07,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,severe of primary HEADACHE conditions for functional,27-34-37-45-54-65-69,0-8-18-22-27,"CLUSTER HEADACHE, the most severe","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:14:07,,1323102979,7/14/2014 21:13:59,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,severe of primary HEADACHE conditions for functional,27-34-37-45-54-65-69,0-8-18-22-27,"CLUSTER HEADACHE, the most severe","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:17:19,,1323104499,7/14/2014 21:17:05,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,45,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:19:45,,1323105489,7/14/2014 21:19:33,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,primary HEADACHE conditions,37-45-54,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:20:58,,1323106008,7/14/2014 21:20:43,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,primary HEADACHE,37-45,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:22:54,,1323106864,7/14/2014 21:22:23,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,"Cluster headache, HEADACHE",0-8-45,0-8-45,"CLUSTER HEADACHE, headache","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010559,7/14/2014 21:38:31,,1323115548,7/14/2014 21:38:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,45,0,,,53,16,HEADACHE,CLUSTER HEADACHE,HEADACHE,45,0-8,"CLUSTER HEADACHE,","Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations.",45,0 8,45,0,53,16,-1,RO-has_definitional_manifestation,904591,"Cluster headache, the most severe of primary headache conditions for functional and social impairment it provokes, has been recently the object of a great amount of clinical, physiopathological, surgical and functional neuroradiological studies aimed to uncover the real mechanisms which underlie its disabling manifestations",headache,Cluster headache
503010560,7/14/2014 20:46:11,,1323088821,7/14/2014 20:45:24,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,92,35,,,102,45,DEPRESSION,FLUOXETINE,the treatment of DEPRESSION and has possible,75-79-89-92-103-107-111,4-14-27-35-46-50-63,selective serotonergic agonist FLUOXETINE has demonstrated efficacy,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:13:35,,1323102772,7/14/2014 21:13:17,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,92,35,,,102,45,DEPRESSION,FLUOXETINE,the treatment of DEPRESSION,75-79-89-92,4-14-27-35-46-50-63-72-79-89-92-75,selective serotonergic agonist FLUOXETINE has demonstrated efficacy in the treatment of depression,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:14:56,,1323103436,7/14/2014 21:14:50,elite,1.0,27888773,GBR,"","",128.199.166.81,92,35,,,102,45,DEPRESSION,FLUOXETINE,the treatment of DEPRESSION and has possible,75-79-89-92-103-107-111,4-14-27-35-46-50-63,selective serotonergic agonist FLUOXETINE has demonstrated efficacy,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:28:39,,1323109937,7/14/2014 21:28:27,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,92,35,,,102,45,DEPRESSION,FLUOXETINE,DEPRESSION,92,35,FLUOXETINE,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:40:33,,1323117035,7/14/2014 21:40:17,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,92,35,,,102,45,DEPRESSION,FLUOXETINE,serotonergic agonist fluoxetine DEPRESSION,14-27-35-92,14-27-35-92,serotonergic agonist FLUOXETINE depression,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:59:07,,1323127682,7/14/2014 21:58:52,instagc,1.0,18960682,GBR,"","",86.29.147.112,92,35,,,102,45,DEPRESSION,FLUOXETINE,DEPRESSION,92,35,FLUOXETINE,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 21:59:24,,1323127823,7/14/2014 21:58:03,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,92,35,,,102,45,DEPRESSION,FLUOXETINE,selective serotonergic agonist fluoxetine efficacy in the treatment of DEPRESSION treatment of nondepressed and depressed alcoholics.,4-14-27-35-63-75-79-89-92-136-146-149-162-166-176-72,4-14-27-35-63-72-75-79-89-92-136-149-162-166-176-146,selective serotonergic agonist FLUOXETINE efficacy in the treatment of depression treatment of nondepressed and depressed alcoholics.,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 22:12:39,,1323135554,7/14/2014 22:12:11,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,92,35,,,102,45,DEPRESSION,FLUOXETINE,treatment of DEPRESSION,79-89-92,4-14-27-35,selective serotonergic agonist FLUOXETINE,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 22:15:31,,1323137401,7/14/2014 22:15:15,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,92,35,,,102,45,DEPRESSION,FLUOXETINE,DEPRESSION,92,35,FLUOXETINE,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010560,7/14/2014 22:16:51,,1323138238,7/14/2014 22:16:36,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,92,35,,,102,45,DEPRESSION,FLUOXETINE,DEPRESSION,92,35,FLUOXETINE,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics.,92,35,92,35,102,45,1,RO-may_treat,908148,The selective serotonergic agonist fluoxetine has demonstrated efficacy in the treatment of depression and has possible efficacy in the treatment of nondepressed and depressed alcoholics,depression,fluoxetine
503010561,7/14/2014 20:51:33,,1323091617,7/14/2014 20:51:25,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 21:07:07,,1323099875,7/14/2014 21:06:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 21:09:42,,1323101012,7/14/2014 21:09:16,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and PARKINSONISM linked to chromosome 17 (FTDP - 17),0-15-24-28-41-48-51-62-65-71-70,0-15-24-28-41-48-51-62-65-71-70,FRONTOTEMPORAL DEMENTIA and Parkinsonism linked to chromosome 17 (FTDP - 17),Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 21:09:47,,1323101048,7/14/2014 21:09:29,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 21:13:58,,1323102928,7/14/2014 21:13:51,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and PARKINSONISM linked to chromosome,0-15-24-28-41-48-51,0-15-24-28-41,FRONTOTEMPORAL DEMENTIA and Parkinsonism linked,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 21:53:43,,1323125557,7/14/2014 21:53:07,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and PARKINSONISM linked to chromosome 17 (FTDP - 17) congenital degenerative disease central nervous system.,0-15-24-28-41-48-51-62-65-71-80-91-104-119-127-135-70,0-15-24-28-41-48-51-62-65-70-71-80-91-119-127-135-104,FRONTOTEMPORAL DEMENTIA and Parkinsonism linked to chromosome 17 (FTDP - 17) congenital degenerative disease central nervous system.,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 22:03:30,,1323129950,7/14/2014 22:02:40,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 22:10:03,,1323133926,7/14/2014 22:09:39,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and PARKINSONISM,0-15-24-28,0-15-24-28,FRONTOTEMPORAL DEMENTIA and Parkinsonism,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 22:15:14,,1323137232,7/14/2014 22:14:59,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010561,7/14/2014 22:16:17,,1323137907,7/14/2014 22:15:49,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,28,0,,,40,23,PARKINSONISM,FRONTOTEMPORAL DEMENTIA,PARKINSONISM,28,0-15,FRONTOTEMPORAL DEMENTIA,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system.,28,0 15,28,0,40,23,-1,RO-has_manifestation,906323,Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17) is a congenital degenerative disease of the central nervous system,Parkinsonism,Frontotemporal dementia
503010562,7/14/2014 21:21:31,,1323106217,7/14/2014 21:20:50,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,29,47,,,34,60,BRAIN,HYDROCEPHALUS,"atrophic BRAIN hydrocephalus,",20-29-47,20-29-47,"atrophic brain HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 21:28:35,,1323109905,7/14/2014 21:28:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,29,47,,,34,60,BRAIN,HYDROCEPHALUS,BRAIN,29,47,"HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 21:43:51,,1323119653,7/14/2014 21:43:46,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,29,47,,,34,60,BRAIN,HYDROCEPHALUS,to the atrophic BRAIN in cases of,13-16-20-29-35-38-44,35-38-44-47-62-66-73,"in cases of HYDROCEPHALUS, the fronto nasal","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 21:50:57,,1323124382,7/14/2014 21:50:42,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,29,47,,,34,60,BRAIN,HYDROCEPHALUS,atrophic BRAIN,20-29,47-73,"HYDROCEPHALUS, nasal","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:00:26,,1323128363,7/14/2014 21:59:55,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,29,47,,,34,60,BRAIN,HYDROCEPHALUS,atrophic BRAIN,20-29,47,"HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:02:33,,1323129403,7/14/2014 22:02:02,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,29,47,,,34,60,BRAIN,HYDROCEPHALUS,"atrophic BRAIN hydrocephalus, fronto nasal",20-29-47-66-73,20-29-47-66-73,"atrophic brain HYDROCEPHALUS, fronto nasal","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:03:22,,1323129868,7/14/2014 22:02:25,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,29,47,,,34,60,BRAIN,HYDROCEPHALUS,"atrophic BRAIN in cases of hydrocephalus,",20-29-35-38-44-47,35-38-44-47,"in cases of HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:09:43,,1323133747,7/14/2014 22:09:22,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,29,47,,,34,60,BRAIN,HYDROCEPHALUS,atrophic BRAIN,20-29,47,"HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:10:25,,1323134101,7/14/2014 22:09:50,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,29,47,,,34,60,BRAIN,HYDROCEPHALUS,BRAIN,29,47,"HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010562,7/14/2014 22:11:20,,1323134727,7/14/2014 22:10:53,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,29,47,,,34,60,BRAIN,HYDROCEPHALUS,BRAIN,29,47,"HYDROCEPHALUS,","With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull.",29,47,29,47,34,60,1,RO-disease_has_primary_anatomic_site,902065,"With respect to the atrophic brain in cases of hydrocephalus, the fronto-nasal approach appeared to be the best and less traumatic way of exposing the frontal base of the skull",brain,hydrocephalus
503010563,7/14/2014 20:49:03,,1323090229,7/14/2014 20:48:53,clixsense,1,27871219,NLD,07,Amsterdam,87.210.207.223,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 21:03:44,,1323098151,7/14/2014 21:03:34,tremorgames,1,26860817,NLD,06,Boxmeer,84.29.157.221,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 21:16:36,,1323104185,7/14/2014 21:16:25,prodege,1,28039757,GBR,L8,Southport,109.155.158.54,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 21:38:21,,1323115398,7/14/2014 21:37:47,prodege,1,2143114,CAN,BC,Vancouver,24.84.160.12,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 21:57:11,,1323126796,7/14/2014 21:56:48,instagc,1,19686223,CAN,BC,Surrey,184.65.16.6,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,Fosphenytoin phenytoin STATUS EPILEPTICUS:,0-17-44-51,0-13-17-44-51,FOSPHENYTOIN and phenytoin status epilepticus:,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 22:05:11,,1323130941,7/14/2014 22:05:00,instagc,1,18960682,GBR,"","",86.29.147.112,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 22:08:59,,1323133310,7/14/2014 22:08:44,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 22:15:00,,1323137090,7/14/2014 22:14:37,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0,FOSPHENYTOIN,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 22:16:08,,1323137830,7/14/2014 22:15:07,instagc,1,28519532,USA,IA,Honey Creek,12.73.110.36,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,STATUS EPILEPTICUS:,44-51,0-13-17,FOSPHENYTOIN and phenytoin,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010563,7/14/2014 22:18:07,,1323139118,7/14/2014 22:17:59,neodev,1,28175665,CAN,ON,Brampton,99.228.31.59,44,0,,,62,12,STATUS EPILEPTICUS,FOSPHENYTOIN,in patients with STATUS EPILEPTICUS:,27-30-39-44-51,0-13-17,FOSPHENYTOIN and phenytoin,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs.,44 51,0,44,0,62,12,1,RO-may_treat,907563,Fosphenytoin and phenytoin in patients with status epilepticus: improved tolerability versus increased costs,status epilepticus,Fosphenytoin
503010564,7/14/2014 20:46:42,,1323089065,7/14/2014 20:46:28,prodege,1,2767509,CAN,BC,Victoria,96.54.172.117,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,late onset SEIZURES,84-89-95,108-120,RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 20:49:40,,1323090606,7/14/2014 20:49:36,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,of late onset SEIZURES and Rasmussen's syndrome,81-84-89-95-104-108-120,89-95-104-108-120-129-132-136,onset seizures and RASMUSSEN'S SYNDROME in the profoundly,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 20:57:16,,1323094573,7/14/2014 20:55:42,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,late onset SEIZURES and Rasmussen's syndrome,84-89-95-104-108-120,84-89-95-104-108-120-129-132-136,late onset seizures and RASMUSSEN'S SYNDROME in the profoundly,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:01:35,,1323096962,7/14/2014 21:01:13,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,SEIZURES and Rasmussen's syndrome,95-104-108-120,95-104-108-120,seizures and RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:13:52,,1323102883,7/14/2014 21:13:47,clixsense,1,6491361,USA,MD,Owings Mills,98.233.248.214,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,of late onset SEIZURES and Rasmussen's syndrome,81-84-89-95-104-108-120,89-95-104-108-120-129-132-136,onset seizures and RASMUSSEN'S SYNDROME in the profoundly,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:14:22,,1323103124,7/14/2014 21:14:16,elite,1.0,27888773,GBR,"","",128.199.166.81,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,of late onset SEIZURES and Rasmussen's syndrome,81-84-89-95-104-108-120,89-95-104-108-120-129-132-136,onset seizures and RASMUSSEN'S SYNDROME in the profoundly,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:15:52,,1323103884,7/14/2014 21:15:27,tremorgames,1,24449707,CAN,QC,Laval,96.21.249.72,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,late - onset SEIZURES,84-88-89-95,108-120,RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:20:24,,1323105792,7/14/2014 21:20:08,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,late onset SEIZURES,84-89-95,108-120,RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:25:29,,1323108159,7/14/2014 21:25:05,elite,1,28276268,USA,MI,Taylor,67.149.247.166,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,SEIZURES,95,108-120,RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010564,7/14/2014 21:33:06,,1323112430,7/14/2014 21:32:42,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,95,108,,,103,128,SEIZURES,RASMUSSEN'S SYNDROME,SEIZURES Rasmussen's syndrome,95-108-120,108-120,RASMUSSEN'S SYNDROME,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit.,95,108 120,95,108,103,128,-1,RO-has_definitional_manifestation,904512,Our results indicate that dominant hemispherectomy in adolescence in the setting of late-onset seizures and Rasmussen's syndrome in the profoundly aphasic patient does not commit the patient to the prognosis of a fixed language deficit,seizures,Rasmussen's syndrome
503010565,7/14/2014 20:47:02,,1323089209,7/14/2014 20:47:00,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,infection with common BACTERIA and is characterized,40-50-55-62-71-75-78,0-14-17-20,BOTRYOMYCOSIS is an unusual,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 20:49:43,,1323090630,7/14/2014 20:49:41,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,infection with common BACTERIA and is characterized,40-50-55-62-71-75-78,0-14-17-20,BOTRYOMYCOSIS is an unusual,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 20:50:01,,1323090809,7/14/2014 20:49:36,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,common BACTERIA,55-62,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 20:51:08,,1323091417,7/14/2014 20:51:01,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,BACTERIA,62,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 21:09:20,,1323100828,7/14/2014 21:07:51,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,common BACTERIA,62-55,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 21:12:06,,1323102159,7/14/2014 21:12:00,elite,1.0,27888773,GBR,"","",128.199.166.81,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,infection with common BACTERIA and is characterized,40-50-55-62-71-75-78,0-14-17-20,BOTRYOMYCOSIS is an unusual,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 21:15:05,,1323103504,7/14/2014 21:14:29,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,Botryomycosis unusual response infection with common BACTERIA and is characterized pyogranulomatous inflammation,0-20-28-40-50-55-62-71-75-78-95-112,0-14-17-20-28-40-55-62-95-112,BOTRYOMYCOSIS is an unusual response infection common bacteria pyogranulomatous inflammation,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 21:29:03,,1323110226,7/14/2014 21:28:40,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,BACTERIA,62,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 21:29:39,,1323110551,7/14/2014 21:29:26,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,Botryomycosis BACTERIA,0-62,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010565,7/14/2014 22:09:05,,1323133337,7/14/2014 22:06:48,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,62,0,,,70,13,BACTERIA,BOTRYOMYCOSIS,BACTERIA,62,0,BOTRYOMYCOSIS,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli.,62,0,62,0,70,13,-1,RO-has_causative_agent,903563,Botryomycosis is an unusual response to infection with common bacteria and is characterized by pyogranulomatous inflammation with formation of eosinophilic granules surrounding colonies of gram-positive cocci or gram-negative bacilli,bacteria,Botryomycosis
503010566,7/14/2014 20:48:03,,1323089731,7/14/2014 20:47:26,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,88,130,,,96,138,SEIZURES,EPILEPSY,benign childhood occipital SEIZURES,61-68-78-88,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 20:57:16,,1323094569,7/14/2014 20:56:44,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,88,130,,,96,138,SEIZURES,EPILEPSY,early onset benign childhood occipital SEIZURES,49-55-61-68-78-88,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:01:51,,1323097123,7/14/2014 20:59:09,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,88,130,,,96,138,SEIZURES,EPILEPSY,benign childhood occipital SEIZURES,61-68-78-88,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:03:40,,1323098091,7/14/2014 21:03:19,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,88,130,,,96,138,SEIZURES,EPILEPSY,early onset benign childhood occipital SEIZURES,49-61-68-78-88-55,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:07:53,,1323100207,7/14/2014 21:06:54,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,88,130,,,96,138,SEIZURES,EPILEPSY,early onset benign childhood occipital SEIZURES (EBOS),49-55-61-68-78-88-97,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:11:30,,1323101873,7/14/2014 21:11:18,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,88,130,,,96,138,SEIZURES,EPILEPSY,benign childhood occipital SEIZURES (EBOS),61-68-78-88-97,118-130,symptomatic EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:27:12,,1323109118,7/14/2014 21:27:02,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,88,130,,,96,138,SEIZURES,EPILEPSY,SEIZURES,88,130,EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:27:30,,1323109325,7/14/2014 21:27:22,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,88,130,,,96,138,SEIZURES,EPILEPSY,SEIZURES,88,130,EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:29:19,,1323110352,7/14/2014 21:29:00,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,88,130,,,96,138,SEIZURES,EPILEPSY,benign childhood occipital SEIZURES,61-68-78-88,130,EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010566,7/14/2014 21:40:16,,1323116736,7/14/2014 21:39:59,neodev,1,27597779,CAN,AB,Calgary,72.29.251.209,88,130,,,96,138,SEIZURES,EPILEPSY,occipital SEIZURES epilepsy.,78-88-130,78-130-88,occipital seizures EPILEPSY.,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy.,88,130,88,130,96,138,-1,RO-has_definitional_manifestation,904993,Twelve had a previously unrecognised syndrome of early onset benign childhood occipital seizures (EBOS) and three had symptomatic epilepsy,seizures,epilepsy
503010567,7/14/2014 20:50:21,,1323090952,7/14/2014 20:50:02,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 21:02:23,,1323097392,7/14/2014 21:02:10,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 21:08:47,,1323100605,7/14/2014 21:08:21,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION and chondroblastic osteosarcoma in mesenchymal tumors.,93-107-123-127-142-155-158-170,93-107-123-127-142-155-158-170,cartilaginous differentiation and CHONDROBLASTIC OSTEOSARCOMA in mesenchymal tumors.,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 21:15:22,,1323103636,7/14/2014 21:15:16,elite,1.0,27888773,GBR,"","",128.199.166.81,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,tissue myoepitheliomas with CARTILAGINOUS DIFFERENTIATION and chondroblastic osteosarcoma,65-72-88-93-107-123-127-142,93-107-123-127-142-155-158-170,cartilaginous differentiation and CHONDROBLASTIC OSTEOSARCOMA in mesenchymal tumors.,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 21:17:00,,1323104346,7/14/2014 21:16:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 21:42:53,,1323118849,7/14/2014 21:41:22,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 22:00:37,,1323128437,7/14/2014 22:00:18,instagc,1.0,18960682,GBR,"","",86.29.147.112,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,soft tissue myoepitheliomas with CARTILAGINOUS DIFFERENTIATION and chondroblastic osteosarcoma in mesenchymal tumors.,60-65-72-88-93-107-123-127-142-155-158-170,93-107-123-127-142-155-158-170,cartilaginous differentiation and CHONDROBLASTIC OSTEOSARCOMA in mesenchymal tumors.,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 22:02:00,,1323129144,7/14/2014 22:01:24,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 22:16:26,,1323137998,7/14/2014 22:15:48,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,soft tissue myoepitheliomas with CARTILAGINOUS DIFFERENTIATION and chondroblastic osteosarcoma,60-65-72-93-107-123-127-142-88,127-142-155-158-170,CHONDROBLASTIC OSTEOSARCOMA in mesenchymal tumors.,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010567,7/14/2014 22:16:46,,1323138159,7/14/2014 22:16:28,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,93,127,,,122,154,CARTILAGINOUS DIFFERENTIATION,CHONDROBLASTIC OSTEOSARCOMA,CARTILAGINOUS DIFFERENTIATION,93-107,127-142,CHONDROBLASTIC OSTEOSARCOMA,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors.,93 107,127 142,93,127,122,154,-1,RO-disease_has_finding,901590,These findings contribute significantly to the diagnosis of soft tissue myoepitheliomas with cartilaginous differentiation and chondroblastic osteosarcoma in mesenchymal tumors,cartilaginous differentiation,chondroblastic osteosarcoma
503010568,7/14/2014 20:46:19,,1323088879,7/14/2014 20:46:08,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,29,11,,,34,20,BONES,FRACTURES,BONES of the forearm,29-35-38-42,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 20:53:06,,1323092417,7/14/2014 20:52:48,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,29,11,,,34,20,BONES,FRACTURES,fractures of both BONES of the forearm,11-21-24-29-35-38-42,0-6-11-21-24-29,There were FRACTURES of both bones,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:00:56,,1323096688,7/14/2014 21:00:28,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,29,11,,,34,20,BONES,FRACTURES,BONES,29,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:04:25,,1323098586,7/14/2014 21:04:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,29,11,,,34,20,BONES,FRACTURES,fractures of both BONES of the forearm,11-21-24-29-35-38-42,11-21-24-29-35-38-42,FRACTURES of both bones of the forearm,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:29:35,,1323110514,7/14/2014 21:29:19,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,29,11,,,34,20,BONES,FRACTURES,fractures BONES forearm,11-29-42,11-29-42,FRACTURES bones forearm,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:30:03,,1323110782,7/14/2014 21:29:52,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,29,11,,,34,20,BONES,FRACTURES,BONES,29,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:31:59,,1323111802,7/14/2014 21:31:41,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,29,11,,,34,20,BONES,FRACTURES,BONES,29,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 21:37:46,,1323114997,7/14/2014 21:37:34,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,29,11,,,34,20,BONES,FRACTURES,BONES,29,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 22:00:25,,1323128361,7/14/2014 21:59:17,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,29,11,,,34,20,BONES,FRACTURES,fractures of both BONES of the forearm,11-21-24-29-35-38-42,11-21-24-29-35-42-38,FRACTURES of both bones of the forearm,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010568,7/14/2014 22:02:49,,1323129540,7/14/2014 22:02:36,instagc,1.0,18960682,GBR,"","",86.29.147.112,29,11,,,34,20,BONES,FRACTURES,BONES,29,11,FRACTURES,There were fractures of both bones of the forearm in 16 and of the radius in six.,29,11,29,11,34,20,1,RO-has_finding_site,905411,There were fractures of both bones of the forearm in 16 and of the radius in six,bones,fractures
503010569,7/14/2014 20:45:28,,1323088391,7/14/2014 20:45:18,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",64,99-110,"INFECTIOUS MONONUCLEOSIS,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 20:48:51,,1323090125,7/14/2014 20:48:40,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"findings include hypertension, FEVER, cervical lymphadenopathy in",33-42-50-64-71-80-96,71-80-96-99-110-125-134-142,"cervical lymphadenopathy in INFECTIOUS MONONUCLEOSIS, cervical trigger points","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 20:49:31,,1323090507,7/14/2014 20:49:29,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"findings include hypertension, FEVER, cervical lymphadenopathy in",33-42-50-64-71-80-96,71-80-96-99-110-125-134-142,"cervical lymphadenopathy in INFECTIOUS MONONUCLEOSIS, cervical trigger points","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 21:10:53,,1323101623,7/14/2014 21:09:21,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",64,99-110,"INFECTIOUS MONONUCLEOSIS,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 21:13:12,,1323102603,7/14/2014 21:12:41,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"hypertension, FEVER, cervical lymphadenopathy in infectious mononucleosis,",50-64-71-80-96-99-110,99-110-125-134-142-149-152-159-160-165,"INFECTIOUS MONONUCLEOSIS, cervical trigger points in tension - type headache,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 21:13:41,,1323102802,7/14/2014 21:13:30,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"findings include hypertension, FEVER, cervical lymphadenopathy in",33-42-50-64-71-80-96,71-80-96-99-110-125-134-142,"cervical lymphadenopathy in INFECTIOUS MONONUCLEOSIS, cervical trigger points","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 21:15:49,,1323103861,7/14/2014 21:15:11,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",64,99-110,"INFECTIOUS MONONUCLEOSIS,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 21:25:18,,1323108057,7/14/2014 21:24:03,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"hypertension, FEVER, cervical lymphadenopathy infectious mononucleosis, cervical trigger tension - type headache, and maxillary sinus tenderness sinusitis.",50-64-71-80-99-110-125-134-152-160-165-175-179-189-195-209-159,71-80-96-99-110-125-134-142-152-159-160-165-175-179-189-195-209,"cervical lymphadenopathy in INFECTIOUS MONONUCLEOSIS, cervical trigger points tension - type headache, and maxillary sinus tenderness sinusitis.","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 22:02:16,,1323129253,7/14/2014 22:01:58,instagc,1.0,18960682,GBR,"","",86.29.147.112,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER, in",64-96,99-110,"INFECTIOUS MONONUCLEOSIS,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010569,7/14/2014 22:14:27,,1323136809,7/14/2014 22:13:34,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,64,99,,,69,123,FEVER,INFECTIOUS MONONUCLEOSIS,"FEVER,",64,99-110,"INFECTIOUS MONONUCLEOSIS,","Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis.",64,99 110,64,99,69,123,-1,RO-disease_has_finding,901885,"Examples of significant abnormal findings include hypertension, fever, cervical lymphadenopathy in infectious mononucleosis, cervical trigger points in tension-type headache, and maxillary sinus tenderness in sinusitis",fever,infectious mononucleosis
503010570,7/14/2014 20:47:54,,1323089618,7/14/2014 20:47:43,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,71-81,0-3-7-22,By the HALOTHANE we,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 21:08:44,,1323100596,7/14/2014 21:08:14,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,the syndrome of MALIGNANT HYPERTHERMIA in pigs of,55-59-68-71-81-94-97-102,0-3-7-17-22-25-59-68-71-81,By the HALOTHANE test we determined syndrome of malignant hyperthermia,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 21:13:24,,1323102684,7/14/2014 21:13:18,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,the syndrome of MALIGNANT HYPERTHERMIA in pigs of,55-59-68-71-81-94-97-102,0-3-7-17-22-25,By the HALOTHANE test we determined,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 21:15:26,,1323103664,7/14/2014 21:15:09,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,syndrome of MALIGNANT HYPERTHERMIA,59-68-71-81,7-17,HALOTHANE test,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 21:30:16,,1323110874,7/14/2014 21:30:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,71-81,7,HALOTHANE,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 22:00:53,,1323128549,7/14/2014 22:00:37,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,71-81,7-17,HALOTHANE test,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 22:02:23,,1323129324,7/14/2014 22:01:51,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA in pigs,71-81-94-97,7-17,HALOTHANE test,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 22:04:56,,1323130788,7/14/2014 22:04:38,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,71-81,7,HALOTHANE,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 22:05:45,,1323131328,7/14/2014 22:05:27,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,MALIGNANT HYPERTHERMIA,71-81,7,HALOTHANE,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010570,7/14/2014 22:09:21,,1323133516,7/14/2014 22:08:13,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,71,7,,,93,16,MALIGNANT HYPERTHERMIA,HALOTHANE,halothane test syndrome MALIGNANT HYPERTHERMIA Belgian Landrace,7-17-59-71-81-109-117,7-59-71-81-109-117,HALOTHANE syndrome malignant hyperthermia Belgian Landrace,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg.,71 81,7,71,7,93,16,1,RO-may_diagnose,906643,By the halothane test we determined the development of the syndrome of malignant hyperthermia in pigs of the Belgian Landrace breed with body weight of 20 kg,malignant hyperthermia,halothane
503010571,7/14/2014 20:48:25,,1323089890,7/14/2014 20:48:13,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS.,97-101-111-114-124,53-56-69-75-89-93-97,of intravaginal 0.75% METRONIDAZOLE gel for the,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 20:52:02,,1323091848,7/14/2014 20:51:53,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75-89-69,0.75% METRONIDAZOLE gel,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 21:01:46,,1323097080,7/14/2014 21:01:36,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75,METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 21:04:48,,1323098754,7/14/2014 21:04:26,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,the treatment of BACTERIAL VAGINOSIS.,97-101-111-114-124,56-69-75-89,intravaginal 0.75% METRONIDAZOLE gel,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 21:17:19,,1323104489,7/14/2014 21:16:48,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,treatment of BACTERIAL VAGINOSIS.,101-111-114-124,56-69-75,intravaginal 0.75% METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 21:27:39,,1323109386,7/14/2014 21:27:26,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75,METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 21:50:49,,1323124304,7/14/2014 21:50:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75,METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 22:07:26,,1323132362,7/14/2014 22:06:32,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75-89,METRONIDAZOLE gel,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 22:09:58,,1323133880,7/14/2014 22:09:41,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75,METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010571,7/14/2014 22:13:00,,1323135778,7/14/2014 22:12:30,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,114,75,,,133,88,BACTERIAL VAGINOSIS,METRONIDAZOLE,BACTERIAL VAGINOSIS.,114-124,75,METRONIDAZOLE,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis.",114 124,75,114,75,133,88,1,RO-may_treat,907884,"Hillier SL, Lipinski C, Briselden AM et al. Efficacy of intravaginal 0.75% metronidazole gel for the treatment of bacterial vaginosis",bacterial vaginosis,metronidazole
503010572,7/14/2014 20:47:27,,1323089402,7/14/2014 20:47:24,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,pattern of nocturnal PAIN which is exquisitely,51-59-62-72-77-83-86,0-8-17-21-35,OSTEOID OSTEOMAS are characterized clinically,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 20:50:59,,1323091347,7/14/2014 20:50:50,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,nocturnal PAIN,62-72,0-8,OSTEOID OSTEOMAS,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:04:15,,1323098471,7/14/2014 21:02:53,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,Osteoid osteomas pattern of nocturnal PAIN which is exquisitely,0-51-59-62-72-77-83-86-8,0-8-17-21-35,OSTEOID OSTEOMAS are characterized clinically,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:04:55,,1323098794,7/14/2014 21:04:41,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,nocturnal PAIN,62-72,0-8,OSTEOID OSTEOMAS,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:11:40,,1323101947,7/14/2014 21:11:35,elite,1.0,27888773,GBR,"","",128.199.166.81,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,pattern of nocturnal PAIN which is exquisitely,51-59-62-72-77-83-86,0-8-17-21-35,OSTEOID OSTEOMAS are characterized clinically,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:12:51,,1323102466,7/14/2014 21:12:21,clixsense,1,6336109,CAN,ON,Lindsay,204.237.88.59,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,Osteoid osteomas PAIN,8-72-0,0-8-111,OSTEOID OSTEOMAS salicylates.,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:12:58,,1323102494,7/14/2014 21:12:35,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,PAIN,72,0-8,OSTEOID OSTEOMAS,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:13:51,,1323102876,7/14/2014 21:13:36,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,nocturnal PAIN which is exquisitely sensitive salicylates.,62-72-77-83-86-111-98,0-8-17-21-35-46-49-51-59-62-72,OSTEOID OSTEOMAS are characterized clinically by a pattern of nocturnal pain,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:21:14,,1323106110,7/14/2014 21:21:00,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,PAIN,72,0-8,OSTEOID OSTEOMAS,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010572,7/14/2014 21:22:04,,1323106473,7/14/2014 21:21:16,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,72,0,,,76,16,PAIN,OSTEOID OSTEOMAS,PAIN,72,0-8,OSTEOID OSTEOMAS,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates.,72,0 8,72,0,76,16,1,RO-disease_has_finding,901643,Osteoid osteomas are characterized clinically by a pattern of nocturnal pain which is exquisitely sensitive to salicylates,pain,Osteoid osteomas
503010573,7/14/2014 20:55:43,,1323093710,7/14/2014 20:55:20,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,72,55,,,76,63,BONE,FRACTURE,fracture risk of BONE.,55-64-69-72,55-64-69-72,FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:00:28,,1323096420,7/14/2014 21:00:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,72,55,,,76,63,BONE,FRACTURE,BONE.,72,55,FRACTURE,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:10:00,,1323101222,7/14/2014 21:09:53,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,72,55,,,76,63,BONE,FRACTURE,fracture risk of BONE.,55-64-69-72,33-43-51-55-64-69-72,stiffness affects the FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:13:22,,1323102669,7/14/2014 21:13:17,elite,1.0,27888773,GBR,"","",128.199.166.81,72,55,,,76,63,BONE,FRACTURE,fracture risk of BONE.,55-64-69-72,33-43-51-55-64-69-72,stiffness affects the FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:28:59,,1323110202,7/14/2014 21:28:35,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,72,55,,,76,63,BONE,FRACTURE,fracture risk of BONE.,55-64-72-69,55-64-69-72,FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:32:12,,1323111911,7/14/2014 21:31:51,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,72,55,,,76,63,BONE,FRACTURE,BONE.,72,55,FRACTURE,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:36:58,,1323114502,7/14/2014 21:35:44,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,72,55,,,76,63,BONE,FRACTURE,impactor stiffness affects the fracture risk of BONE.,24-33-43-55-64-69-72-51,33-43-51-55-64-69-72-24,impactor stiffness affects the FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:52:12,,1323124890,7/14/2014 21:51:59,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,72,55,,,76,63,BONE,FRACTURE,BONE.,72,55-64,FRACTURE risk,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 21:58:02,,1323127158,7/14/2014 21:57:12,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,72,55,,,76,63,BONE,FRACTURE,impactor stiffness fracture risk of BONE.,24-55-64-69-72-33,33-55-64-69-72-24,impactor stiffness FRACTURE risk of bone.,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010573,7/14/2014 22:13:14,,1323135944,7/14/2014 22:12:52,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,72,55,,,76,63,BONE,FRACTURE,BONE.,72,55,FRACTURE,"Thus, in this phase the impactor stiffness affects the fracture risk of bone.",72,55,72,55,76,63,1,RO-has_finding_site,905299,"Thus, in this phase the impactor stiffness affects the fracture risk of bone",bone,fracture
503010574,7/14/2014 20:50:48,,1323091240,7/14/2014 20:50:25,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS rashes.,172-180-186,105-111-117,malar LUPUS rashes,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 20:51:45,,1323091732,7/14/2014 20:51:28,elite,1.0,26544151,GBR,"","",94.196.251.237,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS,172-180,111,LUPUS,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:02:40,,1323097522,7/14/2014 21:02:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS rashes.,172-180-186,105-111-117,malar LUPUS rashes,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:07:20,,1323099966,7/14/2014 21:07:07,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS,172-180,105-111,malar LUPUS,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:09:52,,1323101117,7/14/2014 21:09:34,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,172,111,,,185,116,DISCOID LUPUS,LUPUS,subacute cutaneous and DISCOID LUPUS rashes.,149-158-168-172-180-186,98-102-105-111-117-124-128,60% of malar LUPUS rashes and approximately,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:19:26,,1323105347,7/14/2014 21:17:19,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,172,111,,,185,116,DISCOID LUPUS,LUPUS,cutaneous lupus 60% malar lupus rashes 50% subacute cutaneous and DISCOID LUPUS rashes.,79-89-98-105-111-117-149-158-168-172-180-186-142,79-89-98-105-111-117-142-149-158-168-172-186-180,cutaneous lupus 60% malar LUPUS rashes 50% subacute cutaneous and discoid lupus rashes.,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:29:50,,1323110649,7/14/2014 21:29:28,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS,172-180,111,LUPUS,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 21:54:59,,1323126031,7/14/2014 21:54:46,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS,172-180,111,LUPUS,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 22:03:07,,1323129724,7/14/2014 22:02:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS rashes.,172-180-186,105-111-117,malar LUPUS rashes,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010574,7/14/2014 22:09:05,,1323133340,7/14/2014 22:08:47,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,172,111,,,185,116,DISCOID LUPUS,LUPUS,DISCOID LUPUS,172-180,111,LUPUS,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes.,172 180,111,172,111,185,116,-1,RO-cause_of,900039,Direct immunofluorescence of the affected skin provided supportive evidence of cutaneous lupus in 60% of malar lupus rashes and approximately 50% of subacute cutaneous and discoid lupus rashes,discoid lupus,lupus
503010575,7/14/2014 21:12:02,,1323102136,7/14/2014 21:11:58,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,of relief of PAIN with aspirin is,47-50-57-60-65-70-78,3-7-17-20-28-37-39-47,"the diagnosis of OSTEOID OSTEOMA, a history of","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:13:31,,1323102740,7/14/2014 21:13:25,elite,1.0,27888773,GBR,"","",128.199.166.81,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,of relief of PAIN with aspirin is,47-50-57-60-65-70-78,3-7-17-20-28-37-39-47,"the diagnosis of OSTEOID OSTEOMA, a history of","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:25:20,,1323108066,7/14/2014 21:25:05,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN,60,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:33:26,,1323112539,7/14/2014 21:33:12,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN,60,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:35:56,,1323113971,7/14/2014 21:35:42,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN,60,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:48:46,,1323123253,7/14/2014 21:48:34,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN,60,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 21:56:22,,1323126441,7/14/2014 21:53:59,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,relief of PAIN with aspirin,50-57-60-65-70,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 22:04:21,,1323130388,7/14/2014 22:04:03,instagc,1.0,18960682,GBR,"","",86.29.147.112,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN,60,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 22:10:30,,1323134145,7/14/2014 22:10:09,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,relief of PAIN with aspirin,50-57-60-65-70,20-28,"OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010575,7/14/2014 22:15:47,,1323137589,7/14/2014 22:14:29,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,60,20,,,64,35,PAIN,OSTEOID OSTEOMA,PAIN with aspirin,60-65-70,7-17-20-28,"diagnosis of OSTEOID OSTEOMA,","In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important.",60,20 28,60,20,64,35,1,RO-disease_has_finding,901848,"In the diagnosis of osteoid osteoma, a history of relief of pain with aspirin is important",pain,osteoid osteoma
503010576,7/14/2014 20:48:39,,1323090012,7/14/2014 20:48:28,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,on symptoms of THYROID DISEASE and underwent a,139-142-151-154-162-170-174-184,184-186-199-203-209-220-237-243,"a venipuncture for TOTAL THYROXINE, triiodothyronine resin uptake","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:00:10,,1323096285,7/14/2014 20:59:52,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,on symptoms of THYROID DISEASE and underwent a,139-142-151-154-162-170-174-184,184-186-199-203-209-220-237-243,"a venipuncture for TOTAL THYROXINE, triiodothyronine resin uptake","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:06:09,,1323099355,7/14/2014 21:05:53,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,THYROID DISEASE,154-162,203-209,"TOTAL THYROXINE,","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:10:37,,1323101462,7/14/2014 21:10:06,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,THYROID DISEASE,154-162,203-209,"TOTAL THYROXINE,","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:32:35,,1323112110,7/14/2014 21:32:21,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,THYROID DISEASE,154-162,203-209,"TOTAL THYROXINE,","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:39:11,,1323115972,7/14/2014 21:39:02,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,on symptoms of THYROID DISEASE and underwent a,139-142-151-154-162-170-174-184,184-186-199-203-209-220-237-243,"a venipuncture for TOTAL THYROXINE, triiodothyronine resin uptake","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 21:45:13,,1323120805,7/14/2014 21:45:06,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,on symptoms of THYROID DISEASE and underwent a,139-142-151-154-162-170-174-184,184-186-199-203-209-220-237-243,"a venipuncture for TOTAL THYROXINE, triiodothyronine resin uptake","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 22:03:44,,1323130095,7/14/2014 22:03:29,instagc,1.0,18960682,GBR,"","",86.29.147.112,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,THYROID DISEASE,154-162,203-209,"TOTAL THYROXINE,","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 22:04:35,,1323130566,7/14/2014 22:03:59,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,"THYROID DISEASE venipuncture thyroxine, triiodothyronine resin uptake thyrotropin (TSH)",154-162-186-209-220-237-254-266-243,154-184-186-199-203-209-220-237-243-254-266-162,"thyroid disease a venipuncture for TOTAL THYROXINE, triiodothyronine resin uptake thyrotropin (TSH)","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010576,7/14/2014 22:07:44,,1323132612,7/14/2014 22:07:21,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,154,203,,,169,218,THYROID DISEASE,TOTAL THYROXINE,THYROID DISEASE,154-162,203-209,"TOTAL THYROXINE,","Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration.",154 162,203 209,154,203,169,218,1,RO-may_diagnose,906870,"Each patient had a physical examination performed by his or her primary-care provider, was given a standardized questionnaire that focused on symptoms of thyroid disease and underwent a venipuncture for total thyroxine, triiodothyronine resin uptake and thyrotropin (TSH) concentration",thyroid disease,total thyroxine
503010577,7/14/2014 20:49:10,,1323090307,7/14/2014 20:49:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,could still have TACHYCARDIA provoked.,173-179-185-190-202,119-124-127-131-143-155-158-162,rate of the VENTRICULAR TACHYCARDIA in the group,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 21:14:30,,1323103181,7/14/2014 21:14:25,elite,1.0,27888773,GBR,"","",128.199.166.81,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,could still have TACHYCARDIA provoked.,173-179-185-190-202,119-124-127-131-143-155-158-162,rate of the VENTRICULAR TACHYCARDIA in the group,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 21:39:57,,1323116438,7/14/2014 21:39:21,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 21:41:21,,1323117684,7/14/2014 21:41:10,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:03:13,,1323129773,7/14/2014 22:02:52,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:15:27,,1323137354,7/14/2014 22:15:10,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:16:51,,1323138224,7/14/2014 22:16:29,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:17:24,,1323138589,7/14/2014 22:17:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,131-143,VENTRICULAR TACHYCARDIA,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:18:20,,1323139215,7/14/2014 22:18:08,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,TACHYCARDIA,190,119-124-127-131-143-155-158-162,rate of the VENTRICULAR TACHYCARDIA in the group,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010577,7/14/2014 22:18:20,,1323139225,7/14/2014 22:17:36,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,190,131,,,201,154,TACHYCARDIA,VENTRICULAR TACHYCARDIA,"D - sotalol induction of ventricular tachycardia patients, ventricular tachycardia TACHYCARDIA",0-1-2-24-34-37-49-77-131-143-190,0-1-2-24-34-37-49-77-119-124-127-131-143-162-190,"D - sotalol induction of ventricular tachycardia patients, rate of the VENTRICULAR TACHYCARDIA group tachycardia","D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked.",190,131 143,190,131,201,154,-1,RO-has_definitional_manifestation,904775,"D-sotalol prevented the induction of ventricular tachycardia in 18 of the 38 patients, while significantly slowing the rate of the ventricular tachycardia in the group that could still have tachycardia provoked",tachycardia,ventricular tachycardia
503010578,7/14/2014 20:48:36,,1323089997,7/14/2014 20:48:33,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge is a,0-7-14-24-27,47-56-61-64-71-84-89-92,"reliable test of GLUTEN SENSITIVITY, both as a","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:06:47,,1323099628,7/14/2014 21:06:27,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN,0-7,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:09:11,,1323100780,7/14/2014 21:09:04,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge is a,0-7-14-24-27,47-56-61-64-71-84-89-92,"reliable test of GLUTEN SENSITIVITY, both as a","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:12:09,,1323102198,7/14/2014 21:11:46,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge,0-7-14,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:12:32,,1323102340,7/14/2014 21:12:26,elite,1.0,27888773,GBR,"","",128.199.166.81,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge is a,0-7-14-24-27,47-56-61-64-71-84-89-92,"reliable test of GLUTEN SENSITIVITY, both as a","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:13:14,,1323102611,7/14/2014 21:12:44,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge,0-7-14,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 21:43:22,,1323119261,7/14/2014 21:42:28,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,"Rectal GLUTEN gluten sensitivity, for untreated coeliac disease",0-7-64-71-109-113-123-131,0-7-14-64-71-113-123-131,"Rectal gluten challenge GLUTEN SENSITIVITY, untreated coeliac disease","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 22:03:56,,1323130192,7/14/2014 22:03:15,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN,0-7,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 22:05:52,,1323131377,7/14/2014 22:05:19,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN,0-7,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010578,7/14/2014 22:10:50,,1323134388,7/14/2014 22:10:33,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,7,64,,,13,82,GLUTEN,GLUTEN SENSITIVITY,Rectal GLUTEN challenge,0-7-14,64-71,"GLUTEN SENSITIVITY,","Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease.",7,64 71,7,64,13,82,-1,RO-has_causative_agent,903521,"Rectal gluten challenge is a simple, safe, and reliable test of gluten sensitivity, both as a screening test for untreated coeliac disease and as a confirmatory test in patients with treated coeliac disease",gluten,gluten sensitivity
503010579,7/14/2014 20:48:10,,1323089789,7/14/2014 20:48:07,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,63,11,,,67,23,PAIN,FIBROMYALGIA,significantly lower pressure PAIN thresholds at 18,34-48-54-63-68-79-82,0-6-11-24-34-48,Women with FIBROMYALGIA displayed significantly lower,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 20:49:57,,1323090780,7/14/2014 20:49:48,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,63,11,,,67,23,PAIN,FIBROMYALGIA,PAIN,63,11,FIBROMYALGIA,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:06:38,,1323099590,7/14/2014 21:06:12,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,63,11,,,67,23,PAIN,FIBROMYALGIA,PAIN,63,11,FIBROMYALGIA,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:09:51,,1323101100,7/14/2014 21:09:18,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,63,11,,,67,23,PAIN,FIBROMYALGIA,fibromyalgia displayed significantly lower pressure PAIN thresholds at 18 tender point locations,11-24-34-48-54-63-68-79-82-85-92-98,0-6-11-24-34-48-54-63-68-79-82-85-92-98,Women with FIBROMYALGIA displayed significantly lower pressure pain thresholds at 18 tender point locations,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:11:46,,1323102017,7/14/2014 21:11:42,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,63,11,,,67,23,PAIN,FIBROMYALGIA,significantly lower pressure PAIN thresholds at 18,34-48-54-63-68-79-82,0-6-11-24-34-48,Women with FIBROMYALGIA displayed significantly lower,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:12:49,,1323102458,7/14/2014 21:12:43,elite,1.0,27888773,GBR,"","",128.199.166.81,63,11,,,67,23,PAIN,FIBROMYALGIA,significantly lower pressure PAIN thresholds at 18,34-48-54-63-68-79-82,0-6-11-24-34-48,Women with FIBROMYALGIA displayed significantly lower,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:32:43,,1323112161,7/14/2014 21:32:11,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,63,11,,,67,23,PAIN,FIBROMYALGIA,fibromyalgia PAIN thresholds,63-68-11,11-63-68,FIBROMYALGIA pain thresholds,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 21:43:36,,1323119453,7/14/2014 21:42:55,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,63,11,,,67,23,PAIN,FIBROMYALGIA,PAIN,63,11,FIBROMYALGIA,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 22:00:05,,1323128165,7/14/2014 21:59:51,instagc,1.0,18960682,GBR,"","",86.29.147.112,63,11,,,67,23,PAIN,FIBROMYALGIA,lower pressure PAIN thresholds,48-54-63-68,11,FIBROMYALGIA,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010579,7/14/2014 22:13:42,,1323136220,7/14/2014 22:13:19,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,63,11,,,67,23,PAIN,FIBROMYALGIA,PAIN,63,11,FIBROMYALGIA,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites.",63,11,63,11,67,23,-1,RO-has_definitional_manifestation,904698,"Women with fibromyalgia displayed significantly lower pressure pain thresholds at 18 tender point locations as defined by the American College of Rheumatology criteria, as well as lower pressure pain thresholds at five control sites",pain,fibromyalgia
503010580,7/14/2014 20:44:32,,1323087962,7/14/2014 20:44:19,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,99-107,aspirin HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 20:46:34,,1323089020,7/14/2014 20:46:30,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"deficiency, Wegener's granulomatosis, CHURG STRAUSS SYNDROME, aspirin hypersensitivity and",37-49-59-75-81-89-99-107-124,81-89-99-107-124-128-137,"Strauss syndrome, aspirin HYPERSENSITIVITY and allergic fungal","Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 20:48:51,,1323090122,7/14/2014 20:48:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"deficiency, Wegener's granulomatosis, CHURG STRAUSS SYNDROME, aspirin hypersensitivity and",37-49-59-75-81-89-99-107-124,81-89-99-107-124-128-137,"Strauss syndrome, aspirin HYPERSENSITIVITY and allergic fungal","Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 20:52:38,,1323092169,7/14/2014 20:52:10,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,99-107,aspirin HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 20:52:41,,1323092185,7/14/2014 20:52:18,elite,1.0,26544151,GBR,"","",94.196.251.237,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,107,HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 21:07:43,,1323100122,7/14/2014 21:07:24,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,99-107,aspirin HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 21:14:05,,1323102971,7/14/2014 21:13:59,elite,1.0,27888773,GBR,"","",128.199.166.81,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"deficiency, Wegener's granulomatosis, CHURG STRAUSS SYNDROME, aspirin hypersensitivity and",37-49-59-75-81-89-99-107-124,81-89-99-107-124-128-137,"Strauss syndrome, aspirin HYPERSENSITIVITY and allergic fungal","Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 21:14:19,,1323103101,7/14/2014 21:13:59,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"deficiency, Wegener's granulomatosis, CHURG STRAUSS SYNDROME,",37-49-59-75-81-89,81-89-99-107,"Strauss syndrome, aspirin HYPERSENSITIVITY","Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 21:27:53,,1323109490,7/14/2014 21:27:43,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,107,HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010580,7/14/2014 22:03:28,,1323129933,7/14/2014 22:03:07,instagc,1.0,18960682,GBR,"","",86.29.147.112,75,107,,,97,123,CHURG-STRAUSS SYNDROME,HYPERSENSITIVITY,"CHURG STRAUSS SYNDROME,",75-81-89,107-99,aspirin HYPERSENSITIVITY,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis.",75 81 89,107,75,107,97,123,-1,RO-cause_of,900050,"Underlying conditions such as immune deficiency, Wegener's granulomatosis, Churg-Strauss syndrome, aspirin hypersensitivity and allergic fungal sinusitis may present as rhinosinusitis",Churg-Strauss syndrome,hypersensitivity
503010581,7/14/2014 20:48:29,,1323089905,7/14/2014 20:48:26,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,2,68,,,7,83,VIRUS,VIRAL INFECTION,A VIRUS isolation was not,0-2-8-18-22,57-63-66-68-74-84-87-92,proof of a VIRAL INFECTION of SHML could,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:03:34,,1323098031,7/14/2014 21:03:21,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS isolation,2-8,68-74,VIRAL INFECTION,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:10:49,,1323101590,7/14/2014 21:10:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,2,68,,,7,83,VIRUS,VIRAL INFECTION,A VIRUS isolation,0-2-8,57-63-66-68-74-84-87,proof of a VIRAL INFECTION of SHML,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:17:49,,1323104677,7/14/2014 21:17:34,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS isolation,2-8,68-74-84-87,VIRAL INFECTION of SHML,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:30:11,,1323110818,7/14/2014 21:29:49,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS,2,68-74,VIRAL INFECTION,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:31:58,,1323111801,7/14/2014 21:31:49,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS,2,68-74,VIRAL INFECTION,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:34:32,,1323113168,7/14/2014 21:34:18,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS SHML,2-87,68-74-87,VIRAL INFECTION SHML,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 21:43:36,,1323119441,7/14/2014 21:43:31,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,2,68,,,7,83,VIRUS,VIRAL INFECTION,A VIRUS isolation was not,0-2-8-18-22,57-63-66-68-74-84-87-92,proof of a VIRAL INFECTION of SHML could,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 22:10:54,,1323134445,7/14/2014 22:10:37,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS,2,68-74,VIRAL INFECTION,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010581,7/14/2014 22:16:27,,1323138000,7/14/2014 22:16:14,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,2,68,,,7,83,VIRUS,VIRAL INFECTION,VIRUS,2,68-74,VIRAL INFECTION,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated.",2,68 74,2,68,7,83,-1,RO-has_causative_agent,903782,"A virus isolation was not possible, so that the definite proof of a viral infection of SHML could not be demonstrated",virus,viral infection
503010582,7/14/2014 20:50:04,,1323090848,7/14/2014 20:49:54,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to,67-71-85-88-100-114-118-128,0-4-20-36-40,The MYELODYSPLASTIC SYNDROMES are a,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 20:58:03,,1323095039,7/14/2014 20:57:17,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20-30,MYELODYSPLASTIC SYNDROMES (MDS),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:00:06,,1323096241,7/14/2014 20:59:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20-30,MYELODYSPLASTIC SYNDROMES (MDS),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:05:49,,1323099179,7/14/2014 21:05:29,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20-30,MYELODYSPLASTIC SYNDROMES (MDS),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:06:44,,1323099618,7/14/2014 21:06:22,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,are characterized by INEFFECTIVE HEMATOPOIESIS and evolution to myelogenous leukemias (AMLs),67-71-85-88-100-114-118-128-137-149-159,0-4-20-36-40-137-149-159,The MYELODYSPLASTIC SYNDROMES are a myelogenous leukemias (AMLs),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:12:59,,1323102510,7/14/2014 21:12:26,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20-30,MYELODYSPLASTIC SYNDROMES (MDS),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:16:15,,1323104059,7/14/2014 21:15:56,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20-30,MYELODYSPLASTIC SYNDROMES (MDS),The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:17:08,,1323104411,7/14/2014 21:17:00,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20,MYELODYSPLASTIC SYNDROMES,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 21:20:22,,1323105788,7/14/2014 21:19:40,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20,MYELODYSPLASTIC SYNDROMES,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010582,7/14/2014 22:00:53,,1323128567,7/14/2014 22:00:28,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,88,4,,,113,29,INEFFECTIVE HEMATOPOIESIS,MYELODYSPLASTIC SYNDROMES,INEFFECTIVE HEMATOPOIESIS,88-100,4-20,MYELODYSPLASTIC SYNDROMES,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches.,88 100,4 20,88,4,113,29,1,RO-disease_has_finding,901915,The myelodysplastic syndromes (MDS) are a family of disorders that are characterized by ineffective hematopoiesis and evolution to acute myelogenous leukemias (AMLs) that are strikingly refractory to current therapeutic approaches,ineffective hematopoiesis,myelodysplastic syndromes
503010583,7/14/2014 20:49:51,,1323090726,7/14/2014 20:49:49,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,108,117,,,112,132,ADHD,METHYLPHENIDATE,are sensitive to ADHD and methylphenidate has,91-95-105-108-113-117-133,105-108-113-117-133-137-142,to ADHD and METHYLPHENIDATE has been shown,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 20:59:21,,1323095866,7/14/2014 20:58:55,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD,108,117,METHYLPHENIDATE,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:14:34,,1323103242,7/14/2014 21:14:20,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD,108,117,METHYLPHENIDATE,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:17:33,,1323104577,7/14/2014 21:17:20,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD,108,117,METHYLPHENIDATE,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:21:04,,1323106037,7/14/2014 21:20:14,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,108,117,,,112,132,ADHD,METHYLPHENIDATE,Operant behavioral short term memory simple discriminations ADHD methylphenidate normalize ADHD performance short term memory task.,0-8-46-52-57-68-75-108-117-151-161-166-183-189-194-201,0-8-46-52-57-75-108-117-151-161-166-183-189-194-201,Operant behavioral short term memory discriminations ADHD METHYLPHENIDATE normalize ADHD performance short term memory task.,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:30:41,,1323111105,7/14/2014 21:30:16,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD ADHD,108-161,108-117-161,ADHD METHYLPHENIDATE ADHD,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:39:16,,1323116031,7/14/2014 21:39:12,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,108,117,,,112,132,ADHD,METHYLPHENIDATE,are sensitive to ADHD and methylphenidate has,91-95-105-108-113-117-133,105-108-113-117-133-137-142,to ADHD and METHYLPHENIDATE has been shown,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 21:47:41,,1323122663,7/14/2014 21:47:29,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD,108,117,METHYLPHENIDATE,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 22:05:54,,1323131429,7/14/2014 22:05:40,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD and methylphenidate,108-113-117,108-113-117,ADHD and METHYLPHENIDATE,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010583,7/14/2014 22:13:21,,1323136003,7/14/2014 22:12:35,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,108,117,,,112,132,ADHD,METHYLPHENIDATE,ADHD methylphenidate ADHD,108-117-161,108-117-161,ADHD METHYLPHENIDATE ADHD,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task.",108,117,108,117,112,132,1,RO-may_treat,908175,"Operant behavioral tasks that model learning, short-term memory and simple discriminations are sensitive to ADHD and methylphenidate has been shown to normalize ADHD performance in a short-term memory task",ADHD,methylphenidate
503010584,7/14/2014 20:48:31,,1323089956,7/14/2014 20:48:30,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,as well as SEIZURE prone rodents exhibit,27-30-35-38-46-52-60,0-5-13-17-27-30-35,"Both normal, NON EPILEPTIC as well as","Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 20:53:25,,1323092567,7/14/2014 20:53:13,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE prone,38-46,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 20:59:23,,1323095878,7/14/2014 20:59:04,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE prone rodents,38-46-52,13-17-52,NON EPILEPTIC rodents,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:03:26,,1323097959,7/14/2014 21:03:03,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE prone rodents,38-46-52,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:14:39,,1323103290,7/14/2014 21:14:33,elite,1.0,27888773,GBR,"","",128.199.166.81,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,as well as SEIZURE prone rodents exhibit,27-30-35-38-46-52-60,0-5-13-17-27-30-35,"Both normal, NON EPILEPTIC as well as","Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:14:39,,1323103297,7/14/2014 21:14:20,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE,38,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:19:32,,1323105413,7/14/2014 21:19:06,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE prone,38-46,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:26:36,,1323108823,7/14/2014 21:26:25,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE,38,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:28:22,,1323109713,7/14/2014 21:28:05,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE,38,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010584,7/14/2014 21:54:45,,1323125961,7/14/2014 21:54:33,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,38,13,,,45,26,SEIZURE,NON-EPILEPTIC,SEIZURE,38,13-17,NON EPILEPTIC,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure.",38,13 17,38,13,45,26,-1,RO-has_definitional_manifestation,904835,"Both normal, non-epileptic as well as seizure-prone rodents exhibit a spectrum of anxiogenic-like behaviors in response to stressor exposure",seizure,non-epileptic
503010585,7/14/2014 20:49:30,,1323090489,7/14/2014 20:49:17,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 20:52:00,,1323091837,7/14/2014 20:51:46,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,genetic disorder with MENTAL RETARDATION and caused by,40-48-57-62-69-81-85-92,81-85-92-95-103,and caused by TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 20:57:55,,1323094960,7/14/2014 20:57:44,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 21:29:41,,1323110556,7/14/2014 21:29:23,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 21:30:12,,1323110833,7/14/2014 21:29:52,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 21:33:47,,1323112733,7/14/2014 21:31:25,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 21:33:49,,1323112754,7/14/2014 21:33:39,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 22:06:31,,1323131796,7/14/2014 22:06:15,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 22:08:48,,1323133207,7/14/2014 22:08:07,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,Down syndrome (DS) genetic disorder with MENTAL RETARDATION caused by trisomy 21.,0-5-14-40-48-57-62-69-85-92-95-103,5-14-40-48-57-62-69-85-92-95-103-0,Down syndrome (DS) genetic disorder with mental retardation caused by TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010585,7/14/2014 22:14:36,,1323136870,7/14/2014 22:14:14,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,62,95,,,80,105,MENTAL RETARDATION,TRISOMY 21,MENTAL RETARDATION,62-69,95-103,TRISOMY 21.,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21.,62 69,95 103,62,95,80,105,1,RO-has_manifestation,906118,Down syndrome (DS) is the most frequent genetic disorder with mental retardation and caused by trisomy 21,mental retardation,trisomy 21
503010586,7/14/2014 21:06:01,,1323099283,7/14/2014 21:05:50,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 21:07:22,,1323099989,7/14/2014 21:07:04,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 21:08:43,,1323100593,7/14/2014 21:08:30,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,in suppressing the INFLAMMATION.,139-142-154-158,104-109-120-124-139-142-154,both miconazole and HYDROCORTISONE in suppressing the,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 21:12:34,,1323102351,7/14/2014 21:12:11,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 21:31:03,,1323111322,7/14/2014 21:30:41,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 21:34:17,,1323113016,7/14/2014 21:33:55,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124-158,HYDROCORTISONE inflammation.,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 22:02:13,,1323129220,7/14/2014 22:01:48,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 22:06:17,,1323131645,7/14/2014 22:05:48,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 22:09:43,,1323133737,7/14/2014 22:09:06,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010586,7/14/2014 22:11:16,,1323134693,7/14/2014 22:10:53,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,158,124,,,170,138,INFLAMMATION,HYDROCORTISONE,INFLAMMATION.,158,124,HYDROCORTISONE,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation.,158,124,158,124,170,138,1,RO-may_treat,908222,Daktacort treatment induced a significant improvement of all symptoms within 1 week and was superior to both miconazole and hydrocortisone in suppressing the inflammation,inflammation,hydrocortisone
503010587,7/14/2014 20:45:02,,1323088214,7/14/2014 20:44:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,95,60,,,102,68,ASCITES,HEPATOMA,"mouse ASCITES hepatoma 134,",89-95-103-112,44-52-60,"Yoshida ascites HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 20:47:16,,1323089323,7/14/2014 20:47:07,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,95,60,,,102,68,ASCITES,HEPATOMA,"Rhodamine sarcoma, mouse ASCITES hepatoma 134, and",70-80-89-95-103-112-117,39-44-52-60-70-80-89,"from Yoshida ascites HEPATOMA, Rhodamine sarcoma, mouse","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:02:58,,1323097708,7/14/2014 21:02:41,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,95,60,,,102,68,ASCITES,HEPATOMA,"mouse ASCITES hepatoma 134,",89-95-103-112,44-52-60,"Yoshida ascites HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:10:19,,1323101331,7/14/2014 21:09:52,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,95,60,,,102,68,ASCITES,HEPATOMA,"Rhodamine sarcoma, mouse ASCITES hepatoma 134, and Ehrlich ascites carcinoma cells",70-80-89-95-103-112-117-121-129-137-147,39-44-52-60-70-80-89-95-103-112-117-121-129-137-147,"from Yoshida ascites HEPATOMA, Rhodamine sarcoma, mouse ascites hepatoma 134, and Ehrlich ascites carcinoma cells","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:12:11,,1323102219,7/14/2014 21:11:56,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,95,60,,,102,68,ASCITES,HEPATOMA,"Rhodamine sarcoma, mouse ASCITES hepatoma 134, and",70-80-89-95-103-112-117,39-44-52-60-70-80-89,"from Yoshida ascites HEPATOMA, Rhodamine sarcoma, mouse","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:16:33,,1323104179,7/14/2014 21:15:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,95,60,,,102,68,ASCITES,HEPATOMA,"mouse ASCITES hepatoma - 134,",89-95-103-111-112,44-52-60,"Yoshida ascites HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:31:00,,1323111273,7/14/2014 21:30:41,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,95,60,,,102,68,ASCITES,HEPATOMA,ASCITES,95,60,"HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:48:33,,1323123086,7/14/2014 21:48:21,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,95,60,,,102,68,ASCITES,HEPATOMA,ASCITES,95,60,"HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 21:59:19,,1323127800,7/14/2014 21:58:24,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,95,60,,,102,68,ASCITES,HEPATOMA,"Rhodamine sarcoma, mouse ASCITES hepatoma 134,",70-80-89-95-103-112,44-52-60-70-80-89,"Yoshida ascites HEPATOMA, Rhodamine sarcoma, mouse","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010587,7/14/2014 22:07:30,,1323132427,7/14/2014 22:06:45,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,95,60,,,102,68,ASCITES,HEPATOMA,"mouse ASCITES hepatoma 134,",89-95-103-112,44-52-60,"Yoshida ascites HEPATOMA,","The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides.",95,60,95,60,102,68,-1,RO-disease_may_have_finding,902971,"The fidelity levels of DNA polymerases from Yoshida ascites hepatoma, Rhodamine sarcoma, mouse ascites hepatoma-134, and Ehrlich ascites carcinoma cells derived from rats and mice are very high for in-vitro DNA synthesis on synthetic polynucleotides",ascites,hepatoma
503010588,7/14/2014 20:46:23,,1323088972,7/14/2014 20:46:13,prodege,1,12971342,USA,CA,Los Angeles,198.101.91.82,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Classes I II ANGINA PECTORIS, but the efficacy",121-129-131-134-141-151-155-159,176-184-194-199-211-217-222,therapy increased when ANTIANGINAL drugs were used,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 20:57:57,,1323094978,7/14/2014 20:57:17,sendearnings,1,20717796,USA,CA,San Jose,99.27.90.128,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Classes I II ANGINA PECTORIS, but the efficacy",121-129-131-134-141-151-155-159,176-184-194-199-211-217-222,therapy increased when ANTIANGINAL drugs were used,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 20:58:12,,1323095133,7/14/2014 20:57:45,elite,1,26544151,GBR,"","",94.196.251.237,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"ANGINA PECTORIS,",134-141,199,ANTIANGINAL,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:01:54,,1323097138,7/14/2014 21:01:20,neodev,1,21515166,NLD,11,Nootdorp,83.86.58.179,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Functional Classes I II ANGINA PECTORIS,",110-121-129-131-134-141,159-168-176-184-194-199-211-217-222-171,efficacy of drug therapy increased when ANTIANGINAL drugs were used,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:05:05,,1323098844,7/14/2014 21:04:17,clixsense,1,26889820,GBR,C3,Shelford,92.18.120.203,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"ANGINA PECTORIS,",134-141,199-211,ANTIANGINAL drugs,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:16:05,,1323103985,7/14/2014 21:15:51,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Classes I II ANGINA PECTORIS,",121-129-131-134-141,199,ANTIANGINAL,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:16:39,,1323104211,7/14/2014 21:16:23,prodege,1,7664351,USA,NY,Cicero,74.111.0.21,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Functional Classes I II ANGINA PECTORIS,",110-121-129-131-134-141,159-171-176-184-194-199-211-217-222-288-293-300,efficacy drug therapy increased when ANTIANGINAL drugs were used with severe angina.,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:20:55,,1323105973,7/14/2014 21:20:43,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Classes I II ANGINA PECTORIS,",121-129-131-134-141,199-211,ANTIANGINAL drugs,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:23:58,,1323107428,7/14/2014 21:22:57,clixsense,1,20614047,USA,WA,Deer Park,174.32.162.10,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"Classes I II ANGINA PECTORIS, antianginal severe angina.",121-129-131-134-141-293-300-199,121-130-131-134-141-199-293-300-129,"Classes I - II angina pectoris, ANTIANGINAL severe angina.","Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010588,7/14/2014 21:27:53,,1323109491,7/14/2014 21:27:29,clixsense,1,19803139,NLD,06,Veldhoven,212.61.84.196,134,199,,,149,210,ANGINA PECTORIS,ANTIANGINAL,"ANGINA PECTORIS,",134-141,199-211,ANTIANGINAL drugs,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina.",134 141,199,134,199,149,210,1,RO-may_prevent,907278,"Monotherapy with the running pulse magnetic field was found to produce an antianginal effect in patients with Functional Classes I-II angina pectoris, but the efficacy of drug therapy increased when antianginal drugs were used in combination with running pulse magnetic field in patients with severe angina",angina pectoris,antianginal
503010589,7/14/2014 21:13:17,,1323102637,7/14/2014 21:13:13,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,Review) Benperidol for SCHIZOPHRENIA Review) Depot,174-183-194-198-222-231,253-267-277-286-297-301,schizophrenia (Cochrane Review) OLANZAPINE for schizophrenia,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 21:31:47,,1323111725,7/14/2014 21:31:17,clixsense,1,19162475,GBR,M3,Frome,82.33.126.30,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286,OLANZAPINE,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:03:58,,1323130222,7/14/2014 22:02:34,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,severe mental illness Risperidone atypical antipsychotic medication schizophrenia Perazine schizophrenia Benperidol SCHIZOPHRENIA Depot risperidone schizophrenia Olanzapine schizophrenia schizophrenia learning disability Electroconvulsive therapy schizophrenia Beta blocker supplementation schizophrenia Depot fluphenazine schizophrenia Carbamazepine schizophrenia schizoaffective psychoses,0-7-14-41-66-75-89-104-137-150-183-198-231-237-253-286-301-379-397-406-436-466-499-504-512-559-592-598-615-648-666-684-700-454,0-7-14-41-66-75-89-104-137-150-183-198-231-237-253-286-301-334-379-397-406-436-454-466-499-504-512-559-592-598-615-648-666-684-700,severe mental illness Risperidone atypical antipsychotic medication schizophrenia Perazine schizophrenia Benperidol schizophrenia Depot risperidone schizophrenia OLANZAPINE schizophrenia Antipsychotic schizophrenia learning disability Electroconvulsive therapy schizophrenia Beta blocker supplementation schizophrenia Depot fluphenazine schizophrenia Carbamazepine schizophrenia schizoaffective psychoses,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:08:11,,1323132877,7/14/2014 22:07:46,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286,OLANZAPINE,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:09:38,,1323133715,7/14/2014 22:08:22,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,Benperidol for SCHIZOPHRENIA (Cochrane Review),183-194-198-212-222,286-297-301-325-315,OLANZAPINE for schizophrenia (Cochrane Review),severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:10:08,,1323133954,7/14/2014 22:09:48,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286-297-301,OLANZAPINE for schizophrenia,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:10:51,,1323134417,7/14/2014 22:08:48,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,severe mental illness Risperidone atypical antipsychotic medication schizophrenia Perazine schizophrenia Benperidol for SCHIZOPHRENIA Depot risperidone schizophrenia Olanzapine for schizophrenia Antipsychotic medication schizophrenia Electroconvulsive therapy schizophrenia Beta blocker supplementation standard drug treatment for schizophrenia Depot fluphenazine for schizophrenia Carbamazepine for schizophrenia and schizoaffective psychoses,0-7-14-41-66-75-89-104-137-150-183-194-198-231-237-253-286-297-301-334-348-379-436-454-466-499-504-512-531-540-545-555-559-592-598-611-615-648-662-666-680-684-700,0-7-14-41-66-75-89-104-137-150-183-194-198-231-237-253-286-297-301-334-348-379-436-454-462-466-499-504-512-528-531-540-545-555-559-592-598-611-615-648-662-666-684-700-680,severe mental illness Risperidone atypical antipsychotic medication schizophrenia Perazine schizophrenia Benperidol for schizophrenia Depot risperidone schizophrenia OLANZAPINE for schizophrenia Antipsychotic medication schizophrenia Electroconvulsive therapy for schizophrenia Beta blocker supplementation of standard drug treatment for schizophrenia Depot fluphenazine for schizophrenia Carbamazepine for schizophrenia and schizoaffective psychoses,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:10:52,,1323134422,7/14/2014 22:10:26,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286,OLANZAPINE,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:14:08,,1323136547,7/14/2014 22:13:35,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286,OLANZAPINE,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010589,7/14/2014 22:16:12,,1323137866,7/14/2014 22:15:54,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,198,286,,,211,296,SCHIZOPHRENIA,OLANZAPINE,SCHIZOPHRENIA,198,286,OLANZAPINE,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane.,198,286,198,286,211,296,1,RO-may_treat,907749,severe mental illness (Cochrane Review)  Risperidone versus other atypical antipsychotic medication for schizophrenia (Cochrane Review)  Perazine for schizophrenia (Cochrane Review)  Benperidol for schizophrenia (Cochrane Review)  Depot risperidone for schizophrenia (Cochrane Review)  Olanzapine for schizophrenia (Cochrane Review)  Antipsychotic medication for those with both schizophrenia and learning disability (Cochrane Review)  Electroconvulsive therapy for schizophrenia (Cochrane Review)  Beta-blocker supplementation of standard drug treatment for schizophrenia (Cochrane Review)  Depot fluphenazine for schizophrenia (Cochrane Review)  Carbamazepine for schizophrenia and schizoaffective psychoses (Cochrane,schizophrenia,Olanzapine
503010590,7/14/2014 21:04:07,,1323098407,7/14/2014 21:03:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,41-51-59,bilateral ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:04:24,,1323098579,7/14/2014 21:03:59,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,51-59,ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:05:31,,1323099049,7/14/2014 21:05:15,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,41-51-59,bilateral ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:11:10,,1323101729,7/14/2014 21:10:50,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,95,51,,,101,65,LENSES,ECTOPIA LENTIS,extraction of both LENSES,76-87-90-95,20-27-41-51-59,"severe oligophrenia, bilateral ECTOPIA LENTIS","He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:11:55,,1323102089,7/14/2014 21:11:30,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,95,51,,,101,65,LENSES,ECTOPIA LENTIS,requiring extraction of both LENSES,66-87-90-95-76,20-27-41-51-59,"severe oligophrenia, bilateral ECTOPIA LENTIS","He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:17:16,,1323104475,7/14/2014 21:15:55,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,95,51,,,101,65,LENSES,ECTOPIA LENTIS,"severe oligophrenia, bilateral ectopia lentis of both LENSES",20-27-41-51-59-87-90-95,20-27-41-51-59-87-90-95,"severe oligophrenia, bilateral ECTOPIA LENTIS of both lenses","He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:27:27,,1323109303,7/14/2014 21:27:09,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,41-51-59,bilateral ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 21:39:20,,1323116092,7/14/2014 21:39:17,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,95,51,,,101,65,LENSES,ECTOPIA LENTIS,extraction of both LENSES and operatively corrected,76-87-90-95-102-106-118,20-27-41-51-59-66-76-87,"severe oligophrenia, bilateral ECTOPIA LENTIS requiring extraction of","He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 22:06:45,,1323131954,7/14/2014 22:06:28,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,41-51-59,bilateral ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010590,7/14/2014 22:07:00,,1323132117,7/14/2014 22:06:11,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,95,51,,,101,65,LENSES,ECTOPIA LENTIS,LENSES,95,51-59-41,bilateral ECTOPIA LENTIS,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides.",95,51 59,95,51,101,65,1,RO-has_finding_site,905467,"He had a history of severe oligophrenia, bilateral ectopia lentis requiring extraction of both lenses and operatively corrected genu valgum on both sides",lenses,ectopia lentis
503010591,7/14/2014 20:47:06,,1323089255,7/14/2014 20:47:04,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE prophylaxis was,0-6-13-18-33-45,49-62-65-75-91-102,"methotrexate (1 patient), CYCLOSPORINE patients), methotrexate","Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 20:49:27,,1323090441,7/14/2014 20:49:25,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE prophylaxis was,0-6-13-18-33-45,49-62-65-75-91-102,"methotrexate (1 patient), CYCLOSPORINE patients), methotrexate","Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 20:54:48,,1323093287,7/14/2014 20:54:22,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE,0-6-13-18,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:08:30,,1323100501,7/14/2014 21:07:54,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE (GVHD) prophylaxis,0-6-13-18-26-33,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:12:11,,1323102214,7/14/2014 21:11:14,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE prophylaxis,0-6-13-18-33,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:13:46,,1323102825,7/14/2014 21:13:42,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE prophylaxis was,0-6-13-18-33-45,49-62-65-75-91-102,"methotrexate (1 patient), CYCLOSPORINE patients), methotrexate","Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:26:20,,1323108667,7/14/2014 21:26:04,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE (GVHD),0-6-13-18-26,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:29:53,,1323110681,7/14/2014 21:29:40,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE,0-6-13-18,0-6-13-18-75,Graft versus host disease CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:33:27,,1323112559,7/14/2014 21:33:15,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE,0-6-13-18,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010591,7/14/2014 21:34:58,,1323113416,7/14/2014 21:34:43,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,0,75,,,25,87,GRAFT VERSUS HOST DISEASE,CYCLOSPORINE,GRAFT VERSUS HOST DISEASE (GVHD),0-6-13-18-26,75,CYCLOSPORINE,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients.",0 6 13 18,75,0,75,25,87,1,RO-may_prevent,907100,"Graft versus host disease (GVHD) prophylaxis was methotrexate (1 patient), cyclosporine (2 patients), methotrexate + cyclosporine (3 patients), cyclosporine + physical removal of T cells (2 patients",Graft versus host disease,cyclosporine
503010592,7/14/2014 20:47:23,,1323089363,7/14/2014 20:47:17,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,exposure and potential MERCURY toxicity.,137-146-150-160-168,117-120-125-129-137-146-150-160,at risk for MERCURY EXPOSURE and potential mercury,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 20:57:08,,1323094481,7/14/2014 20:56:27,elite,1.0,26544151,GBR,"","",94.196.251.237,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY toxicity.,160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 21:11:41,,1323101958,7/14/2014 21:11:37,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,exposure and potential MERCURY toxicity.,137-146-150-160-168,117-120-125-129-137-146-150-160,at risk for MERCURY EXPOSURE and potential mercury,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 21:26:49,,1323108919,7/14/2014 21:26:37,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY toxicity.,160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 21:29:26,,1323110407,7/14/2014 21:29:00,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY,160,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 21:30:12,,1323110837,7/14/2014 21:29:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY toxicity.,160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 21:55:13,,1323126094,7/14/2014 21:54:49,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,toxic effects of mercury mercury exposure and potential MERCURY toxicity.,9-15-23-26-137-146-150-160-168-129,9-15-23-26-129-137-146-150-160-168,toxic effects of mercury MERCURY EXPOSURE and potential mercury toxicity.,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 22:02:39,,1323129453,7/14/2014 22:02:14,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY toxicity.,160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 22:04:45,,1323130661,7/14/2014 22:04:33,instagc,1.0,18960682,GBR,"","",86.29.147.112,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,potential MERCURY toxicity.,150-160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010592,7/14/2014 22:10:13,,1323133995,7/14/2014 22:09:15,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,160,129,,,167,145,MERCURY,MERCURY EXPOSURE,MERCURY toxicity.,160-168,129-137,MERCURY EXPOSURE,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity.",160,129 137,160,129,167,145,-1,RO-has_causative_agent,903593,"Although toxic effects of mercury were not demonstrated at these levels of exposure, children of mercury workers are at risk for mercury exposure and potential mercury toxicity",mercury,mercury exposure
503010593,7/14/2014 20:49:47,,1323090678,7/14/2014 20:49:40,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN,32,59-69,LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 20:55:00,,1323093389,7/14/2014 20:54:52,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,32,59,,,36,77,SKIN,LICHENOID ERUPTION,Histological examination of the SKIN was consistent with,13-25-28-32-37-41-52-0,41-52-57-59-69-78-81-85,consistent with a LICHENOID ERUPTION in all cases.,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:11:03,,1323101696,7/14/2014 21:10:50,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN,32,59-69,LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:16:53,,1323104316,7/14/2014 21:16:40,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,32,59,,,36,77,SKIN,LICHENOID ERUPTION,examination of the SKIN was consistent with,13-25-28-32-37-41-52,0-13-41-52-57-59-69,Histological examination consistent with a LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:27:41,,1323109404,7/14/2014 21:27:31,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN,32,59-69,LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:30:45,,1323111120,7/14/2014 21:30:12,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN lichenoid eruption,32-59-69,32-59-69,skin LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:42:42,,1323118727,7/14/2014 21:42:07,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,32,59,,,36,77,SKIN,LICHENOID ERUPTION,examination of the SKIN was consistent with,13-25-28-32-37-41-52,41-52-57-59-69-78-81-85,consistent with a LICHENOID ERUPTION in all cases.,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:54:48,,1323125975,7/14/2014 21:54:15,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN lichenoid eruption,32-59-69,32-59-69,skin LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:57:16,,1323126836,7/14/2014 21:56:24,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,32,59,,,36,77,SKIN,LICHENOID ERUPTION,examination of the SKIN,13-25-28-32,59-69,LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010593,7/14/2014 21:59:38,,1323127940,7/14/2014 21:59:25,instagc,1.0,18960682,GBR,"","",86.29.147.112,32,59,,,36,77,SKIN,LICHENOID ERUPTION,SKIN,32,59-69,LICHENOID ERUPTION,Histological examination of the skin was consistent with a lichenoid eruption in all cases.,32,59 69,32,59,36,77,1,RO-has_finding_site,905296,Histological examination of the skin was consistent with a lichenoid eruption in all cases,skin,lichenoid eruption
503010594,7/14/2014 20:48:01,,1323089700,7/14/2014 20:47:58,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,the number of STAPHYLOCOCCUS AUREUS needed to produce,32-36-43-46-61-68-75-78,18-27-32-36-43-46-61,reported that the NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 20:48:26,,1323089899,7/14/2014 20:48:24,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,the number of STAPHYLOCOCCUS AUREUS needed to produce,32-36-43-46-61-68-75-78,18-27-32-36-43-46-61,reported that the NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:00:15,,1323096303,7/14/2014 20:59:46,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,STAPHYLOCOCCUS AUREUS,46-61,36,NUMBER,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:03:52,,1323098253,7/14/2014 21:03:27,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,STAPHYLOCOCCUS AUREUS,46-61,32-36-43-46-61,the NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:12:03,,1323102140,7/14/2014 21:10:54,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,STAPHYLOCOCCUS AUREUS,46-61,36-43-46-61,NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:26:19,,1323108651,7/14/2014 21:25:56,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,the number of STAPHYLOCOCCUS AUREUS,32-36-43-46-61,27-32-36-43-46-61,that the NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:32:30,,1323112058,7/14/2014 21:32:16,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,STAPHYLOCOCCUS AUREUS,46-61,36-46,NUMBER Staphylococcus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:33:28,,1323112563,7/14/2014 21:32:46,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,number of STAPHYLOCOCCUS AUREUS food - poisoning,36-43-46-61-88-93-92,36-43-46-61-88-92-93,NUMBER of Staphylococcus aureus food - poisoning,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:40:57,,1323117337,7/14/2014 21:40:43,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,STAPHYLOCOCCUS AUREUS,46-61,36-43-46-61,NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010594,7/14/2014 21:43:30,,1323119378,7/14/2014 21:43:26,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,46,36,,,67,42,STAPHYLOCOCCUS AUREUS,NUMBER,the number of STAPHYLOCOCCUS AUREUS needed to produce,32-36-43-46-61-68-75-78,18-27-32-36-43-46-61,reported that the NUMBER of Staphylococcus aureus,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning.",46 61,36,46,36,67,42,-1,RO-has_causative_agent,903885,"Some authors have reported that the number of Staphylococcus aureus needed to produce a food-poisoning is 10(6) CFU per gram of food, however, other authors have reported foods without microorganisms but these have produced food-poisoning",Staphylococcus aureus,number
503010595,7/14/2014 20:49:05,,1323090262,7/14/2014 20:48:49,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS,87-97-99,0-10-12-14-22-30-39-47-57-29,Hepatitis B e antigen (HBeAg) - negative CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 21:05:44,,1323099129,7/14/2014 21:05:20,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS mutants,87-97-99-105,0-10-12-14-22-30-39-47-57,Hepatitis B e antigen (HBeAg) negative CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 21:12:43,,1323102427,7/14/2014 21:12:03,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS mutants,87-97-99-105,39-47-57,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 21:29:37,,1323110537,7/14/2014 21:29:20,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS mutants,87-97-99-105,39-47-57,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 21:33:46,,1323112703,7/14/2014 21:33:28,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS,87-97-99,39-47-57,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 21:54:10,,1323125721,7/14/2014 21:53:54,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS,87-97-99,39-47-57,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 22:00:36,,1323128432,7/14/2014 21:58:44,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS,87-97-99,22-30-39-47-57,(HBeAg) negative CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 22:13:35,,1323136146,7/14/2014 22:13:00,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS mutants,87-97-99-105,30-39-47-57,negative CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 22:14:00,,1323136464,7/14/2014 22:13:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg) negative chronic hepatitis B HEPATITIS B VIRUS HBeAg.,0-10-12-14-22-30-39-47-57-87-97-99-131,0-10-12-14-22-30-39-47-57-87-97-99-131,Hepatitis B e antigen (HBeAg) negative CHRONIC HEPATITIS B hepatitis B virus HBeAg.,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010595,7/14/2014 22:17:05,,1323138395,7/14/2014 22:16:47,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,87,39,,,104,58,HEPATITIS B VIRUS,CHRONIC HEPATITIS B,HEPATITIS B VIRUS,87-97-99,39-47-57,CHRONIC HEPATITIS B,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg.,87 97 99,39 47 57,87,39,104,58,1,RO-has_causative_agent,903602,Hepatitis B e antigen (HBeAg)-negative chronic hepatitis B results from infection with hepatitis B virus mutants unable to produce HBeAg,hepatitis B virus,chronic hepatitis B
503010596,7/14/2014 20:47:55,,1323089624,7/14/2014 20:47:38,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS,12-16-22-30-40,78,"ECLAMPSIA,","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 20:54:37,,1323093201,7/14/2014 20:54:32,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,"non lupus related PREGNANCY COMPLICATIONS include preeclampsia or eclampsia,",12-16-22-30-40-54-62-75-78,54-62-75-78-89-103-107,"include preeclampsia or ECLAMPSIA, hypertension, the HELLP","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 20:57:43,,1323094837,7/14/2014 20:57:31,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS,12-16-22-30-40,78,"ECLAMPSIA,","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 21:13:12,,1323102605,7/14/2014 21:13:04,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS include preeclampsia or,12-16-22-30-40-54-62-75,54-62-75-78-89-103-107,"include preeclampsia or ECLAMPSIA, hypertension, the HELLP","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 21:32:08,,1323111876,7/14/2014 21:30:49,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,"PREGNANCY COMPLICATIONS preeclampsia or eclampsia, hypertension, HELLP syndrome, and thrombocytopenia.",30-40-62-75-78-89-107-113-127-123,30-40-62-75-78-89-107-113-127-123,"pregnancy complications preeclampsia or ECLAMPSIA, hypertension, HELLP syndrome, and thrombocytopenia.","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 21:50:28,,1323124130,7/14/2014 21:50:11,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS,12-16-22-30-40,78,"ECLAMPSIA,","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 22:00:33,,1323128416,7/14/2014 21:59:41,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,"non lupus related PREGNANCY COMPLICATIONS preeclampsia or eclampsia, hypertension, HELLP syndrome, and thrombocytopenia.",12-16-22-30-40-62-75-78-89-107-123-127-113,12-16-22-30-40-62-75-78-89-107-113-127-123,"non lupus related pregnancy complications preeclampsia or ECLAMPSIA, hypertension, HELLP syndrome, and thrombocytopenia.","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 22:04:01,,1323130232,7/14/2014 22:03:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS,12-16-22-30-40,78,"ECLAMPSIA,","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 22:05:40,,1323131264,7/14/2014 22:05:13,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,non lupus related PREGNANCY COMPLICATIONS,12-16-22-30-40,78-89-103,"ECLAMPSIA, hypertension, the","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010596,7/14/2014 22:14:26,,1323136807,7/14/2014 22:14:07,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,30,78,,,53,87,PREGNANCY COMPLICATIONS,ECLAMPSIA,PREGNANCY COMPLICATIONS,30-40,78,"ECLAMPSIA,","Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia.",30 40,78,30,78,53,87,-1,RO-disease_has_finding,901706,"Most common non-lupus-related pregnancy complications include preeclampsia or eclampsia, hypertension, the HELLP syndrome, and thrombocytopenia",pregnancy complications,eclampsia
503010597,7/14/2014 20:47:38,,1323089466,7/14/2014 20:47:35,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,72-79-84-87-100-109-127,13-16-24-29-46-54-58,in delayed type HYPERSENSITIVITY lesions was significantly,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 20:50:40,,1323091133,7/14/2014 20:50:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,higher than in EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,72-79-84-87-100-109-127,13-16-24-29-46-54-58,in delayed type HYPERSENSITIVITY lesions was significantly,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 20:50:56,,1323091313,7/14/2014 20:49:51,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,delayed type hypersensitivity lesions EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,16-24-29-46-87-100-109-127,16-24-29-46-87-100-109-127,delayed type HYPERSENSITIVITY lesions experimental allergic encephalomyelitis lesions.,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 20:51:46,,1323091736,7/14/2014 20:51:22,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,87-100-109-127,29-46,HYPERSENSITIVITY lesions,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 20:55:11,,1323093464,7/14/2014 20:54:49,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,87-100-109-127,16-24-29-46,delayed type HYPERSENSITIVITY lesions,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 21:02:23,,1323097394,7/14/2014 21:02:13,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,87-100-109,16-24-29,delayed type HYPERSENSITIVITY,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 21:04:07,,1323098415,7/14/2014 21:03:54,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,87-100-109-127,16-24-29-46,delayed type HYPERSENSITIVITY lesions,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 21:04:08,,1323098420,7/14/2014 21:03:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,87-100-109-127,16-24-29-46,delayed type HYPERSENSITIVITY lesions,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 21:05:50,,1323099181,7/14/2014 21:04:26,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,87-100-109,16-24-29,delayed type HYPERSENSITIVITY,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010597,7/14/2014 21:19:05,,1323105197,7/14/2014 21:18:50,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,87,29,,,126,45,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS,HYPERSENSITIVITY,EXPERIMENTAL ALLERGIC ENCEPHALOMYELITIS lesions.,87-100-109-127,16-24-29-46,delayed type HYPERSENSITIVITY lesions,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions.,87 100 109,29,87,29,126,45,-1,RO-cause_of,900459,Their number in delayed-type hypersensitivity lesions was significantly higher than in experimental allergic encephalomyelitis lesions,experimental allergic encephalomyelitis,hypersensitivity
503010598,7/14/2014 20:48:08,,1323089769,7/14/2014 20:48:06,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,host disease (GVHD) prophylaxis.,101-106-114-121,20-23-32-37-51-59-62-76,"or combined with MYCOPHENOLATE MOFETIL or methotrexate, was","Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 20:50:02,,1323090802,7/14/2014 20:49:26,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,graft versus host disease (GVHD),88-94-101-106-114,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 21:10:22,,1323101361,7/14/2014 21:10:14,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,host disease (GVHD) prophylaxis.,101-106-114-121,20-23-32-37-51-59-62-76,"or combined with MYCOPHENOLATE MOFETIL or methotrexate, was","Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 21:15:33,,1323103750,7/14/2014 21:15:20,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,graft versus host disease (GVHD) prophylaxis.,88-101-106-114-121-94,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 21:24:44,,1323107767,7/14/2014 21:24:26,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,(GVHD),114,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 21:28:25,,1323109744,7/14/2014 21:28:11,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,prophylaxis.,121,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 22:01:22,,1323128849,7/14/2014 22:00:55,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,(GVHD) prophylaxis.,114-121,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 22:02:02,,1323129150,7/14/2014 22:01:37,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,"Ciclosporine, mycophenolate mofetil or methotrexate, graft versus host disease (GVHD) prophylaxis.",0-37-51-59-62-88-101-106-114-121-94,0-37-51-59-62-88-94-101-106-114-121,"Ciclosporine, MYCOPHENOLATE MOFETIL or methotrexate, graft versus host disease (GVHD) prophylaxis.","Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 22:05:31,,1323131153,7/14/2014 22:04:36,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,"Ciclosporine, mycophenolate mofetil methotrexate, graft versus host disease (GVHD) prophylaxis.",0-37-51-62-88-101-106-114-121-94,0-20-37-51-62-76-88-94-101-106-114-121,"Ciclosporine, or MYCOPHENOLATE MOFETIL methotrexate, was graft versus host disease (GVHD) prophylaxis.","Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010598,7/14/2014 22:13:29,,1323136088,7/14/2014 22:12:56,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,115,37,,,119,58,GVHD,MYCOPHENOLATE MOFETIL,(GVHD) prophylaxis.,114-121,37-51,MYCOPHENOLATE MOFETIL,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis.",,37 51,115,37,119,58,1,RO-may_prevent,907052,"Ciclosporine, alone or combined with mycophenolate mofetil or methotrexate, was used as graft-versus-host disease (GVHD) prophylaxis",GVHD,mycophenolate mofetil
503010599,7/14/2014 20:44:17,,1323087861,7/14/2014 20:44:06,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 20:49:36,,1323090554,7/14/2014 20:49:33,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY is the most,0-9-20-23-27,32-41-54-57-66-70-74,frequent complication of DIABETES and the leading,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:02:10,,1323097276,7/14/2014 21:01:56,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:02:52,,1323097667,7/14/2014 21:02:20,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:07:48,,1323100151,7/14/2014 21:06:13,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY polyneuropathy,0-9-91,57-91,DIABETES polyneuropathy,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:12:56,,1323102489,7/14/2014 21:11:56,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY is the most frequent complication of diabetes polyneuropathy,0-9-20-23-27-32-41-57-91-54,0-9-32-41-54-57-66-70-74-91,Diabetic neuropathy frequent complication of DIABETES and the leading polyneuropathy,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:15:09,,1323103527,7/14/2014 21:14:54,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:23:36,,1323107242,7/14/2014 21:23:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:28:13,,1323109659,7/14/2014 21:27:49,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010599,7/14/2014 21:40:41,,1323117152,7/14/2014 21:40:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,0,57,,,19,65,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,0-9,57,DIABETES,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world.,0 9,57,0,57,19,65,1,RO-cause_of,900359,Diabetic neuropathy is the most frequent complication of diabetes and the leading cause of polyneuropathy in the Western world,Diabetic neuropathy,diabetes
503010600,7/14/2014 20:46:07,,1323088780,7/14/2014 20:45:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 20:50:31,,1323091059,7/14/2014 20:50:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 20:51:07,,1323091416,7/14/2014 20:50:51,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 20:53:27,,1323092579,7/14/2014 20:53:19,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,90,52,,,105,56,LYMPHADENOPATHY,PTLD,differential diagnosis of LYMPHADENOPATHY and fever post,64-77-87-90-106-110-116,26-37-40-52-57-60-64-77,importance of considering PTLD in the differential diagnosis,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 21:04:58,,1323098814,7/14/2014 21:04:47,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 21:10:33,,1323101454,7/14/2014 21:10:16,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,90,52,,,105,56,LYMPHADENOPATHY,PTLD,differential diagnosis of LYMPHADENOPATHY,64-77-87-90,52-57-60-64-77-90,PTLD in the differential diagnosis lymphadenopathy,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 21:14:28,,1323103159,7/14/2014 21:14:06,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 21:43:24,,1323119289,7/14/2014 21:43:04,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,90,52,,,105,56,LYMPHADENOPATHY,PTLD,differential diagnosis of LYMPHADENOPATHY and fever post,64-77-87-90-106-110-116,26-37-40-52-57-60-64,importance of considering PTLD in the differential,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 21:54:32,,1323125842,7/14/2014 21:54:10,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,90,52,,,105,56,LYMPHADENOPATHY,PTLD,differential diagnosis of LYMPHADENOPATHY and fever,64-77-87-90-106-110,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010600,7/14/2014 22:01:46,,1323129018,7/14/2014 22:01:10,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,90,52,,,105,56,LYMPHADENOPATHY,PTLD,LYMPHADENOPATHY,90,52,PTLD,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT.,90,52,90,52,105,56,1,RO-disease_may_have_finding,902895,These cases highlight the importance of considering PTLD in the differential diagnosis of lymphadenopathy and fever post ASCT,lymphadenopathy,PTLD
503010601,7/14/2014 20:52:16,,1323091951,7/14/2014 20:51:47,elite,1.0,26544151,GBR,"","",94.196.251.237,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293,"INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:03:40,,1323098112,7/14/2014 21:03:16,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293,"INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:15:10,,1323103533,7/14/2014 21:14:55,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293-305-309,"INTRAEPITHELIAL NEOPLASIA), and carcinoma","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:17:26,,1323104548,7/14/2014 21:17:18,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293,"INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:40:21,,1323116838,7/14/2014 21:37:40,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,"flat urinary bladder lesions: reactive atypia, atypia of unknown significance, DYSPLASIA (low grade intraepithelial neoplasia), and carcinoma in situ (high - grade intraepithelial neoplasia.",182-190-198-207-216-224-231-234-242-256-266-271-277-293-305-309-319-322-327-332-333-339-355-177,177-182-190-198-207-216-224-231-234-242-256-266-271-277-293-305-309-319-322-327-332-333-339-355,"flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low grade INTRAEPITHELIAL NEOPLASIA), and carcinoma in situ (high - grade intraepithelial neoplasia.","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:52:37,,1323125066,7/14/2014 21:52:13,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,"DYSPLASIA (low grade intraepithelial neoplasia),",256-266-271-277-293,266-271-277-293,"(low grade INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 21:52:45,,1323125147,7/14/2014 21:52:28,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,256-266-271-277-293,"dysplasia (low grade INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 22:05:29,,1323131141,7/14/2014 22:04:39,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293,"INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 22:06:34,,1323131850,7/14/2014 22:05:52,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,"urinary bladder lesions: reactive atypia, atypia DYSPLASIA (low grade intraepithelial neoplasia), carcinoma situ (high grade intraepithelial neoplasia.",182-190-198-207-216-224-256-266-271-277-293-309-322-327-333-339-355,182-190-198-207-216-224-256-266-271-277-293-305-309-319-322-327-333-339-355,"urinary bladder lesions: reactive atypia, atypia dysplasia (low grade INTRAEPITHELIAL NEOPLASIA), and carcinoma in situ (high grade intraepithelial neoplasia.","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010601,7/14/2014 22:12:28,,1323135432,7/14/2014 22:11:25,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,256,277,,,265,302,DYSPLASIA,INTRAEPITHELIAL NEOPLASIA,DYSPLASIA,256,277-293,"INTRAEPITHELIAL NEOPLASIA),","In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia.",256,277 293,256,277,265,302,-1,RO-disease_has_finding,901553,"In 1998, the World Health Organization/ International Society of Urological Pathology (WHO/ISUP) published a consensus classification that included the following categories for flat urinary bladder lesions: reactive atypia, atypia of unknown significance, dysplasia (low-grade intraepithelial neoplasia), and carcinoma in situ (high-grade intraepithelial neoplasia",dysplasia,intraepithelial neoplasia
503010602,7/14/2014 21:05:27,,1323099014,7/14/2014 21:05:06,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:11:49,,1323102025,7/14/2014 21:11:43,elite,1.0,27888773,GBR,"","",128.199.166.81,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,Erythematosus Treatment of DISCOID LUPUS ERYTHEMATOSUS and systemic lupus,6-21-31-34-42-48-62-66-75,48-62-66-75-81,erythematosus and systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:12:09,,1323102197,7/14/2014 21:11:56,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,Erythematosus Treatment of DISCOID LUPUS ERYTHEMATOSUS and systemic lupus,6-21-31-34-42-48-62-66-75,48-62-66-75-81,erythematosus and systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:12:12,,1323102220,7/14/2014 21:12:09,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,Erythematosus Treatment of DISCOID LUPUS ERYTHEMATOSUS and systemic lupus,6-21-31-34-42-48-62-66-75,48-62-66-75-81,erythematosus and systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:33:55,,1323112839,7/14/2014 21:33:39,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:40:18,,1323116812,7/14/2014 21:40:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 21:58:16,,1323127242,7/14/2014 21:57:59,instagc,1.0,18960682,GBR,"","",86.29.147.112,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 22:10:35,,1323134200,7/14/2014 22:10:18,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,75,LUPUS,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 22:11:41,,1323134945,7/14/2014 22:11:22,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010602,7/14/2014 22:15:09,,1323137168,7/14/2014 22:14:55,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,34,75,,,61,80,DISCOID LUPUS ERYTHEMATOSUS,LUPUS,DISCOID LUPUS ERYTHEMATOSUS,34-42-48,66-75-81,systemic LUPUS erythematosus.,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus.,34 42 48,75,34,75,61,80,-1,RO-cause_of,900301,Lupus Erythematosus  Treatment of discoid lupus erythematosus and systemic lupus erythematosus,discoid lupus erythematosus,lupus
503010603,7/14/2014 20:49:25,,1323090426,7/14/2014 20:48:32,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,"LEUKOENCEPHALOPATHY (CADASIL),",125-145,156-165-175-185,cerebral autosomal recessive arteriopathy,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 20:53:40,,1323092730,7/14/2014 20:52:14,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,LEUKOENCEPHALOPATHY,125,125-145,"leukoencephalopathy (CADASIL),","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:00:46,,1323096595,7/14/2014 21:00:25,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,LEUKOENCEPHALOPATHY,125,125-156-165-175,leukoencephalopathy cerebral autosomal recessive,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:03:17,,1323097885,7/14/2014 21:02:59,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,"LEUKOENCEPHALOPATHY (CADASIL),",125-145,125-145,"leukoencephalopathy (CADASIL),","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:05:52,,1323099207,7/14/2014 21:05:29,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,LEUKOENCEPHALOPATHY,125,125,leukoencephalopathy,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:07:49,,1323100209,7/14/2014 21:07:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,"LEUKOENCEPHALOPATHY (CADASIL),",125-145,125-145,"leukoencephalopathy (CADASIL),","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:15:08,,1323103541,7/14/2014 21:14:43,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,LEUKOENCEPHALOPATHY,125,145,"(CADASIL),","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:25:06,,1323107954,7/14/2014 21:24:46,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,"LEUKOENCEPHALOPATHY (CADASIL),",125-145,145,"(CADASIL),","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:25:55,,1323108440,7/14/2014 21:25:41,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,subcortical infarcts and LEUKOENCEPHALOPATHY cerebral autosomal,100-112-121-125-156-165,100-112-121-125-145-156-165,"subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal","Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010603,7/14/2014 21:27:15,,1323109143,7/14/2014 21:26:40,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,125,146,,,144,153,LEUKOENCEPHALOPATHY,CADASIL,LEUKOENCEPHALOPATHY,125,,,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS.",125,,125,146,144,153,-1,RO-has_manifestation,906350,"Monogenic stroke disorders include conditions such as cerebral autosomal dominant arteriopathy with subcortical infarcts and leukoencephalopathy (CADASIL), cerebral autosomal recessive arteriopathy with subcortical infarcts and leukoencephalopathy (CARASIL) and hereditary endotheliopathy, retinopathy, nephropathy and stroke (HERNS",leukoencephalopathy,CADASIL
503010604,7/14/2014 21:02:52,,1323097664,7/14/2014 21:01:07,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,303,234,,,307,251,ADHD,TOURETTE SYNDROME,"hyperactivity disorder (ADHD) probands, their first",279-293-302-309-319-325,217-226-229-234-243-257-261,examined in 1177 TOURETTE SYNDROME and attention,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:06:53,,1323099714,7/14/2014 21:06:30,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,303,234,,,307,251,ADHD,TOURETTE SYNDROME,hyperactivity disorder (ADHD),279-293-302,234-243-252,TOURETTE SYNDROME (TS),"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:08:03,,1323100309,7/14/2014 21:07:44,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,303,234,,,307,251,ADHD,TOURETTE SYNDROME,attention deficit hyperactivity disorder,261-271-279-293,234-243,TOURETTE SYNDROME,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:13:30,,1323102738,7/14/2014 21:13:04,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,303,234,,,307,251,ADHD,TOURETTE SYNDROME,hyperactivity disorder (ADHD),279-293-302,234-243,TOURETTE SYNDROME,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:13:48,,1323102837,7/14/2014 21:13:43,elite,1.0,27888773,GBR,"","",128.199.166.81,303,234,,,307,251,ADHD,TOURETTE SYNDROME,"hyperactivity disorder (ADHD) probands, their first",279-293-302-309-319-325,217-226-229-234-243-257-261,examined in 1177 TOURETTE SYNDROME and attention,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:15:56,,1323103901,7/14/2014 21:15:01,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,303,234,,,307,251,ADHD,TOURETTE SYNDROME,"genetic factors oppositional defiant disorder (ODD) conduct disorder (CD), DSM III R criteria, Tourette syndrome (TS) attention deficit hyperactivity disorder (ADHD)",23-31-42-55-63-72-82-90-99-143-147-151-153-234-243-252-261-271-279-293-302,23-31-42-55-63-72-82-90-99-143-147-151-153-234-243-252-261-271-279-293-302,"genetic factors oppositional defiant disorder (ODD) conduct disorder (CD), DSM III R criteria, TOURETTE SYNDROME (TS) attention deficit hyperactivity disorder (ADHD)","To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 21:23:59,,1323107433,7/14/2014 21:23:13,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,303,234,,,307,251,ADHD,TOURETTE SYNDROME,Tourette syndrome hyperactivity disorder,234-279-293-243,234-243,TOURETTE SYNDROME,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 22:06:42,,1323131928,7/14/2014 22:06:19,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,303,234,,,307,251,ADHD,TOURETTE SYNDROME,(ADHD),302,234-243,TOURETTE SYNDROME,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 22:08:21,,1323132985,7/14/2014 22:07:36,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,303,234,,,307,251,ADHD,TOURETTE SYNDROME,attention deficit hyperactivity disorder (ADHD),261-271-279-293-302,234-243-252,TOURETTE SYNDROME (TS),"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010604,7/14/2014 22:11:08,,1323134607,7/14/2014 22:10:49,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,303,234,,,307,251,ADHD,TOURETTE SYNDROME,attention deficit hyperactivity disorder (ADHD),261-271-279-293-302,234-243-252,TOURETTE SYNDROME (TS),"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls.",,234 243,303,234,307,251,-1,RO-has_manifestation,906017,"To examine the role of genetic factors in oppositional defiant disorder (ODD) and conduct disorder (CD), 38 variables relating to the relevant DSM-III-R criteria, as well as other angry and aggressive behaviors, were examined in 1177 Tourette syndrome (TS) and attention-deficit hyperactivity disorder (ADHD) probands, their first-degree relatives, and controls",ADHD,Tourette syndrome
503010605,7/14/2014 20:47:58,,1323089651,7/14/2014 20:47:51,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,VIII; Kogenate Uses HEMOPHILIA A Prevention and control,192-198-208-214-225-228-239-243,135-141-147-158-165-185-192,BL500 (VA) Synonyms: FACTOR VIII Factor VIII;,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 20:49:35,,1323090559,7/14/2014 20:49:13,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A,214-225,158-165,FACTOR VIII,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 20:50:55,,1323091312,7/14/2014 20:50:40,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,VIII; Kogenate Uses HEMOPHILIA A Prevention and control,192-198-208-214-225-228-239-243,135-141-147-158-165-185-192,BL500 (VA) Synonyms: FACTOR VIII Factor VIII;,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:02:20,,1323097350,7/14/2014 21:01:49,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A,214-225,158-165,FACTOR VIII,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:09:18,,1323100816,7/14/2014 21:08:31,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A hemorrhagic episodes,214-225-254-266,158-165-228-239-243-251-254-266,FACTOR VIII Prevention and control of hemorrhagic episodes,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:13:14,,1323102613,7/14/2014 21:13:08,elite,1.0,27888773,GBR,"","",128.199.166.81,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,VIII; Kogenate Uses HEMOPHILIA A Prevention and control,192-198-208-214-225-228-239-243,135-141-147-158-165-185-192,BL500 (VA) Synonyms: FACTOR VIII Factor VIII;,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:15:19,,1323103596,7/14/2014 21:14:35,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A,214-225,158-165,FACTOR VIII,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:28:15,,1323109666,7/14/2014 21:27:56,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A,214-225,158-165-214,FACTOR VIII Hemophilia,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:32:58,,1323112335,7/14/2014 21:32:48,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,HEMOPHILIA A,214-225,158-165,FACTOR VIII,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010605,7/14/2014 21:42:06,,1323118263,7/14/2014 21:40:44,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,214,158,,,226,169,HEMOPHILIA A,FACTOR VIII,VIII; Kogenate Uses HEMOPHILIA A Prevention and A,192-198-208-214-225-228-239-383,135-141-147-158-165-185-192,BL500 (VA) Synonyms: FACTOR VIII Factor VIII;,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40.",214 225,158 165,214,158,226,169,1,RO-may_treat,907524,"1 ,   2 ,   3 ,   4 ,   7 ,   8 ,   9 ,   10 ,   40 ,   49 ,   50 ,   69 ,   77 ,   120 ,   121 ,   122  Class:  Hemostatics 20:28.16; BL500 (VA)  Synonyms:  Factor VIII (Recombinant); Factor VIII; Kogenate  Uses  Hemophilia A  Prevention and control of hemorrhagic episodes in patients with a deficiency of coagulation factor VIII (antihemophilic factor) associated with hemophilia A (classic hemophilia);  1 ,   2 ,   3 ,   4 ,   5 ,   9 ,   23 ,   24 ,   40",Hemophilia A,Factor VIII
503010606,7/14/2014 20:53:12,,1323092471,7/14/2014 20:53:03,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS (stereo biopsy DCIS.,89-109-117-124,109-124-117,(stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 20:55:09,,1323093450,7/14/2014 20:55:02,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,one for residual MICROCALCIFICATIONS biopsy DCIS.,72-76-80-89-117-124,89-109-117-124-80,residual microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:05:59,,1323099267,7/14/2014 21:05:45,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,residual MICROCALCIFICATIONS,80-89,109-117-124,(stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:08:52,,1323100637,7/14/2014 21:08:44,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,one for residual MICROCALCIFICATIONS biopsy DCIS.,72-76-80-89-117-124,89-109-117-124,microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:10:00,,1323101224,7/14/2014 21:09:43,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,residual MICROCALCIFICATIONS,89-80,109-117-124-89,microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:14:28,,1323103152,7/14/2014 21:12:58,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,residual MICROCALCIFICATIONS biopsy DCIS.,80-89-117-124,89-109-117-124-80,residual microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:24:40,,1323107724,7/14/2014 21:24:02,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,89,124,DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:28:10,,1323109623,7/14/2014 21:28:02,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,MICROCALCIFICATIONS,89,124,DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 21:46:03,,1323121503,7/14/2014 21:45:59,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,one for residual MICROCALCIFICATIONS biopsy DCIS.,72-76-80-89-117-124,89-109-117-124,microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010606,7/14/2014 22:01:06,,1323128681,7/14/2014 22:00:54,instagc,1.0,18960682,GBR,"","",86.29.147.112,89,124,,,108,128,MICROCALCIFICATIONS,DCIS,residual MICROCALCIFICATIONS (stereo biopsy DCIS.,80-89-117-124-109,89-109-117-124-80,residual microcalcifications (stereo biopsy DCIS.,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS.,89,124,89,124,108,128,1,RO-disease_may_have_finding,902520,Ten patients (36%) required reoperations: nine for positive margins and one for residual microcalcifications (stereo biopsy DCIS,microcalcifications,DCIS
503010607,7/14/2014 20:51:50,,1323091744,7/14/2014 20:51:29,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,49,SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 20:55:19,,1323093520,7/14/2014 20:54:35,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,34-42-49,culture proven SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 21:04:47,,1323098756,7/14/2014 21:04:16,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,was lower in CULTURE NEGATIVE SEPSIS,85-89-95-98-106-115,31-34-42-49-56-60-69-89-95-98-106-115,in culture proven SEPSIS and absolute count lower in culture negative sepsis,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 21:14:43,,1323103320,7/14/2014 21:14:29,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,34-42-49,culture proven SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 21:28:01,,1323109521,7/14/2014 21:27:52,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,49,SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 21:32:14,,1323111925,7/14/2014 21:31:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,49,SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 21:37:37,,1323114924,7/14/2014 21:37:02,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,sepsis CULTURE NEGATIVE SEPSIS,49-98-106-115,49-98-106-115,SEPSIS culture negative sepsis,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 22:02:23,,1323129306,7/14/2014 22:02:03,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,49,SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 22:08:50,,1323133237,7/14/2014 22:08:18,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,42-49-34,culture proven SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010607,7/14/2014 22:09:02,,1323133330,7/14/2014 22:08:08,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,98,49,,,121,55,CULTURE NEGATIVE SEPSIS,SEPSIS,CULTURE NEGATIVE SEPSIS,98-106-115,34-42-49,culture proven SEPSIS,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p.,98 106 115,49,98,49,121,55,-1,RO-cause_of,900401,Percentage of CD4(+) was lower in culture proven sepsis and absolute count of CD4(+) was lower in culture negative sepsis (p,culture negative sepsis,sepsis
503010608,7/14/2014 20:46:27,,1323088971,7/14/2014 20:46:12,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,HEROIN,108,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:06:58,,1323099748,7/14/2014 21:06:35,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,HEROIN use,108-115,40-47-58-63,HEROIN DEPENDENCE were detected,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:09:33,,1323100935,7/14/2014 21:09:22,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,more years of HEROIN use term,94-99-105-108-115-125,24-28-37-40-47-58-63-72,the severity of HEROIN DEPENDENCE were detected among,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:16:34,,1323104164,7/14/2014 21:16:16,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,HEROIN,108,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:33:54,,1323112832,7/14/2014 21:33:31,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,heroin dependence HEROIN,40-47-108,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:35:40,,1323113830,7/14/2014 21:34:34,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,heroin dependence HEROIN use,40-47-108-115,40-47-108-115,HEROIN DEPENDENCE heroin use,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:45:50,,1323121366,7/14/2014 21:45:45,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,more years of HEROIN use term,94-99-105-108-115-125,24-28-37-40-47-58-63-72,the severity of HEROIN DEPENDENCE were detected among,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 21:57:58,,1323127134,7/14/2014 21:57:42,instagc,1.0,18960682,GBR,"","",86.29.147.112,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,"HEROIN use term users),",108-115-125-130,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 22:10:31,,1323134171,7/14/2014 22:10:09,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,HEROIN use,108-115,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010608,7/14/2014 22:14:44,,1323136969,7/14/2014 22:14:27,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,108,40,,,114,57,HEROIN,HEROIN DEPENDENCE,HEROIN,108,40-47,HEROIN DEPENDENCE,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use.",108,40 47,108,40,114,57,1,RO-has_causative_agent,903579,"No major differences in the severity of heroin dependence were detected among users with 5 or more years of heroin use (long-term users), but differences were found among newer users (SDS mean scores, 7.3 in heroin injectors; 7.9 in smokers and 4.6 in sniffers; P = 0.006), especially those with fewer than 3 years of use",heroin,heroin dependence
503010609,7/14/2014 20:53:38,,1323092703,7/14/2014 20:53:28,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,of timolol after MYOCARDIAL INFARCTION.,32-35-43-49-60,14-26-32-35-43-49-60,multicenter study of TIMOLOL after myocardial infarction.,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:12:19,,1323102278,7/14/2014 21:12:13,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,of timolol after MYOCARDIAL INFARCTION.,32-35-43-49-60,14-26-32-35-43-49-60,multicenter study of TIMOLOL after myocardial infarction.,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:13:01,,1323102518,7/14/2014 21:12:46,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,timolol after MYOCARDIAL INFARCTION.,35-43-49-60,4-14-26-32-35,Norwegian multicenter study of TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:14:42,,1323103314,7/14/2014 21:14:26,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:30:26,,1323110956,7/14/2014 21:30:17,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:31:57,,1323111799,7/14/2014 21:31:28,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 21:36:03,,1323114027,7/14/2014 21:35:53,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35-49-60,TIMOLOL myocardial infarction.,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 22:05:00,,1323130842,7/14/2014 22:04:27,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 22:08:07,,1323132819,7/14/2014 22:07:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010609,7/14/2014 22:12:13,,1323135268,7/14/2014 22:11:36,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,49,35,,,70,42,MYOCARDIAL INFARCTION,TIMOLOL,MYOCARDIAL INFARCTION.,49-60,35,TIMOLOL,The Norwegian multicenter study of timolol after myocardial infarction.,49 60,35,49,35,70,42,1,RO-may_treat,907627,The Norwegian multicenter study of timolol after myocardial infarction,myocardial infarction,timolol
503010610,7/14/2014 20:49:24,,1323090412,7/14/2014 20:49:21,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,Nine patients with OSTEOSARCOMA were treated with,0-5-14-19-32-37-45,32-37-45-50-62-66-71,were treated with CISPLATINUM and high dose,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 20:52:47,,1323092246,7/14/2014 20:52:32,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,Nine patients with OSTEOSARCOMA were treated with,0-5-14-19-32-37-45,32-37-45-50-62-66-71-19,osteosarcoma were treated with CISPLATINUM and high dose,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 21:00:40,,1323096520,7/14/2014 21:00:15,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA,19,50,CISPLATINUM,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 21:31:20,,1323111461,7/14/2014 21:31:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA,19,19-50,osteosarcoma CISPLATINUM,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 21:44:23,,1323120066,7/14/2014 21:44:18,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,Nine patients with OSTEOSARCOMA were treated with,0-5-14-19-32-37-45,32-37-45-50-62-66-71,were treated with CISPLATINUM and high dose,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 21:49:02,,1323123401,7/14/2014 21:48:48,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA,19,50,CISPLATINUM,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 21:57:41,,1323127032,7/14/2014 21:57:07,instagc,1.0,18960682,GBR,"","",86.29.147.112,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA,19,50,CISPLATINUM,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 22:00:50,,1323128537,7/14/2014 22:00:35,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA treated cisplatinum high dose methotrexate therapy.,19-37-50-66-71-76-89,19-37-50-66-71-76-89,osteosarcoma treated CISPLATINUM high dose methotrexate therapy.,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 22:04:53,,1323130795,7/14/2014 22:03:44,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,Nine patients with OSTEOSARCOMA were treated with cisplatinum,0-5-14-19-32-37-45-50,50-62-66-71-76-89,CISPLATINUM and high dose methotrexate therapy.,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010610,7/14/2014 22:16:03,,1323137745,7/14/2014 22:15:39,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,19,50,,,31,61,OSTEOSARCOMA,CISPLATINUM,OSTEOSARCOMA,19,50,CISPLATINUM,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy.,19,50,19,50,31,61,1,RO-may_treat,908101,Nine patients with osteosarcoma were treated with cisplatinum and high-dose methotrexate therapy,osteosarcoma,cisplatinum
503010611,7/14/2014 21:10:29,,1323101419,7/14/2014 21:10:10,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY,0-7,68-76-81,"delayed type HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 21:13:28,,1323102734,7/14/2014 21:13:22,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY is manifested as,0-7-15-18-29,65-68-76-81-99-103-112,"by delayed type HYPERSENSITIVITY, the reaction being","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:05:12,,1323130942,7/14/2014 22:04:51,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY,0-7,68-76-81,"delayed type HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:05:39,,1323131227,7/14/2014 22:05:23,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,ALLERGY,7,81,"HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:07:44,,1323132598,7/14/2014 22:07:01,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,ALLERGY,7,81,"HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:11:45,,1323134970,7/14/2014 22:11:17,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,ALLERGY,7,81,"HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:18:32,,1323139406,7/14/2014 22:18:21,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY,0-7,68-76-81,"delayed type HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:18:51,,1323139594,7/14/2014 22:18:21,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,"Nickel ALLERGY contact allergic eczema delayed - type hypersensitivity, T lymphocytes.",0-7-32-40-49-68-75-76-81-130-132,0-7-32-40-49-68-75-76-81-130-132,"Nickel allergy contact allergic eczema delayed - type HYPERSENSITIVITY, T lymphocytes.","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:19:24,,1323139924,7/14/2014 22:19:01,sendearnings,1.0,11896941,USA,FL,Seminole,97.106.105.251,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY manifested as,0-7-29-18,68-76-81,"delayed type HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010611,7/14/2014 22:19:39,,1323140090,7/14/2014 22:19:11,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,7,81,,,14,97,ALLERGY,HYPERSENSITIVITY,Nickel ALLERGY,0-7,68-76-81,"delayed type HYPERSENSITIVITY,","Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes.",7,81,7,81,14,97,1,RO-cause_of,900186,"Nickel allergy is manifested as contact allergic eczema elicited by delayed-type hypersensitivity, the reaction being mediated by T lymphocytes",allergy,hypersensitivity
503010612,7/14/2014 20:46:49,,1323089138,7/14/2014 20:46:46,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,seldom present with HEMORRHAGE.,20-27-35-40,0-8-20-27-35,CENTRAL NEUROCYTOMA seldom present with,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 20:48:44,,1323090062,7/14/2014 20:48:39,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,seldom present with HEMORRHAGE.,20-27-35-40,0-8-20-27-35,CENTRAL NEUROCYTOMA seldom present with,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 20:49:57,,1323090779,7/14/2014 20:49:48,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,HEMORRHAGE.,40,0-8,CENTRAL NEUROCYTOMA,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 21:11:51,,1323102054,7/14/2014 21:11:47,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,seldom present with HEMORRHAGE.,20-27-35-40,0-8-20-27-35,CENTRAL NEUROCYTOMA seldom present with,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 21:14:53,,1323103422,7/14/2014 21:14:38,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,HEMORRHAGE.,40,0-8,CENTRAL NEUROCYTOMA,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 21:20:42,,1323105924,7/14/2014 21:20:34,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,HEMORRHAGE.,40,0-8,CENTRAL NEUROCYTOMA,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 21:44:05,,1323119833,7/14/2014 21:44:02,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,seldom present with HEMORRHAGE.,20-27-35-40,0-8-20-27-35,CENTRAL NEUROCYTOMA seldom present with,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 21:45:27,,1323121000,7/14/2014 21:45:08,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,Central neurocytoma HEMORRHAGE.,0-8-40,0-8-40,CENTRAL NEUROCYTOMA hemorrhage.,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 22:04:16,,1323130371,7/14/2014 22:04:04,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,HEMORRHAGE.,40,0-8,CENTRAL NEUROCYTOMA,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010612,7/14/2014 22:04:31,,1323130500,7/14/2014 22:04:22,instagc,1.0,18960682,GBR,"","",86.29.147.112,40,0,,,50,19,HEMORRHAGE,CENTRAL NEUROCYTOMA,HEMORRHAGE.,40,0-8,CENTRAL NEUROCYTOMA,Central neurocytoma seldom present with hemorrhage.,40,0 8,40,0,50,19,1,RO-disease_may_have_finding,902535,Central neurocytoma seldom present with hemorrhage,hemorrhage,Central neurocytoma
503010613,7/14/2014 20:48:38,,1323090007,7/14/2014 20:48:35,instagc,1,25990856,USA,NV,Las Vegas,68.108.98.78,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,the development of AMYLOID ARTHROPATHY and there were,55-59-71-74-82-94-98-104,109-118-131-139-152-162-169,"positive associations between AMYLOIDOSIS, increased levels of","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 20:54:04,,1323092906,7/14/2014 20:53:36,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,AMYLOID ARTHROPATHY,74-82,139,"AMYLOIDOSIS,","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 20:57:30,,1323094706,7/14/2014 20:57:17,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,AMYLOID ARTHROPATHY,74-82,139,"AMYLOIDOSIS,","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 20:59:51,,1323096120,7/14/2014 20:59:23,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,the development of AMYLOID ARTHROPATHY and there were,55-59-71-74-82-94-98-104,109-118-131-139-152-162-169,"positive associations between AMYLOIDOSIS, increased levels of","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:03:59,,1323098329,7/14/2014 21:03:46,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,AMYLOID ARTHROPATHY,74-82,139,"AMYLOIDOSIS,","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:12:15,,1323102240,7/14/2014 21:12:09,elite,1.0,27888773,GBR,"","",128.199.166.81,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,the development of AMYLOID ARTHROPATHY and there were,55-59-71-74-82-94-98-104,109-118-131-139-152-162-169,"positive associations between AMYLOIDOSIS, increased levels of","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:12:43,,1323102428,7/14/2014 21:12:26,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,the development of AMYLOID ARTHROPATHY and there were,55-59-71-74-82-94-98-104,109-118-131-139-152-162-169,"positive associations between AMYLOIDOSIS, increased levels of","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:15:27,,1323103668,7/14/2014 21:15:11,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,vitamin A enhanced the development of AMYLOID ARTHROPATHY,36-44-46-55-59-71-74-82,139-152-162-169-172-178-186,"AMYLOIDOSIS, increased levels of serum amyloid A","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:35:27,,1323113675,7/14/2014 21:34:59,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,AMYLOID ARTHROPATHY,74-82,139,"AMYLOIDOSIS,","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010613,7/14/2014 21:45:05,,1323120703,7/14/2014 21:45:01,clixsense,1,6340330,USA,NY,Fort Plain,67.248.115.74,74,139,,,93,150,AMYLOID ARTHROPATHY,AMYLOIDOSIS,the development of AMYLOID ARTHROPATHY and there were,55-59-71-74-82-94-98-104,109-118-131-139-152-162-169,"positive associations between AMYLOIDOSIS, increased levels of","In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages.",74 82,139,74,139,93,150,-1,RO-cause_of,900376,"In conclusion, it was observed that vitamin A enhanced the development of amyloid arthropathy and there were positive associations between amyloidosis, increased levels of serum amyloid A and increased numbers of tissue infiltrating macrophages",amyloid arthropathy,amyloidosis
503010614,7/14/2014 20:51:07,,1323091396,7/14/2014 20:50:52,elite,1.0,26544151,GBR,"","",94.196.251.237,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:06:11,,1323099377,7/14/2014 21:06:01,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,lesions on the SKIN.,51-59-66-62,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:13:15,,1323102617,7/14/2014 21:12:59,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:28:58,,1323110192,7/14/2014 21:28:39,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:44:30,,1323120240,7/14/2014 21:44:05,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,acute contact dermatitis lesions on the SKIN.,4-18-51-59-62-66-10,4-10-18-51-59-62-66,ACUTE CONTACT DERMATITIS lesions on the skin.,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:45:58,,1323121417,7/14/2014 21:45:51,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,lesions on the SKIN.,51-59-62-66,0-4-10-18-29-36-41,The ACUTE CONTACT DERMATITIS causes many different,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 21:59:40,,1323127960,7/14/2014 21:59:26,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,acute contact dermatitis lesions on the SKIN.,4-10-51-59-62-66-18,4-10-18-41-51-59-62-66,ACUTE CONTACT DERMATITIS different lesions on the skin.,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 22:00:17,,1323128314,7/14/2014 22:00:06,instagc,1.0,18960682,GBR,"","",86.29.147.112,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 22:12:37,,1323135541,7/14/2014 22:12:18,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010614,7/14/2014 22:14:58,,1323137037,7/14/2014 22:14:45,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,66,4,,,70,28,SKIN,ACUTE CONTACT DERMATITIS,SKIN.,66,4-10-18,ACUTE CONTACT DERMATITIS,The acute contact dermatitis causes many different lesions on the skin.,66,4 10 18,66,4,70,28,1,RO-has_finding_site,905031,The acute contact dermatitis causes many different lesions on the skin,skin,acute contact dermatitis
503010615,7/14/2014 21:04:00,,1323098350,7/14/2014 21:03:18,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 21:06:12,,1323099380,7/14/2014 21:05:51,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 21:15:55,,1323103899,7/14/2014 21:15:11,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,"GRAVES' DISEASE with thyrotoxicosis,",97-105-113-118,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 21:17:28,,1323104553,7/14/2014 21:17:14,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,"GRAVES' DISEASE with thyrotoxicosis,",97-105-113-118,97-105-113-118,"Graves' disease with THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 21:19:34,,1323105420,7/14/2014 21:19:12,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 21:28:36,,1323109897,7/14/2014 21:28:15,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 22:05:25,,1323131093,7/14/2014 22:05:03,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,GRAVES' DISEASE,97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 22:05:42,,1323131240,7/14/2014 22:05:26,instagc,1.0,18960682,GBR,"","",86.29.147.112,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,"coincident GRAVES' DISEASE with thyrotoxicosis,",86-97-105-113-118,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 22:07:10,,1323132198,7/14/2014 22:06:36,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,"euthyroid, coincident GRAVES' DISEASE thyrotoxicosis, primary myxodema.",19-86-97-105-118-154-146,19-86-97-105-113-118-146-154,"euthyroid, coincident Graves' disease with THYROTOXICOSIS, primary myxodema.","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010615,7/14/2014 22:12:59,,1323135759,7/14/2014 22:12:39,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,97,118,,,112,132,GRAVES' DISEASE,THYROTOXICOSIS,coincident GRAVES' DISEASE,86-97-105,118,"THYROTOXICOSIS,","One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema.",97 105,118,97,118,112,132,-1,RO-cause_of,900029,"One was clinically euthyroid, whereas the other two were more unusual in that one had coincident Graves' disease with thyrotoxicosis, and one had primary myxodema",Graves' disease,thyrotoxicosis
503010616,7/14/2014 20:47:50,,1323089592,7/14/2014 20:47:42,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,that of the SARCOMATOUS COMPONENTS.,157-162-165-169-181,70-84-94-97-105-121-127-130,"carcinomatous component of UTERINE CARCINOSARCOMA, while it may","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 20:59:31,,1323095948,7/14/2014 20:59:12,elite,1.0,26544151,GBR,"","",94.196.251.237,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:00:23,,1323096392,7/14/2014 21:00:08,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:03:22,,1323097922,7/14/2014 21:03:01,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,70-84-94-97-105,"carcinomatous component of UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:07:22,,1323099994,7/14/2014 21:06:58,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,70-84-94-97-105,"carcinomatous component of UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:09:50,,1323101101,7/14/2014 21:09:19,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,"carcinomatous uterine carcinosarcoma, SARCOMATOUS COMPONENTS.",70-97-169-181-105,70-84-94-97-105,"carcinomatous component of UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:13:49,,1323102841,7/14/2014 21:13:16,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:14:25,,1323103140,7/14/2014 21:13:34,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:17:03,,1323104385,7/14/2014 21:16:52,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010616,7/14/2014 21:24:24,,1323107598,7/14/2014 21:23:58,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,169,97,,,191,119,SARCOMATOUS COMPONENTS,UTERINE CARCINOSARCOMA,SARCOMATOUS COMPONENTS.,169-181,97-105,"UTERINE CARCINOSARCOMA,","MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components.",169 181,97 105,169,97,191,119,-1,RO-disease_has_finding,901637,"MMP-7 may contribute to the invasive nature or growth capacity of the carcinomatous component of uterine carcinosarcoma, while it may not have a relation to that of the sarcomatous components",sarcomatous components,uterine carcinosarcoma
503010617,7/14/2014 20:49:46,,1323090665,7/14/2014 20:49:32,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION,0,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 20:54:07,,1323092915,7/14/2014 20:53:53,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION of astrocytoma to glioblastoma,0-18-21-33-36,18-21-33-36-49-53-57,of astrocytoma to GLIOBLASTOMA and the role,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 20:58:27,,1323095312,7/14/2014 20:58:05,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION of astrocytoma,0-18-21,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:11:28,,1323101871,7/14/2014 21:11:10,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION,0,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:12:25,,1323102303,7/14/2014 21:12:10,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION,0,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:13:01,,1323102519,7/14/2014 21:12:55,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION of astrocytoma to,0-18-21-33,18-21-33-36-49-53-57,of astrocytoma to GLIOBLASTOMA and the role,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:15:11,,1323103530,7/14/2014 21:14:47,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION of astrocytoma to glioblastoma,0-18-21-33-36,0-18-21-33-36,Dedifferentiation of astrocytoma to GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:20:22,,1323105786,7/14/2014 21:20:09,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION of astrocytoma,0-18-21,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 21:31:49,,1323111740,7/14/2014 21:31:28,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION,0,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010617,7/14/2014 22:09:38,,1323133689,7/14/2014 22:09:07,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,0,36,,,17,48,DEDIFFERENTIATION,GLIOBLASTOMA,DEDIFFERENTIATION,0,36,GLIOBLASTOMA,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed.,0,36,0,36,17,48,1,RO-disease_has_finding,901662,Dedifferentiation of astrocytoma to glioblastoma and the role of radiation therapy are discussed,Dedifferentiation,glioblastoma
503010618,7/14/2014 20:52:12,,1323091918,7/14/2014 20:51:51,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"residual recurrent DYSPLASIA,",32-41-51,75-80-86-95-111,high grade SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 21:06:34,,1323099538,7/14/2014 21:06:14,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"residual recurrent DYSPLASIA,",32-41-51,75-80-86-95-111-119,"high grade SQUAMOUS INTRAEPITHELIAL LESIONS (66%),","Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 21:08:13,,1323100369,7/14/2014 21:07:36,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"had residual recurrent DYSPLASIA, including 36 high squamous intraepithelial lesions 14 low grade squamous",28-32-41-51-62-72-75-86-95-111-126-129-133-139,28-32-41-51-62-72-75-80-86-95-111-126-129-139-133,"had residual recurrent dysplasia, including 36 high grade SQUAMOUS INTRAEPITHELIAL LESIONS 14 low grade squamous","Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 21:14:08,,1323103013,7/14/2014 21:13:52,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"residual recurrent DYSPLASIA, including 36 high grade squamous intraepithelial lesions",32-41-51-62-72-75-80-86-95-111,72-75-80-86-95-111,36 high grade SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 21:28:11,,1323109630,7/14/2014 21:27:54,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"DYSPLASIA,",51,86-95-111,SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 22:02:31,,1323129397,7/14/2014 22:01:34,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"residual recurrent DYSPLASIA,",32-41-51,86-95-111,SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 22:03:21,,1323129866,7/14/2014 22:02:02,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"DYSPLASIA, 36 high grade squamous intraepithelial lesions (66%), 14 low grade squamous intraepithelial lesions (25%), 5 atypical squamous cells of undetermined significance (9%.",51-72-75-80-86-95-111-119-126-129-133-139-148-164-172-183-185-194-203-209-212-225-238,51-72-75-80-86-95-111-119-126-129-133-139-148-164-172-183-185-194-203-209-212-225-238,"dysplasia, 36 high grade SQUAMOUS INTRAEPITHELIAL LESIONS (66%), 14 low grade squamous intraepithelial lesions (25%), 5 atypical squamous cells of undetermined significance (9%.","Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 22:09:14,,1323133441,7/14/2014 22:09:00,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"DYSPLASIA,",51,86-95-111,SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 22:11:23,,1323134767,7/14/2014 22:09:44,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"DYSPLASIA,",51,86-95-111,SQUAMOUS INTRAEPITHELIAL LESIONS,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010618,7/14/2014 22:17:43,,1323138815,7/14/2014 22:17:07,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,51,86,,,60,118,DYSPLASIA,SQUAMOUS INTRAEPITHELIAL LESIONS,"residual recurrent DYSPLASIA,",32-41-51,72-75-80-86-95-111-119,"36 high grade SQUAMOUS INTRAEPITHELIAL LESIONS (66%),","Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%.",51,86 95 111,51,86,60,118,-1,RO-disease_has_finding,901611,"Fifty-five patients (27.5%) had residual/recurrent dysplasia, including 36 high-grade squamous intraepithelial lesions (66%), 14 low-grade squamous intraepithelial lesions (25%), and 5 atypical squamous cells of undetermined significance (9%",dysplasia,squamous intraepithelial lesions
503010619,7/14/2014 20:46:58,,1323089190,7/14/2014 20:46:55,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS of the ascending,29-41-51-60-65-68-72,88-92-101-110-117-128-132,and multiple distinct POLYPS throughout the rest,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:12:40,,1323102401,7/14/2014 21:12:34,elite,1.0,27888773,GBR,"","",128.199.166.81,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS of the ascending,29-41-51-60-65-68-72,88-92-101-110-117-128-132,and multiple distinct POLYPS throughout the rest,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:13:31,,1323102743,7/14/2014 21:13:00,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,60,110,,,64,116,MASS,POLYPS,MASS,60,110,POLYPS,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:13:49,,1323102843,7/14/2014 21:13:42,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS of the ascending,29-41-51-60-65-68-72,88-92-101-110-117-128-132,and multiple distinct POLYPS throughout the rest,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:21:33,,1323106240,7/14/2014 21:21:14,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS,29-41-51-60,92-101-110,multiple distinct POLYPS,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:26:24,,1323108699,7/14/2014 21:25:20,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,60,110,,,64,116,MASS,POLYPS,MASS,60,110,POLYPS,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:28:46,,1323110059,7/14/2014 21:28:15,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS of the ascending colon and multiple distinct polyps throughout the rest of the colon.,29-41-51-60-65-68-72-82-88-92-101-110-117-128-132-137-140-144,41-51-60-65-68-72-82-88-92-101-110-117-128-132-137-140-144-29,malignant appearing polypoid mass of the ascending colon and multiple distinct POLYPS throughout the rest of the colon.,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:44:46,,1323120489,7/14/2014 21:44:42,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,60,110,,,64,116,MASS,POLYPS,malignant appearing polypoid MASS of the ascending,29-41-51-60-65-68-72,88-92-101-110-117-128-132,and multiple distinct POLYPS throughout the rest,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:52:26,,1323125009,7/14/2014 21:51:25,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,60,110,,,64,116,MASS,POLYPS,MASS,60,110,POLYPS,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010619,7/14/2014 21:57:55,,1323127112,7/14/2014 21:57:18,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,60,110,,,64,116,MASS,POLYPS,polypoid MASS,51-60,110,POLYPS,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon.,60,110,60,110,64,116,-1,RO-disease_may_have_finding,902997,Colonoscopy revealed a large malignant - appearing polypoid mass of the ascending colon and multiple distinct polyps throughout the rest of the colon,mass,polyps
503010620,7/14/2014 20:46:55,,1323089172,7/14/2014 20:46:50,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,108,24,,,112,28,PAIN,APAP,for postsurgical orthopedic PAIN in a 6,80-84-97-108-113-116-118,0-9-23-30-42-50,Tramadol acetaminophen (APAP) combination tablets were,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 20:48:21,,1323089851,7/14/2014 20:48:04,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,108,24,,,112,28,PAIN,APAP,postsurgical orthopedic PAIN,84-97-108,0-9-23,Tramadol acetaminophen (APAP),"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 20:49:20,,1323090383,7/14/2014 20:49:15,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,108,24,,,112,28,PAIN,APAP,for postsurgical orthopedic PAIN in a 6,80-84-97-108-113-116-118,0-9-23-30-42-50,Tramadol acetaminophen (APAP) combination tablets were,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 20:53:03,,1323092387,7/14/2014 20:52:41,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,108,24,,,112,28,PAIN,APAP,postsurgical orthopedic PAIN,84-97-108,0-9-23,Tramadol acetaminophen (APAP),"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 20:53:41,,1323092738,7/14/2014 20:53:20,elite,1.0,26544151,GBR,"","",94.196.251.237,108,24,,,112,28,PAIN,APAP,PAIN,108,23,(APAP),"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 21:00:37,,1323096503,7/14/2014 21:00:23,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,108,24,,,112,28,PAIN,APAP,postsurgical orthopedic PAIN,84-97-108,0-9-23-30-42,Tramadol acetaminophen (APAP) combination tablets,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 21:07:05,,1323099845,7/14/2014 21:06:48,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,108,24,,,112,28,PAIN,APAP,orthopedic PAIN,97-108,0-9,Tramadol acetaminophen,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 21:12:24,,1323102292,7/14/2014 21:12:21,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,108,24,,,112,28,PAIN,APAP,for postsurgical orthopedic PAIN in a 6,80-84-97-108-113-116-118,0-9-23-30-42-50,Tramadol acetaminophen (APAP) combination tablets were,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 21:13:52,,1323102878,7/14/2014 21:13:30,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,108,24,,,112,28,PAIN,APAP,postsurgical orthopedic PAIN,84-97-108,0-9-23-30-42,Tramadol acetaminophen (APAP) combination tablets,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010620,7/14/2014 21:15:05,,1323103497,7/14/2014 21:14:59,elite,1.0,27888773,GBR,"","",128.199.166.81,108,24,,,112,28,PAIN,APAP,for postsurgical orthopedic PAIN in a 6,80-84-97-108-113-116-118,0-9-23-30-42-50,Tramadol acetaminophen (APAP) combination tablets were,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study.",108,,108,24,112,28,1,RO-may_treat,908128,"Tramadol/acetaminophen (APAP) combination tablets were shown effective and safe for postsurgical orthopedic pain in a 6-day, multicenter, randomized, double-blind, active- and placebo-controlled study",pain,APAP
503010621,7/14/2014 20:45:47,,1323088562,7/14/2014 20:45:30,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 20:48:55,,1323090154,7/14/2014 20:48:39,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 20:53:35,,1323092661,7/14/2014 20:53:05,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 20:59:10,,1323095761,7/14/2014 20:58:51,elite,1.0,26544151,GBR,"","",94.196.251.237,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:07:47,,1323100149,7/14/2014 21:07:35,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,123,75,,,131,83,SEIZURES,EPILEPSY,"established relationships between SEIZURES, excitotoxic hippocampal damage,",89-101-115-123-133-145-157,58-65-72-75-84-89-101,animal models of EPILEPSY have established relationships,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:13:58,,1323102924,7/14/2014 21:13:42,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:17:46,,1323104642,7/14/2014 21:17:28,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,123,75,,,131,83,SEIZURES,EPILEPSY,"temporal lobe epilepsy animal models of epilepsy established relationships between SEIZURES, excitotoxic hippocampal damage,",31-40-45-58-65-72-89-101-115-123-133-145-157-75,58-65-72-75-84-89-101-115-123,"animal models of EPILEPSY have established relationships between seizures,","Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:26:27,,1323108729,7/14/2014 21:25:54,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:33:13,,1323112466,7/14/2014 21:32:53,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010621,7/14/2014 21:49:48,,1323123854,7/14/2014 21:49:34,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,123,75,,,131,83,SEIZURES,EPILEPSY,"SEIZURES,",123,75,EPILEPSY,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment.",123,75,123,75,131,83,-1,RO-has_definitional_manifestation,904640,"Studies of human patients with temporal lobe epilepsy and animal models of epilepsy have established relationships between seizures, excitotoxic hippocampal damage, and memory impairment",seizures,epilepsy
503010622,7/14/2014 20:51:30,,1323091602,7/14/2014 20:51:16,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,73-83-92,cutaneous ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 20:52:30,,1323092091,7/14/2014 20:52:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,83-92,ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:05:05,,1323098857,7/14/2014 21:04:51,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,83-92-73,cutaneous ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:05:14,,1323098903,7/14/2014 21:04:59,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,83-92,ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:12:55,,1323102481,7/14/2014 21:12:48,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"reactions and serious ALLERGIC VASCULITIS, often with purpura",92-102-106-114-123-135-141-146,53-62-73-83-92-102-106-114,allergic reactions; cutaneous ALLERGIC REACTIONS and serious allergic,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:17:12,,1323104454,7/14/2014 21:16:54,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS, often with purpura extremities and extracutaneous involvement",114-123-135-141-146-157-169-173-188,28-37-53-62-73-83-92,Possible anaphylactic allergic reactions; cutaneous ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:17:58,,1323104767,7/14/2014 21:17:42,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,73-83-92,cutaneous ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:32:09,,1323111883,7/14/2014 21:31:59,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,83-92,ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 21:53:34,,1323125483,7/14/2014 21:53:16,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"serious ALLERGIC VASCULITIS,",106-114-123,73-83-92,cutaneous ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010622,7/14/2014 22:05:55,,1323131439,7/14/2014 22:05:40,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,114,83,,,133,101,ALLERGIC VASCULITIS,ALLERGIC REACTIONS,"ALLERGIC VASCULITIS,",114-123,83-92,ALLERGIC REACTIONS,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal.",114 123,83 92,114,83,133,101,-1,RO-cause_of,900064,"Hypersensitivity Reactions  Possible anaphylactic or allergic reactions; cutaneous allergic reactions and serious allergic vasculitis, often with purpura of extremities and extracutaneous involvement (e.g., renal",allergic vasculitis,allergic reactions
503010623,7/14/2014 20:47:36,,1323089434,7/14/2014 20:47:26,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 20:48:22,,1323089853,7/14/2014 20:48:08,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 20:49:37,,1323090550,7/14/2014 20:49:18,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,other neuropathies than DIABETIC NEUROPATHY can be excluded.,71-77-90-95-104-115-119-122,37-41-51-54-63-71-77,(1) diagnosed as DIABETES and other neuropathies,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 20:50:21,,1323090951,7/14/2014 20:50:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:03:20,,1323097909,7/14/2014 21:02:53,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:05:09,,1323098877,7/14/2014 21:04:47,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,other neuropathies than DIABETIC NEUROPATHY can be excluded.,71-77-90-95-104-115-119-122,37-41-51-54-63-71-95-104,(1) diagnosed as DIABETES and other diabetic neuropathy,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:06:26,,1323099483,7/14/2014 21:06:15,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:08:15,,1323100378,7/14/2014 21:08:00,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,other neuropathies than DIABETIC NEUROPATHY can be excluded.,71-77-90-95-104-115-119-122,37-41-51-54-63-71,(1) diagnosed as DIABETES and other,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:10:09,,1323101272,7/14/2014 21:09:43,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,DIABETIC NEUROPATHY,95-104,54,DIABETES,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010623,7/14/2014 21:46:04,,1323121504,7/14/2014 21:45:31,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,95,54,,,114,62,DIABETIC NEUROPATHY,DIABETES,diabetes and DIABETIC NEUROPATHY,54-63-95-104,54-63-95-104,DIABETES and diabetic neuropathy,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded.,95 104,54,95,54,114,62,-1,RO-cause_of,900076,The prerequisite condition includes: (1) diagnosed as diabetes and (2) other neuropathies than diabetic neuropathy can be excluded,diabetic neuropathy,diabetes
503010624,7/14/2014 20:47:35,,1323089430,7/14/2014 20:47:31,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,150,64,,,157,73,VARICES,PHLEBITIS,of the secondary VARICES in connection with,133-136-140-150-158-161-172,45-49-61-64-74-78-83,the terminology of PHLEBITIS and then elucidated,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 20:47:58,,1323089659,7/14/2014 20:47:55,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,150,64,,,157,73,VARICES,PHLEBITIS,of the secondary VARICES in connection with,133-136-140-150-158-161-172,45-49-61-64-74-78-83,the terminology of PHLEBITIS and then elucidated,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 20:48:48,,1323090101,7/14/2014 20:48:33,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 21:13:41,,1323102805,7/14/2014 21:13:35,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,150,64,,,157,73,VARICES,PHLEBITIS,of the secondary VARICES in connection with,133-136-140-150-158-161-172,45-49-61-64-74-78-83,the terminology of PHLEBITIS and then elucidated,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 21:21:14,,1323106113,7/14/2014 21:20:50,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 21:25:05,,1323107934,7/14/2014 21:22:59,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 21:29:11,,1323110288,7/14/2014 21:28:45,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 22:04:00,,1323130231,7/14/2014 22:03:22,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,150,64,,,157,73,VARICES,PHLEBITIS,phlebitis deep veins secondary VARICES post - thrombotic syndroms.,64-118-123-140-150-181-186-197-185,64-118-123-140-150-181-185-186-197,PHLEBITIS deep veins secondary varices post - thrombotic syndroms.,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 22:08:42,,1323133134,7/14/2014 22:08:20,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010624,7/14/2014 22:13:18,,1323135984,7/14/2014 22:12:38,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,150,64,,,157,73,VARICES,PHLEBITIS,VARICES,150,64,PHLEBITIS,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms.,150,64,150,64,157,73,-1,RO-disease_has_finding,901829,The author begins with a brief discussion of the terminology of phlebitis and then elucidated the significance of the deep veins and of the secondary varices in connection with the post-thrombotic syndroms,varices,phlebitis
503010625,7/14/2014 20:56:25,,1323094085,7/14/2014 20:55:51,elite,1.0,26544151,GBR,"","",94.196.251.237,249,232,,,255,240,ARREST,ATROPINE,ARREST arrhythmia,249-256,231,"(ATROPINE,","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:02:37,,1323097500,7/14/2014 21:01:54,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,249,232,,,255,240,ARREST,ATROPINE,"the ARREST arrhythmia is asystole or PEA is slow),",249-256-267-270-279-282-286-289-245,208-224-231-242-245-249-256,"anticholinergic agents (ATROPINE, if the arrest arrhythmia","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:02:40,,1323097526,7/14/2014 21:02:24,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,249,232,,,255,240,ARREST,ATROPINE,ARREST arrhythmia,249-256,208-224,anticholinergic agents,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:04:36,,1323098653,7/14/2014 21:04:21,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,249,232,,,255,240,ARREST,ATROPINE,ARREST arrhythmia,249-256,231,"(ATROPINE,","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:11:57,,1323102103,7/14/2014 21:11:51,elite,1.0,27888773,GBR,"","",128.199.166.81,249,232,,,255,240,ARREST,ATROPINE,"(atropine, if the ARREST arrhythmia is asystole",231-242-245-249-256-267-270,208-224-231-242-245-249,"anticholinergic agents (ATROPINE, if the arrest","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:17:07,,1323104410,7/14/2014 21:16:37,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,249,232,,,255,240,ARREST,ATROPINE,ARREST arrhythmia,249-256,231,"(ATROPINE,","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:28:14,,1323109662,7/14/2014 21:26:20,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,249,232,,,255,240,ARREST,ATROPINE,"(atropine, if the ARREST arrhythmia is asystole",231-242-245-249-256-267-270,208-224-231-242-245-249,"anticholinergic agents (ATROPINE, if the arrest","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:32:20,,1323111972,7/14/2014 21:32:10,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,249,232,,,255,240,ARREST,ATROPINE,ARREST,249,231,"(ATROPINE,","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 21:56:47,,1323126586,7/14/2014 21:55:14,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,249,232,,,255,240,ARREST,ATROPINE,"medications in cardiac resuscitation vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the ARREST arrhythmia is asystole or PEA is slow), sodium bicarbonate metabolic acidosis, hyperkalemia, and certain drug overdoses) calcium chloride hyperkalemia, calcium channel blocker drug overdose, severe hypocalcemia)",18-30-33-41-109-122-135-138-152-168-181-192-196-208-224-231-242-245-249-256-267-270-279-282-286-289-394-401-425-435-445-459-463-471-476-491-499-513-527-535-543-551-556-576-569,18-30-33-41-109-122-135-138-152-168-181-192-196-208-224-231-242-245-249-256-267-270-279-282-286-289-394-401-425-435-445-459-463-471-476-491-499-513-527-535-543-551-556-569-576,"medications in cardiac resuscitation vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (ATROPINE, if the arrest arrhythmia is asystole or PEA is slow), sodium bicarbonate metabolic acidosis, hyperkalemia, and certain drug overdoses) calcium chloride hyperkalemia, calcium channel blocker drug overdose, severe hypocalcemia)","The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010625,7/14/2014 22:06:14,,1323131620,7/14/2014 22:05:41,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,249,232,,,255,240,ARREST,ATROPINE,ARREST arrhythmia,249-256,208-224,anticholinergic agents,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see.",249,,249,232,255,240,1,RO-may_treat,907823,"The commonly used medications in cardiac resuscitation may be grouped into the following general categories: vasopressors (epinephrine or vasopressin), antiarrhythmics (amiodarone, lidocaine, and magnesium), anticholinergic agents (atropine, if the arrest arrhythmia is asystole or PEA is slow), and miscellaneous drugs used to treat specific problems contributing to the arrest state, such as sodium bicarbonate (for severe metabolic acidosis, hyperkalemia, and certain drug overdoses) and calcium chloride (for hyperkalemia, calcium channel blocker drug overdose, or severe hypocalcemia) [ see",arrest,atropine
503010626,7/14/2014 20:47:12,,1323089310,7/14/2014 20:47:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,38-47,mosquito ALLERGY,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 20:51:44,,1323091722,7/14/2014 20:51:36,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,29-35-38-47-55-58-60,bites or mosquito ALLERGY is a mysterious,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:00:46,,1323096594,7/14/2014 21:00:12,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,0-17-20-29-35-38-47-55-58-60,Hypersensitivity to mosquito bites or mosquito ALLERGY is a mysterious,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:03:58,,1323098348,7/14/2014 21:03:41,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,0,47,ALLERGY,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:07:56,,1323100226,7/14/2014 21:07:31,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,38-47,mosquito ALLERGY,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:07:59,,1323100255,7/14/2014 21:07:49,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,29-35-38-47-55-58-60,bites or mosquito ALLERGY is a mysterious,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:12:32,,1323102336,7/14/2014 21:12:12,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites is a mysterious disorder,0-17-20-29-55-60-71-58,0-17-20-29-35-38-47-55-58-60-71,Hypersensitivity to mosquito bites or mosquito ALLERGY is a mysterious disorder,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:25:51,,1323108390,7/14/2014 21:25:31,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY,0,47,ALLERGY,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:32:11,,1323111890,7/14/2014 21:31:41,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,0-17-20-29-47,Hypersensitivity to mosquito bites ALLERGY,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010626,7/14/2014 21:46:08,,1323121532,7/14/2014 21:46:05,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,0,47,,,16,54,HYPERSENSITIVITY,ALLERGY,HYPERSENSITIVITY to mosquito bites,0-17-20-29,29-35-38-47-55-58-60,bites or mosquito ALLERGY is a mysterious,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life.,0,47,0,47,16,54,-1,RO-cause_of,900303,Hypersensitivity to mosquito bites or mosquito allergy is a mysterious disorder that has been reported mainly in Japanese patients (at least 58 patients) in the first two decades of life,Hypersensitivity,allergy
503010627,7/14/2014 20:52:31,,1323092092,7/14/2014 20:52:22,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS in horses and,108-115-128-134-140-143-150,80-93-97-100-108-115-134-140,encephalitis due to EASTERN EQUINE ENCEPHALITIS virus in,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 20:55:48,,1323093764,7/14/2014 20:54:44,elite,1.0,26544151,GBR,"","",94.196.251.237,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,100-108-128-134-115,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 21:04:50,,1323098777,7/14/2014 21:04:37,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS,108-115-128-134,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 21:08:20,,1323100420,7/14/2014 21:07:57,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,100-108-115-128-134,71-80-93-97-100-108-115-128,clinical encephalitis due to EASTERN EQUINE ENCEPHALITIS (EEE),A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 21:13:17,,1323102624,7/14/2014 21:13:02,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,100-108-115-128-134,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 21:39:20,,1323116093,7/14/2014 21:39:07,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS,108-115-128-134,100-108-115-128,EASTERN EQUINE ENCEPHALITIS (EEE),A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 21:45:18,,1323120865,7/14/2014 21:45:14,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,equine encephalitis (EEE) VIRUS in horses and,108-115-128-134-140-143-150,80-93-97-100-108-115-134-140,encephalitis due to EASTERN EQUINE ENCEPHALITIS virus in,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 22:07:51,,1323132661,7/14/2014 22:07:31,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,108-115-128-134-100,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 22:11:21,,1323134742,7/14/2014 22:10:51,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,108-115-128-134-100,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010627,7/14/2014 22:14:54,,1323137002,7/14/2014 22:14:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,129,100,,,139,127,EEE) VIRUS,EASTERN EQUINE ENCEPHALITIS,eastern equine encephalitis (EEE) VIRUS,100-108-115-128-134,100-108-115-128-134,EASTERN EQUINE ENCEPHALITIS (EEE) virus,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus.,134,100 108 115,129,100,139,127,-1,RO-has_causative_agent,903756,A study was undertaken to investigate an increase in reported cases of clinical encephalitis due to eastern equine encephalitis (EEE) virus in horses and to determine the natural vertebrate hosts of that virus,EEE) virus,eastern equine encephalitis
503010628,7/14/2014 20:51:00,,1323091359,7/14/2014 20:50:52,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26-36,RENAL CELL CARCINOMA (RCC),Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 20:51:25,,1323091549,7/14/2014 20:51:09,elite,1.0,26544151,GBR,"","",94.196.251.237,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 20:52:21,,1323092011,7/14/2014 20:52:02,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,in the native KIDNEYS of renal transplant,57-60-64-71-79-82-88,0-15-21-26-42-50,Posttransplant RENAL CELL CARCINOMA usually arises,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 21:15:45,,1323103837,7/14/2014 21:15:31,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 21:25:04,,1323107931,7/14/2014 21:24:43,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 21:25:25,,1323108120,7/14/2014 21:25:06,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26-36,RENAL CELL CARCINOMA (RCC),Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 21:32:24,,1323111999,7/14/2014 21:32:12,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma KIDNEYS,0-15-21-26-71,0-15-21-26,Posttransplant RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 21:48:02,,1323122846,7/14/2014 21:47:42,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,native KIDNEYS,64-71,0-15-21-26,Posttransplant RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 22:02:01,,1323129149,7/14/2014 22:01:21,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) KIDNEYS renal transplant transplanted kidney.,0-15-21-26-36-71-82-88-129-142,0-15-21-26-36-64-71-82-88-129-142,Posttransplant RENAL CELL CARCINOMA (RCC) native kidneys renal transplant transplanted kidney.,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010628,7/14/2014 22:08:18,,1323132938,7/14/2014 22:07:47,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,71,15,,,78,35,KIDNEYS,RENAL CELL CARCINOMA,KIDNEYS,71,15-21-26,RENAL CELL CARCINOMA,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney.,71,15 21 26,71,15,78,35,1,RO-disease_has_primary_anatomic_site,902457,Posttransplant renal cell carcinoma (RCC) usually arises in the native kidneys of renal transplant recipients rather than in the transplanted kidney,kidneys,renal cell carcinoma
503010629,7/14/2014 20:48:30,,1323089919,7/14/2014 20:48:27,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"associated with hereditary INCLUSION BODY MYOPATHY, Paget disease of",99-110-115-126-136-141-151-157-165,182-197-206,frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 20:51:35,,1323091640,7/14/2014 20:51:26,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"associated with hereditary INCLUSION BODY MYOPATHY, Paget disease of",99-110-115-126-136-141-151-157-165,182-197-206,frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:03:20,,1323097911,7/14/2014 21:02:41,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"INCLUSION BODY MYOPATHY,",126-136-141,126-136-141-151-182-197,"inclusion body myopathy, Paget frontotemporal dementia","Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:09:09,,1323100761,7/14/2014 21:07:31,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"hereditary INCLUSION BODY MYOPATHY,",115-126-136-141,126-136-141-151-182-197-206-157,"inclusion body myopathy, Paget disease frontotemporal dementia (IBMPFD.","Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:11:53,,1323102069,7/14/2014 21:11:11,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"INCLUSION BODY MYOPATHY, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126-136-141-151-157-165-168-172-178-182-197-206,136-141-151-157-165-168-172-178-182-197-206-126,"inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.","Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:15:10,,1323103539,7/14/2014 21:14:43,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"hereditary INCLUSION BODY MYOPATHY,",115-126-136-141,182-197-206,frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:27:43,,1323109424,7/14/2014 21:26:13,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"hereditary INCLUSION BODY MYOPATHY, Paget disease frontotemporal dementia (IBMPFD.",115-126-136-141-151-157-182-197-206,115-126-136-141-151-182-197-206-157,"hereditary inclusion body myopathy, Paget disease frontotemporal dementia (IBMPFD.","Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:36:29,,1323114291,7/14/2014 21:36:04,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"INCLUSION BODY MYOPATHY, Paget disease frontotemporal dementia (IBMPFD.",126-136-141-151-157-182-197-206,151-182-197-206-157,Paget disease frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 21:53:53,,1323125621,7/14/2014 21:53:35,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"hereditary INCLUSION BODY MYOPATHY,",115-126-136-141,182-197-206,frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010629,7/14/2014 22:09:47,,1323133786,7/14/2014 22:09:03,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,126,207,,,149,213,INCLUSION BODY MYOPATHY,IBMPFD,"hereditary INCLUSION BODY MYOPATHY,",115-126-136-141,182-197-206,frontotemporal dementia (IBMPFD.,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD.",126 136 141,,126,207,149,213,-1,RO-has_manifestation,906075,"Mutations in the valosin-containing protein (VCP) on chromosome 9p13-p12 were recently found to be associated with hereditary inclusion body myopathy, Paget disease of the bone, and frontotemporal dementia (IBMPFD",inclusion body myopathy,IBMPFD
503010630,7/14/2014 21:08:30,,1323100498,7/14/2014 21:07:49,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,119,67,,,124,70,LUPUS,SLE,spectrum of acute LUPUS pneumonitis 10tvml,101-110-113-119-125-143,67-119-125,SLE lupus pneumonitis,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:17:24,,1323104541,7/14/2014 21:17:08,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,119,67,,,124,70,LUPUS,SLE,acute LUPUS pneumonitis,113-119-125,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:30:09,,1323110813,7/14/2014 21:29:25,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,119,67,,,124,70,LUPUS,SLE,SLE acute LUPUS pneumonitis (tvml 10tvml ; tvml 32tvml.,113-119-125-137-143-150-152-157-67,67-113-119-125-137-143-150-152-157,SLE acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:30:15,,1323110864,7/14/2014 21:29:54,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,119,67,,,124,70,LUPUS,SLE,LUPUS pneumonitis,119-125,67-119-125,SLE lupus pneumonitis,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:31:27,,1323111529,7/14/2014 21:31:06,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,119,67,,,124,70,LUPUS,SLE,LUPUS,119,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:34:17,,1323113013,7/14/2014 21:34:05,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,119,67,,,124,70,LUPUS,SLE,acute LUPUS pneumonitis,113-119-125,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 21:51:37,,1323124677,7/14/2014 21:51:18,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,119,67,,,124,70,LUPUS,SLE,acute LUPUS pneumonitis,113-119-125,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 22:04:17,,1323130369,7/14/2014 22:03:49,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,119,67,,,124,70,LUPUS,SLE,acute LUPUS pneumonitis,113-119-125,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 22:15:47,,1323137577,7/14/2014 22:15:28,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,119,67,,,124,70,LUPUS,SLE,acute LUPUS pneumonitis,113-119-125,67,SLE,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010630,7/14/2014 22:17:35,,1323138707,7/14/2014 22:14:35,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,119,67,,,124,70,LUPUS,SLE,Alveolar hemorrhage 2% 4% of patients with SLE spectrum of acute LUPUS pneumonitis (tvml 10tvml tvml 32tvml.,0-9-44-47-50-53-62-67-101-110-113-119-125-137-143-157-152,0-9-44-46-47-50-53-62-67-101-110-113-119-125-137-152-157-143,Alveolar hemorrhage 2% - 4% of patients with SLE spectrum of acute lupus pneumonitis (tvml 10tvml tvml 32tvml.,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml.,119,67,119,67,124,70,-1,RO-has_manifestation,906387,Alveolar hemorrhage occurs in approximately 2%-4% of patients with SLE and may represent part of the spectrum of acute lupus pneumonitis (tvml 10tvml ; tvml 32tvml,lupus,SLE
503010631,7/14/2014 20:54:34,,1323093178,7/14/2014 20:54:05,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:02:45,,1323097574,7/14/2014 21:02:18,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"rhinophycomycosis [&amp;dblprime; phykos seaweed, mykes , FUNGUS, osis condition] fungal infection",0-56-71-80-92-98-100-111-118-131-138,0-56-71-80-92-100-111-116-118-131-138,"rhinophycomycosis [&amp;dblprime; phykos seaweed, mykes fungus, osis , condition] FUNGAL INFECTION","rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:07:50,,1323100177,7/14/2014 21:05:36,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:09:00,,1323100695,7/14/2014 21:08:31,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:12:30,,1323102318,7/14/2014 21:12:25,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"+ mykes , FUNGUS, osis condition] A",89-92-98-100-111-118-129,116-118-129-131-138-148-153-157,", condition] A FUNGAL INFECTION that may occur","rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:14:17,,1323103075,7/14/2014 21:13:47,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS, + osis",100-108-111,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 21:33:15,,1323112474,7/14/2014 21:32:55,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 22:01:58,,1323129098,7/14/2014 22:01:24,instagc,1.0,18960682,GBR,"","",86.29.147.112,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 22:10:35,,1323134202,7/14/2014 22:10:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010631,7/14/2014 22:14:46,,1323136981,7/14/2014 22:14:13,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,100,131,,,106,147,FUNGUS,FUNGAL INFECTION,"FUNGUS,",100,131-138,FUNGAL INFECTION,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals.",100,131 138,100,131,106,147,-1,RO-has_causative_agent,903937,"rhinophycomycosis    (                         audio )  [&dblprime; +  phykos , seaweed, +  mykes , fungus, +  osis , condition] A fungal infection that may occur in humans or animals",fungus,fungal infection
503010632,7/14/2014 21:02:01,,1323097204,7/14/2014 21:01:47,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 21:11:30,,1323101878,7/14/2014 21:11:24,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,associated with reactive THROMBOCYTOSIS does not exclude,37-48-53-62-77-82-86,94-98-110-113-123-139-142-146,the possibility of ESSENTIAL THROMBOCYTHEMIA if the first,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 21:11:43,,1323101983,7/14/2014 21:10:32,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,associated with reactive THROMBOCYTOSIS does not exclude,37-48-53-62-77-82-86,94-98-110-113-123-139-142-146,the possibility of ESSENTIAL THROMBOCYTHEMIA if the first,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 21:33:38,,1323112651,7/14/2014 21:33:14,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 21:46:31,,1323121874,7/14/2014 21:46:07,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,reactive THROMBOCYTOSIS,53-62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 22:02:50,,1323129562,7/14/2014 22:02:25,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 22:05:38,,1323131267,7/14/2014 22:04:53,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,associated with reactive THROMBOCYTOSIS,37-48-53-62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 22:06:48,,1323131977,7/14/2014 22:05:56,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 22:11:44,,1323134969,7/14/2014 22:11:22,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,reactive THROMBOCYTOSIS,53-62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010632,7/14/2014 22:12:16,,1323135283,7/14/2014 22:11:46,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,62,113,,,76,138,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,62,113-123,ESSENTIAL THROMBOCYTHEMIA,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met.",62,113 123,62,113,76,138,-1,RO-disease_has_finding,901625,"However, the presence of a condition associated with reactive thrombocytosis does not exclude the possibility of essential thrombocythemia if the first three criteria are met",thrombocytosis,essential thrombocythemia
503010633,7/14/2014 20:48:05,,1323089751,7/14/2014 20:48:02,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,112,176,,,119,187,CANDIDA,CANDIDIASIS,and Other Invasive CANDIDA Infections Treatment of,93-97-103-112-120-132-142,145-157-163-176-189-193-201,"candidemia, acute disseminated CANDIDIASIS, and certain other","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 20:48:08,,1323089759,7/14/2014 20:47:56,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,112,176,,,119,187,CANDIDA,CANDIDIASIS,Invasive CANDIDA Infections,103-112-120,157-163-176,"acute disseminated CANDIDIASIS,","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 20:49:15,,1323090342,7/14/2014 20:49:06,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,112,176,,,119,187,CANDIDA,CANDIDIASIS,CANDIDA,112,176,"CANDIDIASIS,","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:01:12,,1323096815,7/14/2014 21:00:58,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,112,176,,,119,187,CANDIDA,CANDIDIASIS,CANDIDA,112,176,"CANDIDIASIS,","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:09:03,,1323100732,7/14/2014 21:08:53,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,112,176,,,119,187,CANDIDA,CANDIDIASIS,and Other Invasive CANDIDA Infections Treatment of,93-97-103-112-120-132-142,145-157-163-176-189-193-201,"candidemia, acute disseminated CANDIDIASIS, and certain other","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:10:49,,1323101593,7/14/2014 21:09:57,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,112,176,,,119,187,CANDIDA,CANDIDIASIS,Invasive CANDIDA,112-103,157-163-176,"acute disseminated CANDIDIASIS,","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:13:57,,1323102911,7/14/2014 21:13:50,elite,1.0,27888773,GBR,"","",128.199.166.81,112,176,,,119,187,CANDIDA,CANDIDIASIS,and Other Invasive CANDIDA Infections Treatment of,93-97-103-112-120-132-142,145-157-163-176-189-193-201,"candidemia, acute disseminated CANDIDIASIS, and certain other","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:19:38,,1323105462,7/14/2014 21:16:47,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,112,176,,,119,187,CANDIDA,CANDIDIASIS,CANDIDA,112,176,"CANDIDIASIS,","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:20:45,,1323105937,7/14/2014 21:19:28,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,112,176,,,119,187,CANDIDA,CANDIDIASIS,"Invasive CANDIDA Infections candidemia, acute disseminated candidiasis, and (peritonitis, abscesses.",103-112-120-145-157-163-176-189-237-251,103-112-120-145-157-163-176-189-237-251,"Invasive Candida Infections candidemia, acute disseminated CANDIDIASIS, and (peritonitis, abscesses.","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010633,7/14/2014 21:44:11,,1323119906,7/14/2014 21:44:07,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,112,176,,,119,187,CANDIDA,CANDIDIASIS,and Other Invasive CANDIDA Infections Treatment of,93-97-103-112-120-132-142,145-157-163-176-189-193-201,"candidemia, acute disseminated CANDIDIASIS, and certain other","1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses.",112,176,112,176,119,187,-1,RO-has_causative_agent,903570,"1 ,   2 ,   3 ,   4 ,   5 ,   8  Class:  Echinocandins 8:14.16; AM700 (VA)  Uses  Candidemia and Other Invasive Candida Infections  Treatment of candidemia, acute disseminated candidiasis, and certain other invasive  Candida  infections (peritonitis, abscesses",Candida,candidiasis
503010634,7/14/2014 20:47:36,,1323089443,7/14/2014 20:46:43,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,diffuse ADENOPATHY,26-34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 20:47:42,,1323089484,7/14/2014 20:47:39,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,throat and diffuse ADENOPATHY suggest infectious mononucleosis,15-22-26-34-45-53-64,26-34-45-53-64-78-85-90,diffuse adenopathy suggest INFECTIOUS MONONUCLEOSIS rather than viral,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:00:02,,1323096188,7/14/2014 20:59:38,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,ADENOPATHY,34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:17:46,,1323104641,7/14/2014 21:17:20,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,ADENOPATHY,34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:29:23,,1323110387,7/14/2014 21:29:13,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,ADENOPATHY,34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:31:30,,1323111541,7/14/2014 21:31:19,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,ADENOPATHY,34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:40:59,,1323117394,7/14/2014 21:40:25,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse ADENOPATHY infectious mononucleosis viral hepatitis.,0-10-15-22-26-34-53-64-90-96,0-10-15-22-26-34-53-64-90-96,Prodromal sore throat and diffuse adenopathy INFECTIOUS MONONUCLEOSIS viral hepatitis.,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 21:44:26,,1323120176,7/14/2014 21:44:23,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,throat and diffuse ADENOPATHY suggest infectious mononucleosis,15-22-26-34-45-53-64,26-34-45-53-64-78-85-90,diffuse adenopathy suggest INFECTIOUS MONONUCLEOSIS rather than viral,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 22:01:21,,1323128813,7/14/2014 22:00:51,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat diffuse ADENOPATHY infectious mononucleosis viral hepatitis.,0-10-15-26-34-53-64-90-96,0-10-15-26-34-45-53-64-90-96,Prodromal sore throat diffuse adenopathy suggest INFECTIOUS MONONUCLEOSIS viral hepatitis.,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010634,7/14/2014 22:05:49,,1323131349,7/14/2014 22:05:30,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,34,53,,,44,77,ADENOPATHY,INFECTIOUS MONONUCLEOSIS,ADENOPATHY,34,53-64,INFECTIOUS MONONUCLEOSIS,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis.,34,53 64,34,53,44,77,1,RO-disease_has_finding,901789,Prodromal sore throat and diffuse adenopathy suggest infectious mononucleosis rather than viral hepatitis,adenopathy,infectious mononucleosis
503010635,7/14/2014 20:46:47,,1323089123,7/14/2014 20:46:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 20:51:57,,1323091817,7/14/2014 20:50:56,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,"ASPHYXIATION asphyxia birth, suicides mechanical birth trauma opiate barbiturate",100-142-161-219-230-236-282-296-154,100-142-161-219-230-236-154,"asphyxiation ASPHYXIA birth, suicides mechanical birth trauma","Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:04:46,,1323098739,7/14/2014 21:04:32,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:09:25,,1323100862,7/14/2014 21:07:51,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,"suicides involving ASPHYXIATION were closely associated with asphyxia birth,",81-90-100-113-118-126-137-142-154,118-142-126,closely associated ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:17:41,,1323104616,7/14/2014 21:17:25,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:31:22,,1323111480,7/14/2014 21:30:50,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:38:47,,1323115673,7/14/2014 21:38:42,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,that suicides involving ASPHYXIATION were closely associated,76-81-90-100-113-118-126,118-126-137-142-151-154-161,"closely associated with ASPHYXIA at birth, suicides","Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 21:43:49,,1323119648,7/14/2014 21:43:37,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 22:01:31,,1323128901,7/14/2014 22:00:54,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010635,7/14/2014 22:09:21,,1323133543,7/14/2014 22:08:52,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,100,142,,,112,150,ASPHYXIATION,ASPHYXIA,ASPHYXIATION,100,142,ASPHYXIA,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor.",100,142,100,142,112,150,-1,RO-cause_of,900221,"Comparison with 2,901 controls, and mutual comparison of categories, showed that suicides involving asphyxiation were closely associated with asphyxia at birth, suicides by violent mechanical means were associated with mechanical birth trauma and drug addiction was associated with opiate and/or barbiturate administration to mothers during labor",asphyxiation,asphyxia
503010636,7/14/2014 20:46:45,,1323089075,7/14/2014 20:46:34,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,12,47,,,23,54,ASSOCIATION,OBESITY,Data on the ASSOCIATION of child overweight,0-5-8-12-24-27-33,27-33-44-47-55-60-67,child overweight or OBESITY with levels of,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 20:47:51,,1323089599,7/14/2014 20:47:37,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 20:58:49,,1323095525,7/14/2014 20:58:13,elite,1.0,26544151,GBR,"","",94.196.251.237,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:12:08,,1323102185,7/14/2014 21:12:02,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,12,47,,,23,54,ASSOCIATION,OBESITY,Data on the ASSOCIATION of child overweight,0-5-8-12-24-27-33,27-33-44-47-55-60-67,child overweight or OBESITY with levels of,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:18:56,,1323105114,7/14/2014 21:18:42,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION overweight,12-33,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:26:03,,1323108563,7/14/2014 21:25:45,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:27:47,,1323109452,7/14/2014 21:27:18,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:35:40,,1323113772,7/14/2014 21:35:28,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:50:10,,1323124004,7/14/2014 21:49:49,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION,12,27-33-47-44,child overweight or OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010636,7/14/2014 21:51:16,,1323124549,7/14/2014 21:50:50,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,12,47,,,23,54,ASSOCIATION,OBESITY,ASSOCIATION of child overweight,12-24-27-33,47,OBESITY,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions.,12,47,12,47,23,54,-1,RO-has_definitional_manifestation,904767,Data on the association of child overweight or obesity with levels of attendance are too sparse to draw conclusions,association,obesity
503010637,7/14/2014 20:48:54,,1323090156,7/14/2014 20:48:52,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,deficiency who developed SUBACUTE COMBINED DEGENERATION of the spinal,49-60-64-74-83-92-105-108-112,14-22-27-39-49-60-64-74,patient with unsuspected COBALAMIN DEFICIENCY who developed subacute,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 20:49:12,,1323090329,7/14/2014 20:48:56,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION,74-83-92,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:13:26,,1323102717,7/14/2014 21:13:10,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION,74-83-92,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:27:08,,1323109076,7/14/2014 21:26:51,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION,74-83-92,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:29:35,,1323110515,7/14/2014 21:29:24,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION,74-83-92,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:31:16,,1323111449,7/14/2014 21:31:01,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION,74-83-92,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:35:36,,1323113755,7/14/2014 21:35:08,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION of the spinal cord,74-83-92-105-108-119-112,39-49-74-83-92-105-108-112-119,COBALAMIN DEFICIENCY subacute combined degeneration of the spinal cord,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 21:44:59,,1323120631,7/14/2014 21:44:52,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,deficiency who developed SUBACUTE COMBINED DEGENERATION of the spinal,49-60-64-74-83-92-105-108-112,14-22-27-39-49-60-64-74,patient with unsuspected COBALAMIN DEFICIENCY who developed subacute,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 22:06:55,,1323132072,7/14/2014 22:05:03,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,patient cobalamin deficiency SUBACUTE COMBINED DEGENERATION the spinal cord nitrous oxide anesthesia.,14-39-49-74-83-92-108-112-119-130-138-144,14-39-49-74-83-92-112-119-130-138-144,patient COBALAMIN DEFICIENCY subacute combined degeneration spinal cord nitrous oxide anesthesia.,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010637,7/14/2014 22:08:16,,1323132936,7/14/2014 22:07:51,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,74,39,,,104,59,SUBACUTE COMBINED DEGENERATION,COBALAMIN DEFICIENCY,SUBACUTE COMBINED DEGENERATION of the spinal cord,74-83-92-105-108-112-119,39-49,COBALAMIN DEFICIENCY,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia.,74 83 92,39 49,74,39,104,59,1,RO-cause_of,900320,We describe a patient with unsuspected cobalamin deficiency who developed subacute combined degeneration of the spinal cord after nitrous oxide anesthesia,subacute combined degeneration,cobalamin deficiency
503010639,7/14/2014 20:57:00,,1323094411,7/14/2014 20:56:43,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM,",123-132,146-155-162,MULTIPLE SYSTEM ATROPHY,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:01:27,,1323096901,7/14/2014 21:01:04,elite,1,28503042,USA,NJ,Woodbridge,54.191.150.115,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM, multiple system atrophy (MSA.",123-132-146-155-162-170,123-132-146-155-162-170,"atypical parkinsonism, MULTIPLE SYSTEM ATROPHY (MSA.","We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:10:46,,1323101562,7/14/2014 21:10:19,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"form of atypical PARKINSONISM, multiple system atrophy",115-120-123-132-146-155-162,120-123-132-146-155-162,"of atypical parkinsonism, MULTIPLE SYSTEM ATROPHY","We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:14:15,,1323103040,7/14/2014 21:13:50,instagc,1,19602039,USA,WA,Bellevue,50.135.214.140,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM,",123-132,146-155-162,MULTIPLE SYSTEM ATROPHY,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:26:37,,1323108840,7/14/2014 21:26:17,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"PARKINSONISM,",132,146-155-162,MULTIPLE SYSTEM ATROPHY,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:37:03,,1323114553,7/14/2014 21:36:47,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"PARKINSONISM,",132,132-146-155-162,"parkinsonism, MULTIPLE SYSTEM ATROPHY","We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 21:51:57,,1323124800,7/14/2014 21:51:38,instagc,1,19636746,USA,NY,Andover,192.182.216.225,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM,",123-132,146-155-162-170,MULTIPLE SYSTEM ATROPHY (MSA.,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 22:12:10,,1323135225,7/14/2014 22:11:46,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM,",123-132,146-155-162,MULTIPLE SYSTEM ATROPHY,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 22:12:11,,1323135233,7/14/2014 22:11:37,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"tau and ApoE genotypes onset of PSP form of atypical PARKINSONISM, multiple system atrophy (MSA.",52-56-60-65-90-99-115-120-123-132-146-155-162-170-96,52-56-60-65-90-96-99-120-123-132-146-155-162-115,"tau and ApoE genotypes onset of PSP form of atypical parkinsonism, MULTIPLE SYSTEM ATROPHY","We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010639,7/14/2014 22:12:37,,1323135547,7/14/2014 22:11:42,neodev,1,11087793,GBR,K6,Southsea,82.24.115.185,132,146,,,144,169,PARKINSONISM,MULTIPLE SYSTEM ATROPHY,"atypical PARKINSONISM,",123-132,146-155-162-170,MULTIPLE SYSTEM ATROPHY (MSA.,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA.",132,146 155 162,132,146,144,169,-1,RO-has_manifestation,906499,"We have therefore analysed the relationship between tau and ApoE genotypes and the age of onset of PSP and another form of atypical parkinsonism, multiple system atrophy (MSA",parkinsonism,multiple system atrophy
503010640,7/14/2014 20:49:00,,1323090214,7/14/2014 20:48:53,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,26,77,,,33,89,NEEDLES,NEEDLESTICKS,the prevalence of NEEDLES engineered with safety features,8-12-23-26-34-45-50-57,57-66-69-77-91-95-109,"features to prevent NEEDLESTICKS, few organizations are","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 20:50:24,,1323090962,7/14/2014 20:50:03,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 20:50:42,,1323091166,7/14/2014 20:50:32,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 20:53:58,,1323092858,7/14/2014 20:53:43,elite,1.0,26544151,GBR,"","",94.196.251.237,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 20:57:16,,1323094567,7/14/2014 20:57:02,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 21:06:13,,1323099388,7/14/2014 21:06:02,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 21:11:36,,1323101919,7/14/2014 21:11:31,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,26,77,,,33,89,NEEDLES,NEEDLESTICKS,the prevalence of NEEDLES engineered with safety,8-12-23-26-34-45-50,57-66-69-77-91-95-109,"features to prevent NEEDLESTICKS, few organizations are","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 21:14:14,,1323103029,7/14/2014 21:14:07,elite,1.0,27888773,GBR,"","",128.199.166.81,26,77,,,33,89,NEEDLES,NEEDLESTICKS,the prevalence of NEEDLES engineered with safety,8-12-23-26-34-45-50,57-66-69-77-91-95-109,"features to prevent NEEDLESTICKS, few organizations are","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 21:45:04,,1323120702,7/14/2014 21:44:33,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,26,77,,,33,89,NEEDLES,NEEDLESTICKS,"of NEEDLES needlesticks,",23-26-77,26-77-23,"of needles NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010640,7/14/2014 21:50:42,,1323124241,7/14/2014 21:50:29,bitcoinget,1,21704174,NLD,07,Beverwijk,83.81.75.251,26,77,,,33,89,NEEDLES,NEEDLESTICKS,NEEDLES,26,77,"NEEDLESTICKS,","Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them.",26,77,26,77,33,89,1,RO-has_causative_agent,903793,"Despite the prevalence of needles engineered with safety features to prevent needlesticks, few organizations are using them",needles,needlesticks
503010641,7/14/2014 20:48:52,,1323090137,7/14/2014 20:48:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,65-74,145-150,LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 20:51:13,,1323091451,7/14/2014 20:50:56,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,of antibodies against BORRELIA BURGDORFERI in three categories,43-46-57-65-74-86-89-95,127-135-142-145-150-158-161-165,endemic region of LYME DISEASE in the northeast,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:09:21,,1323100827,7/14/2014 21:09:13,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,of antibodies against BORRELIA BURGDORFERI in three categories,43-46-57-65-74-86-89-95,127-135-142-145-150-158-161-165,endemic region of LYME DISEASE in the northeast,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:13:45,,1323102824,7/14/2014 21:13:13,neodev,1.0,21515166,NLD,11,Nootdorp,83.86.58.179,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,antibodies against BORRELIA BURGDORFERI,46-57-65-74,145-150,LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:18:49,,1323105082,7/14/2014 21:18:10,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,65-74,127-135-145-150-142,endemic region of LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:25:45,,1323108314,7/14/2014 21:25:27,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,65-74,145-150,LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:30:38,,1323111079,7/14/2014 21:29:37,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,antibodies BORRELIA BURGDORFERI endemic region Lyme disease,46-65-74-127-145-150-135,46-65-74-127-135-145-150,antibodies Borrelia burgdorferi endemic region LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:31:06,,1323111343,7/14/2014 21:30:43,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI Lyme disease,65-74-145-150,145-150,LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 21:48:20,,1323122991,7/14/2014 21:48:03,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,65-74,127-135-142-145-150,endemic region of LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010641,7/14/2014 22:10:08,,1323133982,7/14/2014 22:09:45,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,65,145,,,85,157,BORRELIA BURGDORFERI,LYME DISEASE,BORRELIA BURGDORFERI,65-74,145-150,LYME DISEASE,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported.,65 74,145 150,65,145,85,157,-1,RO-has_causative_agent,903632,The results of the study of the prevalence of antibodies against Borrelia burgdorferi in three categories of subjects from the endemic region of Lyme disease in the northeast Croatia are reported,Borrelia burgdorferi,Lyme disease
503010642,7/14/2014 20:48:48,,1323090112,7/14/2014 20:47:47,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,107,52,,,115,60,OVERDOSE,CHARCOAL,activated charcoal oral N acetylcysteine acetaminophen OVERDOSE.,42-52-68-73-75-93-107,42-52-68-73-75-93-107,activated CHARCOAL oral N acetylcysteine acetaminophen overdose.,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 20:51:51,,1323091750,7/14/2014 20:51:44,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,93-107,52,CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 20:54:21,,1323093063,7/14/2014 20:54:01,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,93-107,42-52,activated CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 20:57:43,,1323094835,7/14/2014 20:57:10,elite,1.0,26544151,GBR,"","",94.196.251.237,107,52,,,115,60,OVERDOSE,CHARCOAL,OVERDOSE.,107,42-52,activated CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:01:18,,1323096839,7/14/2014 21:00:57,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,93-107,52,CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:04:31,,1323098622,7/14/2014 21:04:16,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,107-93,42-52,activated CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:13:40,,1323102799,7/14/2014 21:13:34,elite,1.0,27888773,GBR,"","",128.199.166.81,107,52,,,115,60,OVERDOSE,CHARCOAL,acetylcysteine in acetaminophen OVERDOSE.,75-90-93-107,32-39-42-52-61-68-73,effect of activated CHARCOAL before oral N,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:28:34,,1323109869,7/14/2014 21:27:46,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,107,52,,,115,60,OVERDOSE,CHARCOAL,activated charcoal oral N - acetylcysteine acetaminophen OVERDOSE.,42-68-73-74-75-93-107-52,42-52-68-73-74-75-93-107,activated CHARCOAL oral N - acetylcysteine acetaminophen overdose.,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:35:52,,1323113913,7/14/2014 21:35:37,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,93-107,52-93-107,CHARCOAL acetaminophen overdose.,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010642,7/14/2014 21:41:09,,1323117507,7/14/2014 21:40:58,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,107,52,,,115,60,OVERDOSE,CHARCOAL,acetaminophen OVERDOSE.,93-107,52,CHARCOAL,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose.,107,52,107,52,115,60,1,RO-may_treat,907670,A prospective evaluation of the effect of activated charcoal before oral N-acetylcysteine in acetaminophen overdose,overdose,charcoal
503010643,7/14/2014 20:50:05,,1323090843,7/14/2014 20:49:58,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 20:50:31,,1323091060,7/14/2014 20:50:22,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 21:01:39,,1323097013,7/14/2014 21:01:28,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 21:11:55,,1323102084,7/14/2014 21:11:44,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES can rapidly progress,0-9-13-21,13-21-30-33-40-53-66-69,"rapidly progress to STATUS EPILEPTICUS, contributing to mortality","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 21:14:04,,1323102964,7/14/2014 21:13:53,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 21:34:43,,1323113245,7/14/2014 21:34:33,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 21:35:12,,1323113542,7/14/2014 21:33:47,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 22:03:48,,1323130117,7/14/2014 22:03:31,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 22:05:24,,1323131079,7/14/2014 22:05:13,instagc,1.0,18960682,GBR,"","",86.29.147.112,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010643,7/14/2014 22:06:10,,1323131605,7/14/2014 22:05:50,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,0,33,,,8,51,SEIZURES,STATUS EPILEPTICUS,SEIZURES,0,33-40,"STATUS EPILEPTICUS,","Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment.",0,33 40,0,33,8,51,-1,RO-has_definitional_manifestation,904791,"Seizures can rapidly progress to status epilepticus, contributing to mortality and, in survivors, to neuronal damage and neurological impairment",Seizures,status epilepticus
503010644,7/14/2014 20:48:38,,1323090005,7/14/2014 20:48:23,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,67-69-71-79-88,"p 5 induced ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 20:49:28,,1323090452,7/14/2014 20:49:16,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,79-88,"ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 20:49:53,,1323090746,7/14/2014 20:49:38,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,the treatment of ALLERGIC ASTHMA was demonstrated in,133-137-147-150-159-166-170-183,67-69-71-79-88-99-103-107,"p 5 induced ALLERGIC REACTIONS, and the availability","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 20:50:20,,1323090947,7/14/2014 20:49:59,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,67-69-71-79-88-63,"Der p 5 induced ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:13:05,,1323102556,7/14/2014 21:12:59,elite,1.0,27888773,GBR,"","",128.199.166.81,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,the treatment of ALLERGIC ASTHMA was demonstrated in,133-137-147-150-159-166-170-183,67-69-71-79-88-99-103-107,"p 5 induced ALLERGIC REACTIONS, and the availability","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:28:34,,1323109870,7/14/2014 21:28:17,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,79-88-150-159,"ALLERGIC REACTIONS, allergic asthma","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:32:35,,1323112105,7/14/2014 21:32:23,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,79-88,"ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:37:32,,1323114875,7/14/2014 21:37:18,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,79-88,"ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:44:01,,1323119784,7/14/2014 21:43:56,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,the treatment of ALLERGIC ASTHMA was demonstrated in,133-137-147-150-159-166-170-183,67-69-71-79-88-99-103-107,"p 5 induced ALLERGIC REACTIONS, and the availability","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010644,7/14/2014 21:46:48,,1323122099,7/14/2014 21:46:32,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,150,79,,,165,97,ALLERGIC ASTHMA,ALLERGIC REACTIONS,ALLERGIC ASTHMA,150-159,79-88,"ALLERGIC REACTIONS,","These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study.",150 159,79 88,150,79,165,97,-1,RO-cause_of,900154,"These results showed that STA-1 could effectively suppress the Der p 5-induced allergic reactions, and the availability of STA-1 for the treatment of allergic asthma was demonstrated in this study",allergic asthma,allergic reactions
503010645,7/14/2014 20:48:59,,1323090194,7/14/2014 20:48:55,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,84,113,,,91,128,FISTULA,CROHN'S DISEASE,to sigmoido vesical FISTULA as a complication,64-67-76-84-92-95-97,95-97-110-113-121,a complication of CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 20:50:18,,1323090920,7/14/2014 20:50:06,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,84,113,,,91,128,FISTULA,CROHN'S DISEASE,to sigmoido vesical FISTULA as a complication,64-67-76-84-92-95-97,95-97-110-113-121-84,fistula a complication of CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 20:52:22,,1323092000,7/14/2014 20:52:14,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,84,113,,,91,128,FISTULA,CROHN'S DISEASE,FISTULA,84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 20:54:42,,1323093219,7/14/2014 20:54:23,elite,1.0,26544151,GBR,"","",94.196.251.237,84,113,,,91,128,FISTULA,CROHN'S DISEASE,FISTULA,84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 21:13:09,,1323102570,7/14/2014 21:12:54,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,84,113,,,91,128,FISTULA,CROHN'S DISEASE,sigmoido vesical FISTULA,76-84-67,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 21:27:08,,1323109080,7/14/2014 21:26:28,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,84,113,,,91,128,FISTULA,CROHN'S DISEASE,FISTULA,84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 21:29:21,,1323110368,7/14/2014 21:28:37,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,84,113,,,91,128,FISTULA,CROHN'S DISEASE,pneumaturia sigmoido - vesical FISTULA Crohn's disease.,67-75-76-84-113-121-48,67-75-76-84-113-121-48,pneumaturia sigmoido - vesical fistula CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 21:32:54,,1323112302,7/14/2014 21:32:36,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,84,113,,,91,128,FISTULA,CROHN'S DISEASE,FISTULA,84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 22:12:31,,1323135436,7/14/2014 22:11:45,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,84,113,,,91,128,FISTULA,CROHN'S DISEASE,sigmoido vesical FISTULA,67-76-84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010645,7/14/2014 22:13:57,,1323136422,7/14/2014 22:13:36,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,84,113,,,91,128,FISTULA,CROHN'S DISEASE,sigmoido vesical FISTULA,67-76-84,113-121,CROHN'S DISEASE.,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease.,84,113 121,84,113,91,128,1,RO-has_manifestation,906063,We experienced a case of a 16-year-old boy with pneumaturia due to sigmoido-vesical fistula as a complication of Crohn's disease,fistula,Crohn's disease
503010646,7/14/2014 20:46:30,,1323088994,7/14/2014 20:46:24,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,(secondary) and clonal EOSINOPHILIA including the hypereosinophilic,170-182-186-193-206-216-220,193-206-216-220-238,eosinophilia including the HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 20:51:24,,1323091554,7/14/2014 20:51:15,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,(secondary) and clonal EOSINOPHILIA including the hypereosinophilic,170-182-186-193-206-216-220,193-206-216-220-238,eosinophilia including the HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 21:21:13,,1323106090,7/14/2014 21:20:56,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,(secondary) and clonal EOSINOPHILIA,170-182-186-193,220-238,HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 21:22:26,,1323106683,7/14/2014 21:22:06,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,EOSINOPHILIA,193,220-238,HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 21:32:41,,1323112155,7/14/2014 21:32:26,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,EOSINOPHILIA,193,193-220-238,eosinophilia HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 22:03:04,,1323129706,7/14/2014 22:02:50,instagc,1.0,18960682,GBR,"","",86.29.147.112,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,clonal EOSINOPHILIA,186-193,220-238,HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 22:05:18,,1323131012,7/14/2014 22:04:59,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,clonal EOSINOPHILIA,186-193,220-238,HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 22:08:06,,1323132808,7/14/2014 22:06:56,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,molecular pathophysiology of eosinophilic disorders clonal EOSINOPHILIA hypereosinophilic syndrome.,49-59-75-78-91-186-193-220-238,49-59-75-78-186-193-206-216-220-238-91,molecular pathophysiology of eosinophilic disorders clonal eosinophilia including the HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 22:10:48,,1323134382,7/14/2014 22:10:03,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,EOSINOPHILIA including the hypereosinophilic syndrome.,193-206-216-220-238,193-206-216-220-238,eosinophilia including the HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010646,7/14/2014 22:10:52,,1323134403,7/14/2014 22:10:37,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,193,220,,,205,246,EOSINOPHILIA,HYPEREOSINOPHILIC SYNDROME,clonal EOSINOPHILIA,186-193,220-238,HYPEREOSINOPHILIC SYNDROME.,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome.,193,220 238,193,220,205,246,-1,RO-disease_has_finding,901711,Over the last decade significant advances of the molecular pathophysiology of eosinophilic disorders enable increasingly the distinction between the more common reactive (secondary) and clonal eosinophilia including the hypereosinophilic syndrome,eosinophilia,hypereosinophilic syndrome
503010647,7/14/2014 20:48:06,,1323089756,7/14/2014 20:47:52,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 20:56:48,,1323094313,7/14/2014 20:56:19,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,"ERECTILE DYSFUNCTION diagnostic therapeutic purposes, intracavernous injections papaverine papaverine phentolamine",3-12-43-58-70-80-95-109-140-151,3-12-43-58-70-80-95-109-140-151,"erectile dysfunction diagnostic therapeutic purposes, intracavernous injections PAPAVERINE papaverine phentolamine","In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 20:59:36,,1323095992,7/14/2014 20:59:25,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:00:57,,1323096692,7/14/2014 21:00:47,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:10:05,,1323101243,7/14/2014 21:09:48,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:10:50,,1323101598,7/14/2014 21:09:51,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION intracavernous injections of papaverine,3-12-80-95-106-109,80-95-106-109,intracavernous injections of PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:20:34,,1323105858,7/14/2014 21:20:23,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,80-95-106-109,intracavernous injections of PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:31:04,,1323111333,7/14/2014 21:30:48,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:32:31,,1323112054,7/14/2014 21:32:15,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION,3-12,109,PAPAVERINE,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010647,7/14/2014 21:34:30,,1323113151,7/14/2014 21:33:32,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,3,109,,,23,119,ERECTILE DYSFUNCTION,PAPAVERINE,ERECTILE DYSFUNCTION intracavernous injections of papaverine and combination phentolamine,3-12-80-95-106-109-120-128-151,3-80-95-106-109-120-128-151-12,erectile dysfunction intracavernous injections of PAPAVERINE and combination phentolamine,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed.",3 12,109,3,109,23,119,1,RO-may_diagnose,906641,"In erectile dysfunction formerly, for both diagnostic and therapeutic purposes, intracavernous injections of papaverine and the combination papaverine/phentolamine were employed",erectile dysfunction,papaverine
503010648,7/14/2014 20:48:02,,1323089723,7/14/2014 20:47:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS and M. leprae,0-3-16-20-23,34-39-49-57-71-75-84,"more virulent, causing TUBERCULOSIS, and leprosy, respectively.","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 20:53:18,,1323092500,7/14/2014 20:53:07,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS and M. leprae,0-3-16-20-23,34-39-49-57-71-75-84,"more virulent, causing TUBERCULOSIS, and leprosy, respectively.","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:12:29,,1323102316,7/14/2014 21:12:12,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,0-3,57,"TUBERCULOSIS,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:16:04,,1323103978,7/14/2014 21:15:51,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS and M. leprae,0-3-16-20-23,34-39-49-57-71-75-84,"more virulent, causing TUBERCULOSIS, and leprosy, respectively.","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:22:47,,1323106826,7/14/2014 21:22:29,elite,1.0,28276268,USA,MI,Taylor,67.149.247.166,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,0-3,57,"TUBERCULOSIS,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:28:44,,1323110020,7/14/2014 21:28:36,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,0-3,57,"TUBERCULOSIS,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:32:14,,1323111927,7/14/2014 21:31:59,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS M. leprae,0-3-20-23,57-75,"TUBERCULOSIS, leprosy,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:33:30,,1323112565,7/14/2014 21:33:07,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,"M. TUBERCULOSIS tuberculosis, leprosy,",0-3-57-75,57-75,"TUBERCULOSIS, leprosy,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 21:59:50,,1323128036,7/14/2014 21:59:40,instagc,1.0,18960682,GBR,"","",86.29.147.112,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS,0-3,57,"TUBERCULOSIS,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010648,7/14/2014 22:17:06,,1323138402,7/14/2014 22:16:27,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,0,57,,,15,69,M. TUBERCULOSIS,TUBERCULOSIS,M. TUBERCULOSIS and M. leprae,0-3-16-20-23,57-71-75,"TUBERCULOSIS, and leprosy,","M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively.",0 3,57,0,57,15,69,1,RO-has_causative_agent,903650,"M. tuberculosis and M. leprae are more virulent, causing tuberculosis, and leprosy, respectively",M. tuberculosis,tuberculosis
503010649,7/14/2014 20:54:31,,1323093145,7/14/2014 20:54:20,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,and reduction of THROMBOCYTOSIS was observed in,83-87-97-100-115-119-128,140-142-151-156-166-182-186,6 patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 21:14:19,,1323103095,7/14/2014 21:14:06,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,100,156-166,ESSENTIAL THROMBOCYTHEMIA,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 21:18:09,,1323104843,7/14/2014 21:17:50,instagc,1.0,27770607,USA,TX,El Paso,72.183.248.75,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,reduction of THROMBOCYTOSIS,87-97-100,156-166,ESSENTIAL THROMBOCYTHEMIA,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 21:22:19,,1323106624,7/14/2014 21:21:35,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,100,156-166-182-186-100,thrombocytosis ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:02:35,,1323129416,7/14/2014 22:02:17,instagc,1.0,18960682,GBR,"","",86.29.147.112,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,100,156-166,ESSENTIAL THROMBOCYTHEMIA,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:07:38,,1323132513,7/14/2014 22:07:10,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"polycythemia polycythemia vera, THROMBOCYTOSIS thrombocythemia myelofibrosis.",15-64-77-100-166-186,15-64-77-100-156-166-186,"polycythemia polycythemia vera, thrombocytosis ESSENTIAL THROMBOCYTHEMIA myelofibrosis.","Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:11:35,,1323134892,7/14/2014 22:10:52,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,"polycythemia polycythemia vera, THROMBOCYTOSIS patients with essential thrombocythemia and myelofibrosis.",15-64-77-100-142-156-166-182-186-151,15-64-77-142-151-156-166-182-186-100,"polycythemia polycythemia vera, thrombocytosis patients with ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.","Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:11:45,,1323134958,7/14/2014 22:10:49,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,reduction of THROMBOCYTOSIS,87-97-100,156-166-182-186,ESSENTIAL THROMBOCYTHEMIA and myelofibrosis.,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:13:33,,1323136114,7/14/2014 22:13:16,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,100,156-166,ESSENTIAL THROMBOCYTHEMIA,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010649,7/14/2014 22:14:49,,1323136986,7/14/2014 22:14:27,neodev,1.0,11087793,GBR,K6,Southsea,82.24.115.185,100,156,,,114,181,THROMBOCYTOSIS,ESSENTIAL THROMBOCYTHEMIA,THROMBOCYTOSIS,100,156-166,ESSENTIAL THROMBOCYTHEMIA,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis.",100,156 166,100,156,114,181,-1,RO-disease_has_finding,901650,"Improvement of polycythemia was observed in all 5 patients with polycythemia vera, and reduction of thrombocytosis was observed in 5 out of 6 patients with essential thrombocythemia and myelofibrosis",thrombocytosis,essential thrombocythemia
503010650,7/14/2014 20:49:02,,1323090225,7/14/2014 20:48:59,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,87,25,,,91,32,SKIN,ITCHING,and located on SKIN that has become,72-76-84-87-92-97-101,0-8-22-25-33-41-50,simplex chronicus An ITCHING papular eruption that,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 20:51:43,,1323091717,7/14/2014 20:51:34,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25-33-41,ITCHING papular eruption,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 20:59:52,,1323096130,7/14/2014 20:59:37,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25-33-41,ITCHING papular eruption,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 21:07:36,,1323100087,7/14/2014 21:06:45,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,87,25,,,91,32,SKIN,ITCHING,and located on SKIN that has become thickened pigmented,72-76-84-87-92-97-101-108-122,0-8-22-25-33-41-50-76-84-87-101-108-122,simplex chronicus An ITCHING papular eruption that located on skin become thickened pigmented,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 21:14:47,,1323103363,7/14/2014 21:14:29,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,87,25,,,91,32,SKIN,ITCHING,and located on SKIN that has become thickened pigmented,72-76-84-87-92-97-101-108-122,0-8-22-25-33-41-50-55-58-72-84-87,simplex chronicus An ITCHING papular eruption that is circumscribed and on skin,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 21:27:21,,1323109232,7/14/2014 21:27:09,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25,ITCHING,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 21:38:43,,1323115640,7/14/2014 21:38:32,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25,ITCHING,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 21:39:01,,1323115823,7/14/2014 21:38:53,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,87,25,,,91,32,SKIN,ITCHING,and located on SKIN that has become,72-76-84-87-92-97-101,0-8-22-25-33-41-50,simplex chronicus An ITCHING papular eruption that,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 22:04:24,,1323130427,7/14/2014 22:03:58,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25-33,ITCHING papular,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010650,7/14/2014 22:04:38,,1323130577,7/14/2014 22:04:18,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,87,25,,,91,32,SKIN,ITCHING,SKIN,87,25,ITCHING,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching.,87,25,87,25,91,32,1,RO-disease_has_primary_anatomic_site,902025,simplex chronicus     An itching papular eruption that is circumscribed and located on skin that has become thickened and pigmented as a result of scratching,skin,itching
503010651,7/14/2014 20:47:30,,1323089411,7/14/2014 20:47:28,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,37,71,,,45,77,KYPHOSIS,MPS II,with marked clinical KYPHOSIS in whom the,16-21-28-37-46-49-54,54-58-68-71-75-78-82-89,the diagnosis of MPS II was proved by,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 20:48:19,,1323089838,7/14/2014 20:48:16,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,37,71,,,45,77,KYPHOSIS,MPS II,with marked clinical KYPHOSIS in whom the,16-21-28-37-46-49-54,54-58-68-71-75-78-82-89,the diagnosis of MPS II was proved by,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 20:48:32,,1323089970,7/14/2014 20:48:23,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,37,71,,,45,77,KYPHOSIS,MPS II,KYPHOSIS,37,71-75,MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:00:21,,1323096366,7/14/2014 21:00:07,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,37,71,,,45,77,KYPHOSIS,MPS II,clinical KYPHOSIS,37-28,71-75,MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:10:12,,1323101293,7/14/2014 21:10:02,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,37,71,,,45,77,KYPHOSIS,MPS II,with marked clinical KYPHOSIS in whom the,16-21-28-37-46-49-54,54-58-68-71-75-78-82-89,the diagnosis of MPS II was proved by,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:23:13,,1323107020,7/14/2014 21:22:42,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,37,71,,,45,77,KYPHOSIS,MPS II,KYPHOSIS,37,71-75,MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:26:10,,1323108614,7/14/2014 21:25:21,clixsense,1.0,20614047,USA,WA,Deer Park,174.32.162.10,37,71,,,45,77,KYPHOSIS,MPS II,clinical KYPHOSIS MPS II,28-37-71-75,28-37-71-75,clinical kyphosis MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:43:03,,1323118971,7/14/2014 21:42:43,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,37,71,,,45,77,KYPHOSIS,MPS II,with marked clinical KYPHOSIS in whom the,16-21-28-37-46-49-54,54-58-68-71-75-78-82-89,the diagnosis of MPS II was proved by,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 21:47:29,,1323122509,7/14/2014 21:47:16,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,37,71,,,45,77,KYPHOSIS,MPS II,clinical KYPHOSIS,28-37,71-75,MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010651,7/14/2014 22:00:53,,1323128543,7/14/2014 22:00:38,instagc,1.0,18960682,GBR,"","",86.29.147.112,37,71,,,45,77,KYPHOSIS,MPS II,marked clinical KYPHOSIS,21-28-37,71-75,MPS II,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells.",37,71 75,37,71,45,77,-1,RO-has_manifestation,906479,"We report a boy with marked clinical kyphosis in whom the diagnosis of MPS II was proved by demonstrating a severe deficiency of serum and leucocyte iduronate-sulphate sulphatase and an accelerated incorporation of radiosulphate into his cultured fibroblast glycosaminoglycans, which could not be corrected by the product of other typed reference MPS II cells",kyphosis,MPS II
503010652,7/14/2014 20:51:14,,1323091480,7/14/2014 20:51:00,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 20:59:45,,1323096078,7/14/2014 20:59:22,prodege,1.0,28255346,GBR,L9,Sheffield,2.125.183.137,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:06:29,,1323099504,7/14/2014 21:06:12,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:13:07,,1323102553,7/14/2014 21:13:01,clixsense,1.0,6491361,USA,MD,Owings Mills,98.233.248.214,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,64 patients with HAEMATURIA and subsequent histologically,26-29-38-43-54-58-69,58-69-84-91-101-104-108-116-125-130,subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:15:31,,1323103712,7/14/2014 21:15:25,elite,1.0,27888773,GBR,"","",128.199.166.81,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,64 patients with HAEMATURIA and subsequent histologically,26-29-38-43-54-58-69,58-69-84-91-101-104-108-116-125-130,subsequent histologically proven CARCINOMA OF THE BLADDER revealed that bladder,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:16:23,,1323104118,7/14/2014 21:16:05,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,64 patients with HAEMATURIA and subsequent histologically proven carcinoma,26-29-38-43-54-58-69-84-91,91-101-104-108-116-125-130-138-146-152-155-169-165,CARCINOMA OF THE BLADDER revealed that bladder tumours could be diagnosed pre operatively,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:20:07,,1323105655,7/14/2014 21:19:53,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:28:34,,1323109856,7/14/2014 21:28:12,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 21:30:39,,1323111084,7/14/2014 21:30:27,clixsense,1.0,19162475,GBR,M3,Frome,82.33.126.30,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010652,7/14/2014 22:06:27,,1323131750,7/14/2014 22:05:52,instagc,1.0,19636746,USA,NY,Andover,192.182.216.225,43,91,,,53,115,HAEMATURIA,CARCINOMA OF THE BLADDER,HAEMATURIA,43,91-101-104-108,CARCINOMA OF THE BLADDER,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria.,43,91 101 104 108,43,91,53,115,1,RO-disease_may_have_finding,902786,A retrospective review of 64 patients with haematuria and subsequent histologically proven carcinoma of the bladder revealed that bladder tumours could be diagnosed pre-operatively in 34 of 46 (76%) of patients with gross haematuria and 12 of of 18 (67%) of those with microhaematuria,haematuria,carcinoma of the bladder
503010653,7/14/2014 20:48:05,,1323089754,7/14/2014 20:48:03,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"used for testing BRONCHIAL HYPERREACTIVITY, have been shown",43-48-52-60-70-87-92-97,0-13-22-33-43,"METHACHOLINE CHLORIDE solutions, routinely used","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 20:50:31,,1323091058,7/14/2014 20:50:15,elite,1.0,26544151,GBR,"","",94.196.251.237,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13,METHACHOLINE CHLORIDE,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:02:12,,1323097289,7/14/2014 21:02:02,tremorgames,1.0,26860817,NLD,06,Boxmeer,84.29.157.221,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13,METHACHOLINE CHLORIDE,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:05:35,,1323099071,7/14/2014 21:04:56,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13-22,"METHACHOLINE CHLORIDE solutions,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:06:53,,1323099712,7/14/2014 21:06:27,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13-22,"METHACHOLINE CHLORIDE solutions,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:11:17,,1323101776,7/14/2014 21:11:01,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"Methacholine chloride solutions, routinely used for testing BRONCHIAL HYPERREACTIVITY,",0-13-22-43-48-52-60-70-33,0-13-22-33-43-48-52-60-70,"METHACHOLINE CHLORIDE solutions, routinely used for testing bronchial hyperreactivity,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:12:24,,1323102301,7/14/2014 21:12:18,elite,1.0,27888773,GBR,"","",128.199.166.81,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"used for testing BRONCHIAL HYPERREACTIVITY, have been shown",43-48-52-60-70-87-92-97,0-13-22-33-43,"METHACHOLINE CHLORIDE solutions, routinely used","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:12:34,,1323102353,7/14/2014 21:12:18,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13-22,"METHACHOLINE CHLORIDE solutions,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:22:11,,1323106531,7/14/2014 21:21:54,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"Methacholine chloride solutions, BRONCHIAL HYPERREACTIVITY,",0-13-22-60-70,0-13-22-60-70,"METHACHOLINE CHLORIDE solutions, bronchial hyperreactivity,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010653,7/14/2014 21:30:40,,1323111091,7/14/2014 21:30:13,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,60,0,,,85,21,BRONCHIAL HYPERREACTIVITY,METHACHOLINE CHLORIDE,"BRONCHIAL HYPERREACTIVITY,",60-70,0-13-22,"METHACHOLINE CHLORIDE solutions,","Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time.",60 70,0 13,60,0,85,21,1,RO-may_diagnose,906521,"Methacholine chloride solutions, routinely used for testing bronchial hyperreactivity, have been shown to degrade over time",bronchial hyperreactivity,Methacholine chloride
503010654,7/14/2014 20:44:47,,1323088089,7/14/2014 20:44:33,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,International HEADACHE Society,94-108-117,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 20:48:45,,1323090076,7/14/2014 20:48:43,prodege,1.0,12971342,USA,CA,Los Angeles,198.101.91.82,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,of the International HEADACHE Society in 1988.,87-90-94-108-117-125-128,19-28-31-33-42-50-53-57,included as a MIGRAINE VARIANT in the first,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 20:49:15,,1323090351,7/14/2014 20:49:12,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,of the International HEADACHE Society in 1988.,87-90-94-108-117-125-128,19-28-31-33-42-50-53-57,included as a MIGRAINE VARIANT in the first,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 20:52:51,,1323092263,7/14/2014 20:52:42,tremorgames,1.0,28013393,USA,CA,Rancho Cordova,71.197.67.37,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,HEADACHE Society,108-117,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:05:18,,1323098930,7/14/2014 21:05:06,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,International HEADACHE Society,94-108-117,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:11:19,,1323101791,7/14/2014 21:11:05,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,HEADACHE,108,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:15:30,,1323103698,7/14/2014 21:15:10,instagc,1.0,19602039,USA,WA,Bellevue,50.135.214.140,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,HEADACHE,108,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:16:20,,1323104094,7/14/2014 21:15:06,sendearnings,1.0,20717796,USA,CA,San Jose,99.27.90.128,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,migraine variant in the first Classification of the International HEADACHE Society in 1988.,33-42-50-53-57-87-90-94-108-117-125-128-72,33-42-50-53-57-63-72-87-90-94-117-108,MIGRAINE VARIANT in the first Headache Classification of the International Headache Society,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:34:51,,1323113335,7/14/2014 21:34:33,instagc,1.0,28301350,GBR,K4,Plymouth,92.28.215.248,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,migraine HEADACHE,33-108,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010654,7/14/2014 21:46:07,,1323121517,7/14/2014 21:45:49,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,108,33,,,116,49,HEADACHE,MIGRAINE VARIANT,HEADACHE,108,33-42,MIGRAINE VARIANT,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988.,108,33 42,108,33,116,49,-1,RO-has_definitional_manifestation,904551,This condition was included as a migraine variant in the first Headache Classification of the International Headache Society in 1988,Headache,migraine variant
503010655,7/14/2014 20:45:16,,1323088321,7/14/2014 20:45:03,clixsense,1.0,27871219,NLD,07,Amsterdam,87.210.207.223,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 20:49:16,,1323090360,7/14/2014 20:49:02,clixsense,1.0,25419319,GBR,H8,Liverpool,94.4.192.228,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,"1700 hours, frontal SEIZURES between 2300 and 0500",167-172-179-187-196-204-209-213,87-92-95-103-112-117-126-135-150,lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 20:51:28,,1323091568,7/14/2014 20:51:08,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:03:52,,1323098254,7/14/2014 21:03:41,elite,1.0,28503042,USA,NJ,Woodbridge,54.191.150.115,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:14:05,,1323102967,7/14/2014 21:13:33,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:17:18,,1323104486,7/14/2014 21:17:08,tremorgames,1.0,24449707,CAN,QC,Laval,96.21.249.72,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:23:57,,1323107414,7/14/2014 21:23:37,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:34:32,,1323113146,7/14/2014 21:34:19,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,187-179,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:45:44,,1323121312,7/14/2014 21:45:35,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,"1700 hours, frontal SEIZURES between 2300 and",167-172-179-187-196-204-209,87-92-95-103-112-117-126-135-150,lobe of origin: TEMPORAL LOBE SEIZURES occurred preferentially between,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010655,7/14/2014 21:49:33,,1323123735,7/14/2014 21:49:18,bitcoinget,1.0,21704174,NLD,07,Beverwijk,83.81.75.251,187,103,,,195,125,SEIZURES,TEMPORAL LOBE SEIZURES,frontal SEIZURES,179-187,103-112-117,TEMPORAL LOBE SEIZURES,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours.",187,103 112 117,187,103,195,125,-1,RO-has_definitional_manifestation,904867,"We recorded 450 seizures that showed an uneven distribution over the day, depending on lobe of origin: temporal lobe seizures occurred preferentially between 1100 and 1700 hours, frontal seizures between 2300 and 0500 hours, and parietal seizures between 1700 and 2300 hours",seizures,temporal lobe seizures
503010656,7/14/2014 20:50:50,,1323091267,7/14/2014 20:50:22,prodege,1.0,2767509,CAN,BC,Victoria,96.54.172.117,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,30-44,micronutrient DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 20:56:18,,1323094042,7/14/2014 20:53:59,instagc,1.0,28524232,CAN,ON,Toronto,99.244.116.246,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,micronutrient deficits (moderate undernutrition) PROTEIN CALORIE MALNUTRITION (PCM.,30-44-53-63-101-109-117-130,30-44-53-63-101-109-130-117,micronutrient DEFICITS (moderate undernutrition) protein calorie malnutrition (PCM.,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 21:16:51,,1323104309,7/14/2014 21:15:35,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION (PCM.,101-109-117-130,44-30,micronutrient DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 21:44:03,,1323119817,7/14/2014 21:43:51,prodege,1.0,2143114,CAN,BC,Vancouver,24.84.160.12,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,44-30,micronutrient DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:12:34,,1323135495,7/14/2014 22:12:13,instagc,1.0,19686223,CAN,BC,Surrey,184.65.16.6,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,micronutrient deficits (moderate undernutrition) PROTEIN CALORIE MALNUTRITION,30-44-53-63-101-109-117,30-44-53-63-101-109-117,micronutrient DEFICITS (moderate undernutrition) protein calorie malnutrition,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:14:28,,1323136821,7/14/2014 22:13:35,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION (PCM.,101-109-117-130,30-44-53-63,micronutrient DEFICITS (moderate undernutrition),Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:17:12,,1323138447,7/14/2014 22:16:51,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,44,DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:17:29,,1323138651,7/14/2014 22:17:13,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,30-44,micronutrient DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:18:18,,1323139197,7/14/2014 22:18:01,pedtoclick,1.0,20864559,GBR,B8,Bromley,213.106.94.78,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,44,DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010656,7/14/2014 22:19:07,,1323139749,7/14/2014 22:18:38,instagc,1.0,28519532,USA,IA,Honey Creek,12.73.110.36,101,44,,,129,52,PROTEIN CALORIE MALNUTRITION,DEFICITS,PROTEIN CALORIE MALNUTRITION,101-109-117,30-44,micronutrient DEFICITS,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM.,101 109 117,44,101,44,129,52,-1,RO-cause_of,900167,Selective food intake induced micronutrient deficits (moderate undernutrition) and can later lead to protein calorie malnutrition (PCM,protein calorie malnutrition,deficits
503010657,7/14/2014 20:48:15,,1323089808,7/14/2014 20:48:12,instagc,1.0,25990856,USA,NV,Las Vegas,68.108.98.78,41,0,,,45,9,HAIR,HAIR LOSS,excessive shedding of HAIR and the,19-29-38-41-58-62,0-5-10-19-29,HAIR LOSS includes excessive shedding,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:09:17,,1323100803,7/14/2014 21:09:01,clixsense,1.0,26889820,GBR,C3,Shelford,92.18.120.203,41,0,,,45,9,HAIR,HAIR LOSS,HAIR,41,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:09:42,,1323101009,7/14/2014 21:09:26,prodege,1.0,7664351,USA,NY,Cicero,74.111.0.21,41,0,,,45,9,HAIR,HAIR LOSS,excessive shedding of HAIR (effluvium),19-29-38-41-46,0-5-10-19-29-38-41-66,"HAIR LOSS includes excessive shedding of hair alopecias,","Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:13:20,,1323102663,7/14/2014 21:13:13,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,41,0,,,45,9,HAIR,HAIR LOSS,excessive shedding of HAIR and the,19-29-38-41-58-62,0-5-10-19-29,HAIR LOSS includes excessive shedding,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:13:41,,1323102806,7/14/2014 21:13:26,prodege,1.0,28039757,GBR,L8,Southport,109.155.158.54,41,0,,,45,9,HAIR,HAIR LOSS,"excessive shedding of HAIR and the alopecias,",19-29-38-41-58-62-66,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:29:24,,1323110393,7/14/2014 21:29:05,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,41,0,,,45,9,HAIR,HAIR LOSS,HAIR,41,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:29:53,,1323110684,7/14/2014 21:29:38,clixsense,1.0,19803139,NLD,06,Veldhoven,212.61.84.196,41,0,,,45,9,HAIR,HAIR LOSS,HAIR,41,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:43:45,,1323119586,7/14/2014 21:43:36,clixsense,1.0,6340330,USA,NY,Fort Plain,67.248.115.74,41,0,,,45,9,HAIR,HAIR LOSS,excessive shedding of HAIR and the,19-29-38-41-58-62,0-5-10-19-29,HAIR LOSS includes excessive shedding,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 21:58:22,,1323127291,7/14/2014 21:57:57,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,41,0,,,45,9,HAIR,HAIR LOSS,excessive shedding of HAIR,19-29-38-41,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010657,7/14/2014 22:08:42,,1323133112,7/14/2014 22:08:26,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,41,0,,,45,9,HAIR,HAIR LOSS,HAIR,41,0-5,HAIR LOSS,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair.",41,0 5,41,0,45,9,1,RO-disease_has_primary_anatomic_site,902246,"Hair loss includes excessive shedding of hair (effluvium) and the alopecias, in which there is a decrease in the amount of hair",hair,Hair loss
503010658,7/14/2014 20:52:59,,1323092351,7/14/2014 20:52:43,elite,1.0,26544151,GBR,"","",94.196.251.237,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,VESSEL,105,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 21:12:25,,1323102304,7/14/2014 21:12:10,clixsense,1.0,28037714,GBR,P5,Covent Garden,90.199.50.107,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,increased from cutaneous VESSEL vasodilation.,80-90-95-105-112,49-60-65-69-75-80-90-95-105,suggesting that the BLOOD FLOW INCREASED from cutaneous vessel,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 21:29:48,,1323110638,7/14/2014 21:29:36,clixsense,1.0,16827630,GBR,A7,Birmingham,86.146.169.103,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,cutaneous VESSEL vasodilation.,105-112-95,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 21:32:55,,1323112304,7/14/2014 21:32:31,neodev,1.0,27597779,CAN,AB,Calgary,72.29.251.209,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,acupuncture VESSEL,105-5,69-75-80-112,BLOOD FLOW INCREASED vasodilation.,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:04:58,,1323130808,7/14/2014 22:04:46,instagc,1.0,18960682,GBR,"","",86.29.147.112,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,cutaneous VESSEL vasodilation.,95-105-112,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:10:15,,1323134035,7/14/2014 22:10:00,clixsense,1.0,21034659,AUS,04,Brisbane,49.189.14.88,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,VESSEL,105,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:16:35,,1323138075,7/14/2014 22:16:18,instagc,1.0,24252915,GBR,B7,Bristol,77.98.139.82,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,cutaneous VESSEL vasodilation.,95-105-112,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:17:56,,1323138950,7/14/2014 22:17:33,elite,1.0,27385296,GBR,U8,Edinburgh,77.102.46.226,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,VESSEL,105,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:17:59,,1323138993,7/14/2014 22:17:44,neodev,1.0,28175665,CAN,ON,Brampton,99.228.31.59,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,VESSEL vasodilation.,105-112,69-75-80-90-95-105-112,BLOOD FLOW INCREASED from cutaneous vessel vasodilation.,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
503010658,7/14/2014 22:19:00,,1323139672,7/14/2014 22:17:51,sendearnings,1.0,11896941,USA,FL,Seminole,97.106.105.251,105,69,,,111,89,VESSEL,BLOOD FLOW INCREASED,cutaneous VESSEL vasodilation.,95-105-112,69-75-80,BLOOD FLOW INCREASED,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation.,105,69 75 80,105,69,111,89,1,RO-has_finding_site,905157,Hoku acupuncture also increased palm temperature suggesting that the blood flow increased from cutaneous vessel vasodilation,vessel,blood flow increased
